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Abstract 
 
Cancer/testis (C/T) antigens are a unique class of tumour associated proteins that are 
prominently expressed in cancer cells of different histological origin. Placenta is one of the 
three non-cancerous tissues known to express these antigens. During the first trimester (FT) 
of pregnancy, placental invasion resembles to that in tumour, and is controlled by several 
vasoactive substances including 5-hydroxytryptamine (5-HT). Interestingly, in pre-
eclampsia (a pregnancy related multi-system complication), the levels of 5-HT are found to 
be increased, whilst the overall trophoblast invasion is low, when compared to normal (NT) 
placenta. Previous studies have compared the status of factors that are involved in 
trophoblast invasion between NT and PE placenta. However, the expression patterns of all 
known 5-HT receptors in PE placentae have not been fully investigated, even though the 5-
HT mediates its various actions via these receptors. Likewise, the status of C/T antigens 
which are also proposed to be involved in cancer cell proliferation, differentiation, migration 
and invasion in PE placentae is not known.  
On account of the differences in trophoblast invasion between NT and PE placenta, it was 
hypothesised that the expression of C/T antigens and 5-HT receptors vary. Also, since the 
circulating 5-HT is increased and the invasive potentials of trophoblast cells is decreased in 
PE, it was hypothesised the two events may influence one another. Therefore, this case 
controlled study, compared the C/T antigen and 5-HT receptor expression profiles amongst 
11 FT, 13 NT, and 12 PE placentae. The study also focused on the effects of 5-HT on 
trophoblast invasion using placental cell lines. 
Significant differences in the status of the C/T antigens were found between NT and PE 
placentae using quantitative real-time PCR, western blotting and immunohistochemistry 
(IHC). Especially MAGEA1 (p<0.0001) and MAGEA4 (p<0.001) antigens are significantly 
up-regulated in PE placentae. Significant differences in expression were also observed 
between term (NT) and FT placentae. This is the first study to report the changes in both 
mRNA and proteins together with the cellular expression patterns of these C/T antigens in 
NT, PE and FT. On the 5-HT receptor side, 5-HT1B and 5-HT2B receptor were found to be 
significantly down-regulated in PE. Since very few studies looked at the effects of 5-HT in 
placental cells, the effects of 5-HT on migration/invasion using placental cell lines were also 
studied. 5-HT at 20 to 40µM, induced the migration and invasion of these cells. The 
expressions of the two 5-HT receptors and six C/T antigens, were also up-regulated at these 
concentrations. Thus, this study suggests 5-HT may be an important factor for trophoblast 
invasion. Hence, the shallow invasion in PE may be linked to the differential expression of 
5-HT receptors and C/T antigens.  
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1.0 Introduction 
The placenta has been a curiosity for many researchers due to its close resemblance to cancer 
(Ferretti et al, 2007; Fest et al, 2008; Spellman and Fottrell, 1973). The invasion patterns of 
tumour cells and placental cells during early pregnancy are remarkably similar. Similar 
angiogenic agents, growth factors and immune regulators are involved in both processes 
(Soundararajan and Rao, 2004). However, unlike tumour, placental invasion is tightly 
regulated. Thus, an understanding of the mechanisms controlling regulated placental 
invasion has been of interest in order to implicate the same practice in tumour cells.  
 
 Placenta 
The placenta is a specialised multifunctional organ that develops during pregnancy. The 
word ‘placenta’ originates from two terms, firstly from the Latin term ‘placenta’ meaning 
“a flat cake” and secondly from a Greek term ‘plakoenta’ meaning “flat” (www1). Both 
terms refer to its round-flat shape as seen in humans. The placenta is developed from both 
foetal and maternal components (as depicted in Figure 1.1) which form a vital connection 
for the sustenance of the foetus (James et al, 2005). It is a villous organ that allows the 
exchange of nutrients and gases from maternal blood to the placental trophoblast cells, 
thereby enabling the growth of the foetus and playing an important role in the continuous 
supply of nutrients, exchange of waste materials and the development of foetal immunity 
(Red-Horse et al, 2004). It also functions as an endocrine organ which produces hormones 
to protect the foetus against maternal immunity. The development of the placenta and the 
embryo are closely linked.  
 
Figure 1.1: Placenta - The interface between mother and foetus. 
 
The figure depicts the localisation of the placenta in the uterus and the cross section of 
placenta showing the blood ciruclation. [Figure adapted from www2] 
Chapter 1: Introduction 
3 
 
1.1.1 Formation of placenta (placentation) 
Placental formation follows an intricate sequence of events initiated by the fertilisation of 
the oocytes. Figure 1.2 represents the stages of placental development starting from 
ovulation to implantation of the blastocyst.  
                    
Figure 1.2: Representation of the early stages of placental development starting from 
ovulation to implantation.  
[Figure revised from www3] 
 
The stages seen in Figure 1.2 are described in detail below: 
1.1.1.1 Ovulation to formation of blastocyst: 
During ovulation, the mature ovum (haploid oocyte) is released from Graafian follicles in 
the ovary into the oviducts and then into the fallopian tube. This process is initiated and 
controlled by the secretion of endocrine hormones such as luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH). Fertilisation takes place in the fallopian tube where 
the mature oocytes are fertilised by a sperm cell to form a diploid zygote. This is counted as 
Day 0 of pregnancy or placental development where the nucleus of the ova and the sperm 
unite (Hamilton and Boyd, 1960). After fertilization, the zygote moves along the fallopian 
tube into the uterus and undergoes several stages of cleavage and differentiation. The mitotic 
division starts with 2-cell stage (Day 1), 4-cell stage (Day 2), 8-cell stage (Day 3), and 
continues until the zygote reaches the uterus. After multiple mitotic divisions, a round mass 
of cells (blastomere) is formed with 12-16 cells (Day 4) which is called morula (www4). The 
outer lining zona pellucida is rigid and does not allow dividing cells to expand. This results 
in a collection of cells, which look like a mulberry from where the name morula is derived.  
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At Day 4-5 the morula rolls from the fallopian tube to the uterine cavity, where it transforms 
into a blastocyst. The cells on the outer side of the morula thicken and flatten out while the 
cells inside become more compact and adhere to one another forming a cavity (Hamilton 
and Boyd, 1960). This eventually gives rise to an outer layer of trophoblast cells and an inner 
cell mass. The blastocyst hatches from the zona pellucida by constant contraction and 
expansion (Day 5-6). The free blastocyst then aligns along the uterine wall. The inner cell 
mass forms the foetus while the outer trophoblast layer leads to the implantation of the 
blastocyst into the uterus to form the placenta. 
1.1.1.2 Implantation 
At day 6-7, the blastocyst implants into the endometrium of the uterus. The implantation is 
completed by day 10. The implantation stage takes place in three steps: 
• Apposition: the blastocyst positions itself with the inner cell mass (ICM) against the 
uterine wall, but the interaction is not stable. This stage is called apposition. At this 
stage, initial adherence is sustained by the presence of microvilli on the 
syncytiotrophoblast layer (a multinucleated layer formed by the fusion of 
cytotrophoblast cells), which comes in contact with the micro-protrusions called 
pinopodes on the uterine epithelium (Figure 1.3, Panel I).  
• Adhesion: physical interaction occurs between the blastocyst and the epithelium to 
develop a stable adhesion.  
• Invasion: immediately after adhesion, the syncytiotrophoblast cells release lytic 
enzymes and factors that erode the epithelium as well as basal lamina in order to start 
invading the stroma of the uterus. By day 10, the blastocyst is fully embedded in the 
uterus and the epithelial layer grows over the blastocyst concealing it. The 
trophoblast cells undergo multiple changes to facilitate invasion and placental 
development.  
1.1.1.3 Trophoblast differentiation 
As mentioned in Section 1.1.1.2, during invasion, trophoblast cells lying directly under the 
inner mass undergo differentiation to form a multinucleated syncytiotrophoblast which 
displays invasive properties (Huppertz, 2008). This syncytiotrophoblast penetrates the 
uterine epithelium crossing the basal lamina and embeds the embryo into the stroma (Figure 
1.3 Panel II). This usually takes place within a certain time period called the “window of 
receptivity” (Lunghi et al, 2007), which is controlled by the levels of oestrogen.  
The remaining mononucleated trophoblast cells are now referred to as cytotrophoblasts. 
They form the second layer and do not come into contact with the maternal interface. 
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Cytotrophoblasts have, however, a major function for placental development as they act as 
stem cells for syncytiotrophoblast cells, which upon rapid division and fusion ultimately lead 
to the expansion of the placenta. Eight days after implantation, lacunae (large fluid filled 
spaces) are formed within the syncytiotrophoblast (Figure 1.3 Panel III). Some masses of 
syncytiotrophoblast are found in between the lacunae and are termed trabeculae, which 
develop further into the villous tree of the placenta. Once the embryo and the surrounding 
tissues are completely embedded in the endometrium and the syncytiotrophoblast are fully 
developed, the extra-embryonic mesodermal cells migrate over the top of the inner surface 
of the cytotrophoblast to form the chorion (Norwitz et al, 2001). The cytotrophoblasts then 
penetrate the trabeculae and migrate towards the maternal side of the placenta. These cells 
differentiate into extravillous and villous pathways. The pathway for trophoblast 
differentiation is represented in Figure 1.4.  
 
Figure 1.3: Implantation of blastocysts into the endometrium. 
Panel I. Apposition and adhesion of the blastocyst on the uterine epithelium with the help 
of microvilli on the surface of syncytiotrophoblast cells and pinopodes on the surface of 
epithelial cell (Day 6-7). Panel II. The invasion of the syncytiotrophoblast into the 
endometrial stroma (Day 8-9). Panel III. Blastocyst fully embedded and concealed within 
the endothelium (Day 10). There is formation of the lacunar network in the chorion and the 
syncytiotrophoblasts called the trabeculae. The cytotrophoblasts invade the trabeculae and 
migrate towards the maternal side. The blue arrows indicate the circulation of endocrine 
hormones, growth factors and cytokines which help with the maintainance of the pregnancy 
at its early stages. [Figure slightly revised from Norwitz et al, 2001].  
AC- Amniotic Cavity; BC- Blastocyst Cavity; BED- Bilaminar Embryonic Disk; C- 
Capillary; CC- Chorionic Cavity; CT- Cytotrophoblast; DS- Decidualised Stroma; ES- 
Endometrial Stroma; G- Endometrial Glands; ICM- Inner Cell Mass; LN- Lacunar 
Network; M- Microvilli; P- Pinopodes; ST- Syncytiotrophoblast; UC- Uterine Cavity; UE- 
Uterine Epithelium;  YS- Yolk  Sac 
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Figure 1.4: Pathway representing trophoblast differentiation. 
 
The outer trophoblast layer of the blastocyst gives rise to stem cell cytotrophoblast which 
differentiates into two major pathways with autonomous functions. The differentiation 
processes that the cells undergo are highlighted in black boxes. [Figure adapted from Gude 
et al, 2004 and Tarrade et al, 2001] 
 
 
The interstitial trophoblast (Interstitial Cytotrophoblast, iCTB) further invades the stroma 
whereas the endovascular trophoblast (EVT; Endovascular Cytotrophoblast, eCTB) invades 
the spiral arteries of the uterus. The ‘physiological changes of pregnancy’ begin when a sub-
population of EVT moves as a column from the anchoring villi spreading laterally to form 
the trophoblastic shell and longitudinally invading the spiral arteries of the decidua (James 
et al, 2005) (Figure 1.5). Around 100 to 150 spiral arteries are transformed extending to the 
inner third of the myometrium. The invading EVT first plugs the maternal spiral arteries and 
then subsequently replaces the maternal endothelial lining and the myometrial section of the 
vessels (processes called endovascular and interstitial invasion, respectively) (Soundararajan 
and Rao, 2004; Ramsey et al, 1976). These processes transform the vessels into large bore 
conduits by the loss of their musculo-elastic structure and into high capacitance vessels by 
their increase in diameter converting them from “high resistance, low capacitance” to “low 
resistance, high capacitance” vessels (Johns et al, 2006). The fibrinoid layer replaces the 
muscular and elastic components of maternal blood vessels.  
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This transformation leads to adequate supply of maternal blood flow, required for the growth 
of the placenta/foetus; thereby leading to placentation. At the 10th week of pregnancy, the 
plug dissipates, thus establishing direct contact between the spiral arteries and the placental 
villi. The net result is the formation of the placenta with low resistance materno-foetal 
interface and the establishment of a blood supply between the foetus and the mother. 
 
 
 
Figure 1.5: Invasion of spiral arteries by endovascular trophoblast. 
 
The stem cell CTB (light green) in tertiary villous form CTB columns invading the uterine 
wall [A]. Syncytiotrophoblast (STB) forms the outer layer of the villi, which is in connection 
with the intervillous spaces (IVS). As the pregnancy progresses, CTB cells differentiate into 
endovascular CTB (eCTB; green) and interstitial CTB (iCTB; dark green) [B]. The eCTB 
forms a plug on the spiral arteries and builds the pressure. This helps the iCTB and eCTB to 
replace the endothelial lining and displaces the smooth muscle cells of the artery [C]. The 
plug disappears once the spiral arteries are remodelled and there is sufficient blood supply 
to the placenta. [Figure revised from Red-Horse et al, 2004] 
 
1.1.2 Pregnancy stages and placental anatomy 
Pregnancy is divided into three stages known as First, Second and Third Trimesters, and the 
placental development is often termed according to these stages.  
 
1.1.2.1 First trimester (Week 1-13) 
The first trimester of pregnancy begins with the implantation of the blastocyst into the uterine 
wall and marks the beginning of angiogenesis. The first trimester is the most critical one, as 
it determines the development of the foetus. Exchange of materials in the early embryo is 
done through diffusion and osmosis, but as the demand of the foetus increases with 
development, a more defined materno-foetal circulation needs to develop for sufficient 
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exchange of nutrients and gases. Consequently, placental villi systems start developing, 
which bring the maternal and foetal blood circulations closer. However, there is no direct 
mixing of the two blood circulations. As explained earlier in Figure 1.3, Panel III, large 
spaces are formed in the syncytiotrophoblast layer called lacunae. This mechanism occurs 
around day 9-10 post conception (p.c.). Figure 1.6[I] also represents the lacunar stage while 
the cytotrophoblast penetrates the syncytiotrophoblast around the day 11-13 p.c. forming the 
primary villi of the placenta (Figure 1.6[II]). The mesoblast from the foetal side grows into 
the cytotrophoblast forming the outer-most layer of syncytiotrophoblast followed by layers 
of cytotrophoblast and inner mesoblast. This forms the secondary villi around the day 16 p.c. 
(Figure 1.6[III]). By the end of the first trimester, the secondary villi gives rise to the tertiary 
villi with the foetal capillary network penetrating the mesoblast as seen in figure 1.6[IV]. 
The tertiary villi continues to develop and grow until the end of the pregnancy. The 
cytotrophoblast also starts differentiating at the end of the first trimester, as explained earlier 
in Section 1.1.1.3.  
 
1.1.2.2 Second trimester (Week 14-26) 
The second trimester is marked by vascularisation of the chorionic villi system (Chaddha et 
al, 2004). The tertiary villi form numerous branches. Some of them are anchored to the 
decidua and are called anchoring villi, from where the eCTB plugs the spiral arteries 
followed by iCTB lining the arteries (Figure 1.5, Section 1.1.1.3). Some branches of the villi 
do not anchor to the decidua and are thus called floating villi. The tertiary villi change to 
intermediate immature villi, which mature into intermediate villi and which further give rise 
to either stem villi or terminal villi (mesenchymatous). The stem villi give the structural 
support to the villous tree, whereas the terminal villi elongate the tree. At the end of the 4th 
month, the cytotrophoblast in the tertiary villi starts to disappear and the space between the 
capillaries and the intervillous space (IVS) is lined only by the syncytiotrophoblast layer. 
These villi are called free villi (Figure 1.6[V]). Very few studies have been conducted on the 
importance of chorionic villi development during pregnancy. 
 
1.1.2.3 Third trimester (Week 27 to 40) 
In the third trimester, the eCTB are almost absent. The iCTB cells invade two thirds of the 
myometrium. The tertiary villus system is maintained until the end of the pregnancy in order 
to maintain the surface for exchange. The capillaries move closer to the syncytiotrophoblast 
layers as seen in free villi, ensuring closer connection between the maternal and foetal blood 
circulations.  
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Figure 1.6: Different types of villus formation during placental development. 
 
[I] Lacunar stage shows formation of large spaces called lacunae in the syncytiotrophoblast layer. [II] Primary villus shows cytotrophoblast 
penetrating the syncytiotrophoblast. [III] The mesoblast from the foetal side fills up the cytotrophoblast forming the innermost core of the secondary 
villus. [IV] Foetal capillaries form a mesh in the mesoblast core of the tertiary villi. [V] The cytotrophoblast layer starts disappearing in the free villi 
thus reducing the distance between the foetal capillaries and the maternal circulation. [Figure adapted from www4] 
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1.1.3 Structure of full term placenta 
A mature full-term placenta is around 22cm in diameter with a central thickness of 2.5cm 
and an average weight of 470g (Huppertz, 2008). These parameters vary from one placenta 
to another, but the weight of it is directly related to the foetus. The placenta has two surfaces; 
the maternal and the foetal surface.  
 
• Maternal surface:  
The surface, attached to the uterine wall forms the maternal surface. It has an irregular 
surface lined with different trophoblast cells and maternal cells and covered with grooves 
and clefts as seen in Figure 1.7.A.  
 
• Foetal surface:  
The surface, which has an umbilical cord connected to its center, is the foetal surface (Figure 
1.7.B). It contains the chorionic plate which is covered by the amnion. The umbilical cord is 
a continuation of the chorionic vessels which arise from the chorionic mesenchyme. The 
chorionic arteries branch from the two umbilical arteries and supply the villous trees. The 
villous trees continue to the chorionic veins and finally to a single umbilical vein. 
 
 
 
Figure 1.7: Macroscopic anatomy of a normal placenta (28 weeks). 
 
[A] Represents the maternal surface; [B] Represents the foetal surface. [Figure adapted from 
www5] 
 
1.1.4 Function of placenta  
The fundamental function of the placenta is to nourish the foetus. The dense network of 
chorionic villi, lacunae, veins and arteries within the placenta allows it to temporarily 
perform the following functions for the embryo until its organs develop, or become 
functional after birth (Donnelly and Campling, 2010; Gude et al, 2004) (Figure 1.8): 
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• Gaseous exchange (foetal lungs) 
• Uptake of nutrients (gastrointestinal tract) 
o Glucose 
o Amino acids 
o Fatty acids 
o Calcium 
o Iron 
• Fluid regulation and elimination of waste metabolites (kidney function) 
• Release of steroid and peptide hormones (endocrine function) 
• Protection from xenobiotics.  
 
 
Figure 1.8: Exchange of materials between the mother and the foetus. 
 
[Donnelly and Campling, 2010] 
 
The maternal blood supplies the foetus with nutrients and gas and removes waste materials. 
However, there is no mixing of the foetal and maternal blood.  
 
1.1.5 Complications during placental development 
When compared to other mammalian species, human reproduction is not fully competent in 
establishing a fully functional placenta (Jauniaux and Burton, 2005). Failure in one of the 
key aspects of placentation can lead to abnormal placental development. Complications due 
to abnormal placentation in embryonic or second-trimester lead to foetal death and early 
pregnancy loss. Complications at the third trimester can lead to three severe diseases: pre-
eclampsia (PE), intra-uterine growth restriction (IUGR) and abruption (Chaddha et al, 2004). 
PE is the leading cause of perinatal death and is studied in detail in this thesis. 
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o Pre-eclampsia 
Pre-eclampsia (PE) is derived from the Greek word ‘eklampsis’, meaning sudden flash or 
development (Red-Horse et al, 2004). PE is a pregnancy disorder that is diagnosed in 2-3% 
of pregnancies in the third trimester (Lunghi et al, 2007).   
o Clinical features: 
Increased blood pressure and proteinuria are the distinctive clinical features of this disease. 
Systolic blood pressure (BP) ≥ 140 mmHg and /or diastolic BP≥90 mmHg range is seen in 
hypertensive patients. Proteinuria is confirmed when the protein in the urine is >300 mg in 
24 hours. PE may lead to IUGR in some cases (Fisher et al, 2009). A placenta in PE is 
smaller than in normal pregnancy (NT) as seen below in Figure 1.9.  
 
Figure 1.9: Structural differences in NT and PE placentae. 
 
The PE placenta is smaller in size when compared to NT placenta. [Figure adapted from 
Akhlaq et al, 2012] 
 
o Placentation in PE: 
Current evidence shows that the major factor for the cause of pre-eclampsia is poor 
placentation (Mohaupt, 2007) and the only cure for PE is removal of the placenta thus 
confirming this as the root cause (Centlow et al, 2010). Unlike normal placentation, poor 
placentation in PE is shown by inadequate intravascular invasion by the cytotrophoblast, and 
the resultant defective transformation of the maternal spiral arteries. The trophoblast 
invasion into the spiral arteries is shallow. Thus, the PE placenta remains in a state of high 
resistance. PE is also associated with defective plug formation and a thinner trophoblast 
shell. In a normal placenta, the blood flow takes place from the periphery where the plug 
formation is incomplete but in a PE placenta, the blood flow mostly takes place from the 
centre.  
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The spiral arteries of non-pregnant, normal pregnancy and PE vessels are compared in Figure 
1.10. The diameter of spiral arteries in normal pregnancy is four times greater than the 
diameter of the non-pregnant vessels and that of PE are half of the diameter of normal 
pregnancy.  
 
 
Figure 1.10: Difference in the diameters of spiral arteries in non-pregnant, normal 
pregnancy and pre-eclampsia. 
 
[Figure revised from Moffett-King, 2002 and Red-Horse et al, 2004] 
 
The defective remodeling of spiral arteries may be due to the combination of defect in EVT 
differentiation to the invasive type, rise in apoptosis rate, uncontrolled migratory and 
invasive function of EVT, and failure of cells to adopt endovascular properties. The net result 
is poor formation of the placenta and thus miscarriages. The trophoblasts in PE were found 
to be immature intermediates that failed to aggregate together to form sheets on the spiral 
arteries (Redline and Patterson, 1995; Fisher et al, 2009). These immature trophoblasts 
remain in round clusters thus leading to irregular oxygen tensions, which eventually cause 
oxidative stress and formation of reactive oxygen species (ROS). These events cause the 
maternal body to respond providing clinical features like hypertension and proteinuria 
(Fisher et al, 2009). 
o Immune mechanism in pre-eclampsia 
Placentation involves specific maternal immune responses to fetal alloantigens. Human 
trophoblast has limited expression of strong Human Leukocyte Antigens (HLA) and express 
only HLA-E, F, and G (Redman and Sargent, 2010). HLA-G regulates the cells of the 
maternal immune system to accommodate the foetus, by suppression of CD4+ and CD8+ 
proliferation, regulating the regulatory T-cells [T(reg)], B cells, NK cells and inflammatory 
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cells (macrophages and dendritic cells). Any impairment in this immune system at its early 
stages of development may cause PE. T(reg) cells of the decidua have short term memory of 
the paternal HLA-C which down-regulates the anti-paternal responses (Redman and Sargent, 
2010). Thus, PE is predominantly a disease of the first partum. 
In summary, the normal placentation is a highly invasive process, which is tightly controlled 
in such a way to be a transient event. On the other hand, in PE placentation, the invasion is 
not fully complete.  
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As mentioned at the beginning of this chapter (Section 1.1), the process of invasion during 
tumorigenesis has similar characteristics with trophoblast invasion during placental 
development, particularly in the first trimester of pregnancy (Ferretti et al, 2007; 
Soundararajan and Rao 2004). The following section will briefly discuss the invasive process 
during tumorigenesis and compare the subtle differences between the two. 
 
1.2 Tumour 
A tumour is defined as an abnormal mass of tissue formed by uncontrolled division of cells. 
This uncontrolled division takes place due to mutations in the cells leading to defective repair 
mechanisms. They can be of two types: benign (cause no threat to the body) or malignant 
(leading to serious damage to body and ultimately death of the patient). Cancer is one of the 
leading cause of worldwide death in recent years (www6). Therefore, there is a critical need 
for exploring new avenues of therapeutic modalities. 
1.2.1 Hallmarks of cancer 
Six vital alterations in the cell physiology were proposed by Hanahan and Weinberg, in the 
year 2000, for the transformation of normal cells to malignant cells (Figure 1.11). These 
‘hallmarks’ are shared by most of the tumour cells and are essential for their growth and 
metastasis (Hanahan and Weinberg, 2011). These six hallmarks are described below. 
 
Figure 1.11: Hallmarks of Cancer. 
The figure represents the 6 characteristic changes taking place in cancer cells for its growth 
and transformation. [Adapted from Hanahan and Weinberg, 2011] 
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1. Sustaining proliferative signalling 
Mitogenic growth signals are required by normal cells to transform from a quiescent state to 
an active proliferative state. These growth signals are transmitted by diffusible growth 
factors, extracellular matrix components and cell-to-cell adhesion/interaction molecules 
which bind to transmembrane receptors on healthy cells. In the absence of these growth 
signals the normal cells perish and die (Hanahan and Weinberg, 2011). Changes in the 
internal environmental condition switch tumour cells to an autocrine production of growth 
signals (Herzig and Christofori, 2002). For example glioblastomas and sarcomas produce 
PGDF (platelet derived growth factor) and TGF α (tumour growth factor α) respectively to 
which they become responsive, creating autocrine stimulation. Alternatively, there are also 
mutations in the signal transduction pathway that lead to production of mitogenic signals. 
The growth receptors on the surface of the cells also undergo alterations, which lead to up-
regulation of these receptors on tumour cells (Kroll et al, 2010).  
 
2. Evading growth suppressors  
Proliferation in normal cells are controlled by growth suppressors that force healthy cells 
into the quiescent (G0) state from an active state or signals cells to permanently abandon 
their proliferative state by entering into a postmitotic state. Hanahan and Weinberg (2011) 
state that emerging tumour cells must evade anti-proliferative signals in order to drive 
malignant growth. Also inactivation of tumour suppressor genes in many human and animal 
cancers have been reported that stops cell growth and proliferation.  
 
3. Resisting cell death 
A stable rate of cell proliferation and cell death helps to maintain the growth of normal 
tissues. Apoptosis (programmed cell death) is the most common pathway followed by dying 
cells.  A variety of physiological signals triggers a cascade of proteins that lead to the 
disruption of the cell membrane, breaks down the cytoplasmic and nuclear components, 
degrades chromosomes and fragments nucleus. Almost all tumour cells develop an ability to 
evade apoptosis by down regulating proapoptotic factors (such as Bax, Bim, and Puma), and 
increasing the expression of anti-apoptotic regulators (Bcl-2, Bcl-xL) or that of survival 
signals (Igf1/2) (Hanahan and Weinberg, 2011). 
 
4. Enabling replicative immortality 
Normal cells have a definite potential to replicate but at some point they lose their ability to 
divide and enters senescence (Hanahan and Weinberg, 2011). It has been reported, tumours 
can prevent senescence by inactivating their tumour suppressor proteins (p53 and pRb) 
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which leads to uncontrolled cell division and growth of the tumour (Herzig and Christofori, 
2002).  In addition, a progressive shortening of telomeres after each cell cycle may also lead 
to cell death. In cancer cells, the overexpression of telomerase surmounts telomere 
shortening and ultimately leads to indefinite cell proliferation (Kim et al, 1994). 
 
5. Inducing angiogenesis 
The major problem confronted by a growing tumour mass is the supply of oxygen and 
nutrients (Kroll et al, 2010). Cells closer to the blood vessels grow, while cells further away 
from the blood vessels degrade. In order for a tumour mass to grow, increased blood supply 
is required. This is achieved by formation of new blood vessels from pre-existing vessels, a 
process known as angiogenesis (Otrock et al, 2007; Buschmann and Schaper, 1999). 
Angiogenesis is also required for metastasis of the tumour cells (Herzig and Christofori, 
2002). Tumour angiogenesis begins with the secretion of angiogenic factors from the tumour 
cells, which proceed to stimulate the neighbouring tissues. This leads to production of 
proteins, which further encourage the formation of new blood vessels. Vascular endothelial 
growth factor (VEGF), angiopoietins and fibroblast growth factors are some of the 
angiogenic factors released by tumours. Inflammatory cells, which infiltrate the tumour site 
and the surrounding fibroblast cells, also add to the secretion of angiogenic factors. With the 
secretion of angiogenic factors and proteases like MMPs, the vascular basement membrane 
(VBM) of the blood vessels undergoes structural changes to form a provisional matrix. 
Proliferation and migration of endothelial cells occurs with the formation of this matrix. 
Production of growth factors leads to transition of the provisional matrix to intermediate and 
ultimately to mature new VBM. In presence of the pericytes and endothelial cells, VBM 
leads to formation of new blood vessels. Formation of new blood vessels supplies more 
blood, along with nutrients and oxygen to the tumour, resulting in growth and proliferation 
of the tumour cells (Carmeliet and Jain, 2000; Francavilla et al, 2009). 
 
6. Activating invasion and metastasis  
During the different stages of cancer, tumour cells start invading neighboring tissues and 
organs. This invasion can be due to mechanical as well as enzymatic process. In the 
mechanical process, growth of tumour mass increases pressure on the surrounding cells 
leading to invasion. In the enzymatic process, the growing tumour cells secrete some 
proteolytic enzymes [such as matrix metalloproteinases (MMPs)], which degrade the 
extracellular matrix (ECM) barrier and destroys the neighboring cells (Otrock et al, 2007).  
Metastasis is the spread of the tumour from the site of origin to secondary sites. This usually 
occurs at the end-stage of the disease (Schedin and Elias, 2004). These metastatic cells 
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degrade the basement membranes (BM) of the primary site and starts invading the 
neighbouring cells and tissues. Likewise single tumour cells can also invade the blood 
vessels (or the lymphatic vessels), a process called intravasation. These cells are carried 
along with the flow of the blood (or the lymph) till they are blocked either by the bone 
marrow, the lymph nodes or the blood vessels of the secondary sites (Schedin and Elias, 
2004; Herzig and Christofori, 2002). At the secondary sites, the cells attach to the vessel 
walls and by degrading the vessel wall, the tumour cells evade out from the BVs, a process 
termed extravasation. Tumour cells may immediately start growing or may remain in a state 
of dormancy for many months or years at the secondary site. When favourable stimuli are 
secreted, dormant tumours start proliferating again. 
Four new additional hallmarks were stated by Hanahan and Weinberg in 2011 and these are 
specified below.  
 
7.  Deregulating cellular energetics 
In normal respiring cells, the glucose is converted to pyruvate by glycolysis followed by the 
TCA cycle   to produce ATP and carbon dioxide via the respiratory chain in the 
mitochondria. However, during anaerobic conditions, glycolysis alone is to reduce the 
oxygen usage. This results in the accumulation of lactic acid (Warburg metablism). This 
effects is observed in tumour cells even with the presence of oxygen resulting in around 18 
fold reduction in ATP production. This deficit of ATP is compensated by tumour cells by 
upregulating glucose transporters (i.e. GLUT-1), and thus increasing the glucose uptake into 
the cell (Jones and Thompson, 2009; Hsu and Sabatini, 2008; DeBerardinis et al, 2008).  
8.  Avoiding immune destruction 
Tumour cells create a microenvironment by which they escape the immune response 
(Kaufman and Disis, 2004). Tumour cells can regulate the secretion of 
cytokines/chemokines, the expression of growth factor receptors and the homing of 
regulatory cells. They can also release vesicular bodies which carry “molecular messages” 
of the tumour (Whiteside, 2009). They interact with dendritic cells (DC) and produce tumour 
signals (Bennaceur et al, 2009). The local DCs are usually immature, therefore incapable of 
processing the tumour cells for destruction. Moreover, regulatory T cells (T-regs) infiltrate 
the tumour sites and suppress the T-cell binding to antigens. In addition to this, the phenotype 
of helper CD4 is also directed towards Th2 pathways to inhibit cellular immunity. As a result 
of these changes, antigen presentation is hindered and expression of MHC molecules on the 
surface of tumour cells is altered, making them invisible for the immune system. Finally, 
tumour cells secrete cytokines such as IL-6, IL-10 and Transforming growth factor-beta 
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(TGF-β), which help in further suppressing the immune response. In some organisms, such 
as lower vertebrates, the above stages alone can lead to a cancerous form of tumour 
(cancerous forms are usually the end-stage tumours which are fatal to the organism). 
However, in higher organisms like humans, metastasis and angiogenesis are necessary for 
the tumour to become cancerous (Kroll et al, 2010). 
9. Genomic instability and mutation 
Mutations of cells can lead to selective subclones in a microenvironment and thus cause its 
dominance and outgrowth. Multistep tumour progression is believed to be a succession of 
clonal expansions, each triggered by the acquisition of a mutant genotype (Hanahan and 
Weinberg, 2011). DNA repair mechanisms detect and resolve any defects in the DNA to 
ensure that the rate of spontaneous mutations are kept low after every cell replication. In 
cancer cells there is increase rate of mutation either due to its sensitivity to mutagenic agents 
or the breakdown of the DNA repair mechanism which ultimately leads to tumour formation 
(Negrini et al, 2010; Salk et al, 2010).  
10. Tumour promoting inflammation 
Cells of the immune system infiltrate the tumour and lead to inflammations (Pages et al., 
2010). Most of the cells in the inflammation may contribute to some of the hallmarks of 
cancer by supplying growth factors, proangiogenic factors, matrix-metalloproteinases and 
survival factors (DeNardo et al, 2010; Karnoub and Weinberg, 2006; Grivennikov et al, 
2010; Qian and Pollard, 2010).  
 
 
1.3 Placentation vs. Tumorigenesis 
Even though placenta is a normal temporary organ, the trophoblast especially in the first 
trimester gives the placenta ‘pseudo-malignant’ and ‘physiological metastasis’ 
characteristics. As seen in Figure 1.13 both the placentation and tumorigenesis starts with a 
highly invasive mass of cells.  
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Figure 1.12: The close resemblance of the blastocyst and a tumour at their early stage 
of development. 
 
1.3.1 Resemblance of placenta to tumour 
There are certain cellular processes and molecular circuits, which are common to both 
tumour and placental cells.  Some of these processes are summarised below.   
 
1.3.1.1  Cell invasion  
The tumour cells manipulate the extra cellular matrix (ECM) network at various stages and 
thus invade the normal cells. Cell invasion involves binding of cells to the ECM components 
(e.g. type II collagen, fibronectin and laminin) through integrin and/or non-integrin 
receptors; degradation/manipulation of ECM using enzymes [such as MMPs and urokinase 
type plasminogen activator (uPA)]. uPA is required for activation of some MMPs. Finally, 
migration of the cells through the degraded ECM takes place [which requires α5β1 integrin 
and asparagine (Asn) linked oligosaccharides on the cell surface] (Lala et al, 2002).  
Placentation, like tumour invasion, is a multi-step process that involves the attachment of 
the trophoblast to the ECM, degradation of ECM and migration through the degraded ECM.  
Trophoblast is the first epithelium that develops during placentation and acts as the prototype 
for the later epithelial developments. Trophoblast cells are often referred to as ‘pseudo-
malignant’ due to their highly proliferative nature, their escape from the immune response, 
and their migration and invasion of neighbouring tissues (Ferretti et al, 2007). As explained 
in Section 1.1.1.3, a specific sub-population of the trophoblast called the “extravillous 
trophoblast” (EVT) is involved in the uterine endometrium invasion. Like any other invading 
/ tumour cell, the EVT requires proteases to digest its surrounding environment, thus 
becoming invasive in nature (Bischof et al, 2003).  
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Matrix metalloproteinases such as MMP2 and MMP-9 and their inhibitors (tissue inhibitor 
of metalloproteinases - TIMP) play an important part in EVT invasion (Cohen et al, 2006). 
The expression of TIMPs regulates the invasion of trophoblasts by inhibiting the activity of 
MMPs. Moreover, trophoblast cells that are destined for further invasion of the neighbouring 
cells modulate their surface proteins (e.g. integrins like α6β4 and α1β1) which help migration 
through the degraded ECM (Bischof et al, 1995; Damsky et al, 1994). 
 
1.3.1.2   High rate of cell proliferation  
In cancer cells, the overexpression of telomerase surmounts telomere shortening and 
ultimately leads to indefinite cell proliferation (Kim et al, 1994). Unlike other somatic cells 
(and like cancer cells), human trophoblast cells also express telomerase and undergo 
undefined cell proliferation during the early stages of placentation (Chen et al, 2002). These 
high rates of proliferation are essential for normal functioning and development of placenta. 
However, the expression of telomerase is stopped once the placenta is established. This 
makes placentation a controlled phenomenon. There is also the presence of numerous growth 
factors and growth factor receptors in both trophoblastic and malignant cells (Ferretti et al, 
2007). This suggests that an autocrine or paracrine loop may also assist the high rate of 
proliferation in these cell types. Some of the important loops are epidermal growth factor 
(EGF)/EGF Receptor (EGFR), VEGF/VEGF Receptor (VEGFR), Platelet derived growth 
factor (PDGF)/PDGF Receptor (PDGFR) and Colony Stimulating Factor1 (CSF1)/CSF1 
Receptor (CSF1R). These loops further interrelate with the mitogen-activated protein kinase 
(MAPK) signalling pathways. 
 
 Avoiding apoptosis 
The rapid growth of tumour and placenta is not only due to high cell proliferation, but also 
to avoidance of apoptosis. By balancing the expression of apoptotic detecting signals like 
growth factors and sensors, these cells maintain their integrity. Amongst the numerous 
important signals and detectors, the insulin-like growth factor-1 (IGF-1) and its receptors 
have come into the limelight. It has already been proved that the expression of these signals 
increases proliferation as well as the metastasis of malignant cells (Ferretti et al, 2007). 
However, the signals have shown only proliferative improvement in trophoblast cells. In 
addition to these signals, it has been discovered that like tumour cell, trophoblast cells 
express anti-apoptotic proteins (e.g. survivin) (Fest et al, 2008). 
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1.3.1.4  Escape from the immune system 
As explained in Section 1.2, tumour cells cover up surface antigens or shed surface proteins 
that would lead to their detection by the lymphocyte T cells. This helps tumour cells to 
escape immune detection. In the same way, the embryo is semi-allogeneic to the mother. 
Despite the genetic differences between the mother and the developing embryo, the immune 
system of the mother does not reject the embryo. This is achieved by various hormones and 
proteins secreted during pregnancy that blocks the mother’s immune response against the 
embryo (Beer and Billingham, 1974). The maternal blood and lymphatic system is also 
separated from the foetus by the placenta. The foetal trophoblast cells escape the maternal 
immune surveillance as they fail to express MHC molecules on their surface (Ferretti et al, 
2007). 
 
1.3.1.5  ‘Pseudo-Vasculogenesis’ in placenta 
Tumour cells and the embryo require new blood supply in order to grow. This is achieved 
by the process of angiogenesis. Angiogenesis switches to an invasive phase due to the 
secretion of proteins like basic Fibroblast Growth Factor (bFGF) and VEGF during tumour 
growth. Expression of these factors is also seen in human trophoblast cells (Hamai et al, 
1998).  
 
1.3.1.6  Oncogenes in human placenta 
Oncogenes are responsible for undefined cell proliferation, which leads to cancer. These are 
altered forms of the proto-oncogenes, which include growth factors and their receptors, 
nuclear transcription factors, proteins involved in the control of the cell cycle and 
intercellular signal transducers (Bischof and Campana, 2000). Some of these factors and/or 
receptors are also expressed in placenta and are discussed as follows. 
• Growth factors 
PDGF is one of the products of oncogenes. The β chain of PDGF is encoded by the c-sis 
proto-oncogene which is expressed during trophoblast proliferation. Interestingly, it is also 
reported to be expressed by a variety of cancer cell lines (Goustin et al, 1985). 
• Growth factor receptors 
Cancer cells have several growth factor receptors. Receptors such as Macrophage-Colony 
Stimulating Factor Receptor (MCSF-R), EGFR and VEGFR are encoded by the proto-
oncogenes c-fms, c-erb B and c-flt, respectively. These proto-oncogenes are also involved 
in trophoblast proliferation and invasion. Another proto-oncogene, HER-2/neu (c-erbB2), 
which belongs to a family of EGFR, has been found to be expressed in high levels in 
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placental, foetal epithelial cells and in human carcinomas (Quenby et al, 1998). Studies 
carried out on normal placenta, gestational choriocarcinoma and partial mole samples have 
shown the presence of c-erbB3 and c-erbB4 genes (Tuncer et al, 2000). In addition, c-met 
(which encodes for hepatocyte growth factor receptor) and c-kit (which encodes for mast 
cell growth factor receptor), also belong to the receptor tyrosine kinase family and are found 
to be present in both cancer cells and in placenta (Kauma et al, 1997; Doneda et al, 1997). 
• Transcription factors 
The proto-oncogenes c-jun and c-fos form a transcriptional complex called AP-1 complex 
(Activator Protein-1). Studies have demonstrated that AP-1 is necessary for the expression 
of MMP-9 during trophoblast invasion (Bischof et al, 2003). Fos and Jun are abundantly 
expressed by trophoblast cells. A binding site for Fos-Jun can be found on the promoters of 
MMPs (e.g. MMP-9). Thus, any changes in the expression of the Fos and Jun oncogenes 
alter the levels of MMPs and ultimately lead to changes in invasion by the trophoblasts 
(Soundararajan and Rao, 2004). 
One of the most important proto-oncogenes is c-Myc. The product of c-Myc is a transcription 
factor which is required for cell cycle progression. c-Myc expression promotes the 
expression of hTERT, which in return helps with the undefined proliferation of cancer cells. 
Interestingly, c-Myc acts in similar fashion during trophoblast proliferation (Quenby et al, 
1998). All of these proto-oncogenes, factors and proteins function as a complex network 
controlling proliferation, invasion and metastasis of neoplastic cells as well as trophoblast 
cells (Holtan et al, 2009). Figure 1.14 summarises the parallels between the molecular circuit 
of the maternal-foetal interface in placenta and the microenvironment of the tumour where 
the secretion and expression of various oncogenes, angioproteins and other factors maintain 
both the early pregnancy and the tumour growth. 
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Figure 1.13: Resemblance of the microenvironment in placenta and tumour. 
 
 [Figure adapted from Holtan et al, 2009]. 
 
1.3.2 Differences between placenta and tumour 
Like tumorigenesis, placentation follows the same processes of invasion and migration. 
However, placentation is a temporary malignancy, whereas tumorigenesis is an indefinite 
malignancy. In other words, the placenta “knows” exactly where and when to stop cell 
proliferation and its tumorigenic features are only temporary. It is for this reason that 
placenta is often described as a 'well-behaved' tumour (Soundararajan and Rao, 2004).  
Trophoblast cells are highly invasive in the first trimester of pregnancy (12 weeks p.c.). 
Nonetheless, they lose their invasiveness as the pregnancy progresses. Only one-third of the 
myometrium is invaded and this stops by the second trimester. Conversely, the tumour cells 
continuously invade their surroundings. Unlike cancer cells, EVT cells senescent after 5-15 
passages (during cell culture) and become anchorage-dependent (Lala et al, 2002). The 
terminal trophoblast undergoes a programmed differentiation at the end phase of placental 
development. This programmed event is regulated by changes in gene expression and 
hormones secreted during pregnancy leading to apoptosis. The differentiation of trophoblast 
also leads to the loss in telomerase activity through suppression of hTERT by TGFβ1. This 
allows the cells to become mortal again. Some of the proto-oncogenes, which participate 
during trophoblast proliferation like c-Myc, are also regulated during the differentiation 
phase (Quenby et al, 1998).  
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Furthermore, the secretion of hormones such as oestrogen and gonadotropin releasing 
hormone control the differentiation of the trophoblast cells. Therefore, there are various 
intrinsic and extrinsic factors that control the transient nature of the trophoblast. There is 
thus a firm demarcation between tumour as a disease and placentation as a normal 
development by the end of the first trimester as variations in gene expression arise.  
 
1.4 New avenues for exploration 
The variations in gene expression in tumour and placenta provide a new avenue for 
exploration. Due to the multifunctional nature of placenta, it expresses more than 20,000 
DNA sequences (Centlow et al, 2010). For this reason, placenta has been the target organ 
for investigating and identifying new genes. Genomic and proteomic studies are being 
performed on human placental samples to study the functions of the genes in placenta. 
Cancer-testis antigens and 5-hydroxytryptamine (serotonin) receptors are among the several 
genes expressed by placenta.  
Cancer-testis antigen is a type of tumour antigen that is expressed only by cancer cells and 
reproductive tissues such as testis and placenta (e.g. NY-ESO-1) (Scanlan et al, 2002). In 
recent years, cancer-testis (C/T) antigens have become the target for designing therapeutic 
vaccines for cancer treatment. Hence, the study of these antigens in placenta could reveal 
their molecular actions and this may lead to identification of certain targets for vaccine 
production. 
Similarly, researchers have pointed out that 5-hydroxytryptamine (5-HT) and its receptors 
may have a fundamental role in placental development and pregnancy maintenance (Oufkir 
et al, 2010). Bolte et al, 2001 have shown that 5-HT influences the early extravillous 
trophoblast (EVT) and endothelial layer of the spiral arteries via 5-HT1B or 5-HT2A 
receptors. However, there is not enough information on (a) the effects of 5-HT on early 
trophoblast (EVT) invasion and (b) the changes in the expression profiles of different 5-HT 
receptors produced by increased 5-HT during this invasion. Since 5-HT is important for 
migration and proliferation, it would also be interesting to investigate the effects of 5-HT on 
the expression profiles of different C/T antigens. 
 
1.4.1 Expression of C/T antigens 
The mRNA expression of C/T antigens is observed only in few normal tissues like ovary, 
placenta and testis. This restricted expression of C/T antigens suggests that there are some 
common mechanisms between these tissues. Testis is the only organ which shows expression 
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for all the C/T antigens. Moreover, the level of expression is higher in testis than in any the 
other somatic tissue. Due to this restricted expression, C/T antigens have been interesting 
targets for the development of cancer vaccines (Li et al, 2005).   
The different mRNA expression studies of these C/T antigens have so far revealed the 
following (Scanlan et al, 2002): 
• Individual C/T antigen shows variable frequencies of expression in different cancer 
histotypes with melanoma showing the highest frequency of expression. 
• Different C/T antigens show variable frequencies in single tumour types. 
• Certain tumours show expression for a group of C/T antigens, while others show no 
expression of the C/T antigens suggesting that the expression of C/T antigens is 
clustered. 
• Different stages of tumour development show various expression frequencies for C/T 
antigens, thus the expression of C/T antigens correlates with tumour progression. 
 
It should be noted that the expression patterns for mRNA cannot always be linked to protein 
expression patterns. However, due to the limited availability of monoclonal antibodies 
against C/T antigens, very few studies have demonstrated the expression of C/T antigens at 
the protein level (Miles et al, 2007; Mathieu et al, 2009; Linley et al, 2012). 
 
1.4.1.1   Characteristics of C/T antigens 
For a tumour antigen to be classified as C/T antigen, it should possess the following 
characteristics (Scanlan et al, 2002): 
• Expressed only by gametogenic and cancer tissues. 
• Heterogenous proteins are expressed due to multigene families. 
• The coding gene often maps to Chromosome X. 
• Produces an immune response in cancer patients. 
• Expression is controlled by DNA methylation and histone modifications 
• Expression is associated with tumour metastasis and progression. 
 
1.4.1.2   Functions of C/T antigens 
The functions of the C/T antigens in gametogenic tissues and cancer are still not understood, 
but are often allocated according to the sequence homology of a closely related protein 
(Kalejs and Erenpreisa, 2005). The proposed functions of these antigens are: 
• as part of spermatozoa components, 
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• as part of synaptonemal complex components, 
• to play a role in regulating transcription, 
• to participate in the signal transduction, 
• to perform functions of helicase, 
• involved in cell-cell interaction 
• involved in enzymatic reactions, 
• and apoptosis inhibition. 
The products of these genes are also believed to participate in various biological processes 
such as chromosomal recombination, signal transduction and translation (Linley et al, 2012; 
Mathieu et al, 2014). It is still not understood if the expression of these genes plays a role in 
tumorigenesis or if they are produced after the transformation of normal cells to tumour cells. 
Since cancer cells share features with placentation or gametogenesis, the C/T genes 
expressed in gametogenesis may give similar features to cancer cells. 
 
1.4.1.3  CT antigens of interest 
Although many different C/T antigens have been studied by various immunologists, with 
interesting results (Miles et al, 2007; Mathieu et al, 2009; Linley et al, 2012), some novel 
C/T antigens whose functions and expressions in different normal tissues have not yet been 
investigated. Fifteen C/T antigens were selected as C/T antigens of interest. These 15 
antigens were selected according to their functions and importance in placenta (summarised 
in Table 1.1).  
The techniques for identifying tumour antigens have dramatically changed over the years. 
The research has advanced from T-cell cloning and SEREX (serological identification of 
cDNA expression libraries) to more complex methods like representative difference analysis 
(RDA), differential display (DD), suppression subtractive hybridization (SH) and 
bioinformatics. Thus, it is difficult to clearly define the C/T antigen products as ‘antigens’, 
as some of these techniques are only based on mRNA expression and do not depend on the 
demonstration of immunogenicity.  
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Table 1.1: C/T antigens of interest for comparative studies in NT and PE placentae. 
*antigens identified at John van Geest Cancer Research Centre, NTU 
[Data summarised from Jungbluth et al, 2007; Monte et al, 2006; Cho et al, 2002; Gnjatic 
et al, 2006; Mathieu et al, 2009; Miles et al, 2007] 
 
 
Further information on these C/T antigens are given below.  
 CAGE (Cancer-Associated Gene) 
A novel cancer/testis antigen gene, CAGE (cancer-associated gene) was identified by 
Bomsoo Cho and colleagues using SEREX (Cho et al, 2002). CAGE protein was found 
mostly in the nucleus and was confirmed to be localised on chromosome X (Xp22.11). 
CAGE is also known as DDX53 as it encodes a DEAD box domain. It was also found to 
have no introns and exists as a single copy. CAGE protein is approximately 75 kDa (630 
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amino acids) in size. Among other helicase proteins, CAGE shows homology to p72, p68 
and HAGE, out of which HAGE is also a C/T antigen.  
 Expression 
 CAGE is expressed in testis and cancer cells with negligible expression in other normal 
tissues. Demethylation of its promoter activates its transcription, which is increased in 
tumour cells. However, methylation status does not always directly correlate with increased 
CAGE expression, suggesting that there are other factors involved in its expression. 
Although the expression of CAGE was studied in normal tissues by Cho et al (2002), 
placenta was not included in their study.  
 Function 
Proteins containing DEAD box domains are associated with a family of enzymes called 
helicases. These proteins play a major role in RNA metabolism, spermatogenesis and 
cellular growth. It has also been reported that CAGE activates the extra-cellular signal-
regulated kinases ERK and p38 MAPK, therefore promoting cell motility (Kim et al, 2010). 
CAGE, therefore, enhances invasion potential whilst down-regulating the expression of p53, 
which hinders apoptosis. 
 
 CAGE1 (Cancer Antigen 1) 
Cancer antigen 1 (CAGE1) is different from the cancer-associated gene (CAGE). CAGE1 is 
also known as cancer/testis antigen 95 and cancer/testis antigen 3 (CTAG3/CT3). CAGE1 
encodes a long coiled coil domain (Alsheimer et al, 2005). No signal peptide was found for 
the localisation of CAGE1 into the lumen of acrosomes. It is located in chromosome 6 
(6p24.3).  
 Expression 
CAGE1 is expressed in cancer tissues and testis. There was nothing in the literature to 
confirm the expression of CAGE1 in placenta. CAGE1 was seen to be expressed during post-
meiotic stages of spermatogenesis.  
 Function 
Due to its coiled coil domains, CAGE1 may function as a structural protein for acrosomes 
thus enhancing spermatogenesis. 
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 Melanoma Antigen (MAGE-A) subfamily 
MAGE-A belongs to the MAGE-I family along with MAGE-B and MAGE-C groups. 
MAGE-A is the first group of C/T antigens to be cloned successfully by Van der Bruggen et 
al in the early 1990s from a melanoma patient; hence the annotation, melanoma antigen 
(Sang et al, 2011). MAGE-A also forms the largest subfamily with 12 members encoding a 
common domain (Mage Homology Domain; MHD). MAGE-A genes were found to be 
expressed in different forms of cancer and restricted expression to testis, ovary and placenta 
amongst normal tissues. The MAGE-A family forms a locus at q28 of chromosome X and 
contains one protein-coding exon with several noncoding exons preceding it (Artamonova 
and Gelfand, 2003). 
o MAGE-A1 
Melanoma antigen-1 (MAGE-1) was the first member of the MAGE-A family to be 
identified.  It was isolated from a MZ-2 human melanoma cell line. It was later defined as 
MAGE-A1.  
 Expression 
MAGE-A1 is the most frequently expressed C/T antigen. The increase in MAGE-A1 protein 
was correlated with an increase in the clinical stages of cancer patients (Zhang et al, 2010). 
The MAGE-A1 is activated by DNA methylation.  
 Function 
MAGE-A1 protein is found to repress the transactivation function of p53 (Monte et al, 2006). 
It has also been found that the MAGE-A1 binds to the transcription regulator SKI-interacting 
protein (SKIP), which is involved in several signaling pathways. It is implicated in cell 
differentiation during spermatogenesis.  
o MAGE-A3 
MAGE-A3 expression was found to be correlated with elevated levels of plasmocytes 
proliferation in multiple myeloma patients (Jungbluth et al, 2007). MAGE-A3 has also been 
shown to bind to pro-caspase-2, thus hindering its activation and providing a protection to 
the cancer cells by inactivating the apoptotic pathway (Sang et al, 2011).  
o MAGE-A4 
The carboxyl terminal (107 amino acids in length) of MAGE-A4 was found to induce 
apoptosis by both p53-dependent and p53-independent mechanisms. Blocking of the up-
regulation of p21 by MAGE-A4 leads to the inhibition of the p21-mediated cell cycle arrest. 
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However, no such changes were observed using intact MAGE-A4 protein (Sang et al, 2011). 
It is therefore believed that intact MAGE-A4 acts more like a tumour suppressor than an 
onco-protein.  
 
 Per ARNT Sim domain containing1 (PASD1) 
PASD1 is a diffuse large B-cell lymphoma (DLBCL)-associated C/T antigen thus showing 
a wide range of expression patterns in hematological malignancies. PASD1 contains a PAS 
domain, an aryl-hydrocarbon receptor nuclear translocator (ARNT) domain and a nuclear 
receptor recognition motif (LXXLL) (Campbell et al, 2011). Various isoforms of PASD1 
have also been reported. PASD1 is also seen to be located on chromosome X position q28 
like MAGEA family members. 
 Function 
PASD1 is assumed to act as a transcription factor, but nothing is known about its definite 
function. Due to the presence of three domains (PASD1, ARNT and LXXLL), it is predicted 
to mediate responses to environmental stimuli (Campbell et al, 2011).  
 
 GAGE (G melanoma antigen) Family 
G melanoma antigen (GAGE) family consists of 8 members and can be divided into three 
groups based on different features (Gjerstorff et al, 2006). The three groups include GAGE-
1; GAGE-2, and -8; and GAGE-3, and -7. These genes encode highly identical acidic 
proteins (Gjerstorff et al, 2008). Like other C/T antigens, transcription of GAGE proteins is 
correlated with hypo-methylation of their promoters. Immunohistochemistry staining of 
normal tissues by monoclonal antibodies to GAGE reveals expression in oocytes and in 
primary spermatocytes (Gjerstorff et al, 2006). GAGE-1 is the only C/T antigen showing 
expression in oocytes of both the resting and mature ovary. GAGE expression is seen during 
the second trimester. However, its expression is down-regulated when the primary 
spermatocytes mature to secondary spermatocytes. Due to its localization in the nucleus of 
spermatocytes, it is seen as a regulator of germ line cells. GAGE genes may inhibit apoptosis, 
but the functions of GAGE genes are not clearly understood. It is believed that GAGE 
proteins have evolved recently by positive selection (Gjerstorff et al, 2008). This family is 
rapidly expanding, leading to many paralogous genes.  
o GAGE-1 
Among GAGE genes, only GAGE-1 antigen possesses a unique exon encoded C-terminal. 
GAGE-1 also lacks a phosphorylated tyrosine (Y9) which is present in other GAGE family 
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members. GAGE-1 is expressed in melanoma and lung adenocarcinomas. It is located in 
between p11.23-p11.22 of chromosome X.  
o Prostate Associated Antigen 4 (PAGE-4/ GAGE-C1) 
PAGE-4, also known as GAGE-C1 is a gene belonging to a gene family homologous to GAGE 
along with five other members (PAGE-1, -2, -2B, -3 and -5). PAGE family genes are small 
proteins with 102-146 amino acids revealing highly charged/ hydrophilic residues and 
hydrophobic residues [intrinsically disordered proteins (IDPs)] (Hellman et al, 2011). Due to 
divergence in expansion, PAGE-4 is significantly different from the GAGE family, although 
they have conserved introns and exons. GAGE and PAGE families show common ancestry, 
nonetheless the identity is only 55%. PAGE-4/ GAGE-C1 is also located on chromosome X 
in between p11.23-p11.22 like GAGE-1. It is characterized as a disordered protein with a 
nuclear localisation signal at its N-terminal. 
 Expression 
In addition to expression in tumour, testis and ovary tissues, PAGE-4 is also found to be 
expressed in placenta, prostate and uterus (Sampson et al, 2007). PAGE-4 is up regulated by 
TGFβ in prostatic cells. However, the TGFβ-mediated expression of PAGE-4 is not prostate 
cell-specific, as similar patterns were observed in JEG3 (a choriocarcinoma cell line).  
 Function 
Differences in the function of GAGE and PAGE protein families are expected due to 
differences in protein structures. The function of PAGE-4 is still not clearly understood. It 
can bind double stranded DNA (dsDNA). Anti-apoptotic properties have been highlighted 
recently for PAGE-4 (Sampson et al, 2007).  
• Prostate Associated Antigen 5 (PAGE-5/GAGE-E1) 
PAGE-5, also known as GAGE-E1, has recently been studied by NMR with a view to 
characterizing the protein and its function (Hellman et al, 2011). It consists of 130 amino 
acids, and the monomeric form of the protein is only 11kDa. Like PAGE-4, PAGE-5 is also 
a highly disordered protein, but with few predominant secondary structures. It is proposed 
that these secondary structures act as interaction sites for PAGE-5 in cancer and germ cells. 
PAGE-5 is located at p11.21 on chromosome X.  
 Foetal and Adult Testis Expressed 1 (FATE-1) 
FATE-1 was previously known as BJ-HCC-2 due to its high expression in hepatocellular 
carcinoma. It is mapped to chromosome Xq28. FATE-1 promoter encodes two binding sites 
for steroidogenic factor-1 (SF-1), which is a sex determining and differentiation factor.  
 Expression 
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Immunohistochemical analysis has revealed high expression of FATE-1 in germ cells and 
sertoli cells present in the seminiferous tubules (Yang et al, 2005). Staining was stronger in 
spermatogonia and in primary spermatocytes and gradually decreased with maturation of the 
spermatogonia. This pattern of expression was also seen in the GAGE family. Very faint 
staining was observed in Langerhans’ islet cells with practically no staining being apparent 
in other normal tissues.  
The mRNA expression of FATE-1 was seen in testis and a few normal tissues like kidney, 
heart, lung and brain (Olesen et al, 2011). The expression in placenta was reported to be 
negative (Dong et al, 2003). Like MAGEA4 in transitional cell carcinoma and NY-ESO-1 
in melanoma, FATE-1 is expressed in moderate and poorly differentiated HCC.  
 Function 
It has been reported that the expression of FATE-1 is correlated with the expression of the 
SRY (Sex determining region) gene (Olesen et al, 2011). It is thought to play some role in 
early testicular development. Wilms’ tumor gene 1 (WT-1) is another sex-determining factor 
and seems to be co-expressed with FATE-1. Both SF1 and WT-1 are involved in tumour 
development thus suggesting a role for FATE-1 in tumorigenesis as well (Olesen et al, 2011).  
 
 Helicase Antigen (HAGE) 
The helicase antigen HAGE was identified by Martelange and colleagues in Boon’s 
laboratory at the Ludwig Cancer Institute, Brussels in the year 2000 (Martelange et al, 2000). 
It was first identified together with sarcoma antigen (SAGE) by using representational 
difference analysis. HAGE is also known as DDX43. The HAGE gene is not located on the 
X chromosome, but has been mapped to chromosome 6 (6q12-q13) as is CAGE-1. It encodes 
for a putative 73 kDa protein (648 amino acids in length).  Like CAGE, this protein belongs 
to the DEAD-box family of ATP-dependent RNA-helicases.  
 Expression 
Expression of HAGE was found to be significantly up-regulated in tumours of various 
histology with relatively low levels or negative expression in normal tissues apart from testis 
(Mathieu et al, 2009).  
 Function 
RNA helicases are involved in transcription, translation and other RNA functions. Their 
involvement in cancer development has already been proved, thus suggesting that HAGE 
expression may be linked with processes favouring tumour growth (Roman-Gomez et al, 
2007). Hypomethylation of the HAGE gene is correlated with increased expression, 
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advanced disease and poor prognosis. Thus, HAGE is a potential target for immunotherapy 
vaccines (Mathieu et al, 2010). HAGE is thought to increase cellular proliferation. Studies 
by Linley et al (2012), have revealed that the HAGE gene enhanced expression of NRAS 
(neuroblastoma RAS oncogene), thus leading to regulation of AKT and ERK 
phosphorylation. The regulation of this pathway would enhance the cell proliferation in 
tumour cells.  
 
 NY-ESO-1 
NY-ESO-1, NY stands for New York City where it was discovered at the Ludwig Institute 
for Cancer Research and Weill Medical College of Cornell University in 1998 by Chen et 
al; ESO stands for oesophageal cancer (Gnjatic et al, 2006). This gene was identified during 
SEREX (Serological analysis of recombinant tumour complementary DNA (cDNA) 
expression libraries) analysis of oesophageal cancer. The protein coded by the NY-ESO-1 
gene is known as CTAG1 and shows the characteristics of C/T antigens with an expression 
which is restricted to germ cells and cancer cells. According to the C/T nomenclature, NY-
ESO-1 belongs to the CT6 family and according to the MAGE nomenclature, it is named 
LAGE-2. NY-ESO-1 was mapped at the telomeric end of the Xq28 region of chromosome 
X (Scanlan et al, 2002). NY-ESO-1 is an 18 kDa protein made up of 180 amino acids.   
 Expression 
Using monoclonal antibodies, the restricted expression of NY-ESO-1 in germ cells and 
cancer cells was confirmed. ES121 determined the expression of NY-ESO-1 exclusively in 
spermatogonia of the testis and oogonia of the ovary. NY-ESO-1 expression is gradually lost 
with sperm cell differentiation and shows rare expression in a few somatic tissues from 
ovary, uterus, placenta and normal breasts (Scanlan et al, 2004). NY-ESO-1 is the most 
frequently expressed amongst all the C/T antigens and in different histological cancer types. 
 Function 
Due to the lack of its homolog in a (non-human) animal model, the study of this gene is 
difficult and the function of NY-ESO-1 remains unknown. So far, NY-ESO-1 has been 
shown to be the most immunogenic C/T antigen with the activation of both the humoral and 
cellular immune responses in patients with tumours expressing this gene (Satie et al, 2002; 
Tureci et al, 2006). The antibody response differs depending on the tumour grade in 
melanoma patients, indicating that NY-ESO-1 can be used as a marker for advanced tumour 
stages (Goydos et al, 2001). For these reasons, NY-ESO-1 has been targeted for developing 
vaccines for immunotherapy in cancer patients. 
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 BUC11 
BUC11 (Breast-associated UniGene cluster 11) is one of the members of an unpublished 
gene family. BUC6, BUC9, BUC10 are the other members of this family. This gene family 
was identified by Expressed Sequence Tag (EST) database mining technique at The John 
van Geest Cancer Research Centre, Nottingham Trent University. 
o Expression 
The mRNA expression of BUC11 was analysed in various normal and cancerous tissue 
samples. BUC11 could not be considered as a true C/T antigen, as it was found to be 
expressed in normal tissues. It was also found not to be tumour-specific as it is not expressed 
in all tumours. It is expressed at high levels in testicular cancer, 25% in prostate cancer and 
at low levels in melanomas (Personal communication with Dr M. Mathieu, The John van 
Geest Cancer Research Centre, Nottingham Trent University). Interestingly, BUC11 mRNA 
expression was detected in both normal and cancerous breast samples. The expression was 
seen in 97% of samples. By using a custom-made anti-BUC11 antibody, BUC11 was found 
to be not associated with breast tumour formation and progression of the disease. Antibodies 
against BUC11 were detected in 60.6% of the patients. However when in vitro 
silencing/induction were performed, BUC11 was seen to participate in cell proliferation. 
 
 T128 
T128 is another novel prostate antigen identified by SEREX from prostate cancer patients at 
The John van Geest Cancer Research Centre, Nottingham Trent University. The expression 
analysis of this gene depicted over-expression in malignant tissues and prostate cancer 
tissues, along with expression in testis. When the reactivity of this gene was investigated in 
patients’ sera, the prostate cancer sera was seen to have reacted, but a few samples of normal 
sera also reacted with this gene. Thus, more studies on the characteristics and immunogenic 
properties of T128 are required. 
 
  T21 
Prostate cancer antigen T21 is a novel antigen identified in samples from patients with 
prostate cancer by modified SEREX by The John van Geest Cancer Research Centre, 
Nottingham Trent University and has been added to the C/T family (Miles et al, 2007). T21 
is mapped at chromosome 12q21.33 encoding a protein of 534 amino acids. Another gene 
called centrosomal protein 290kDa (CEP290) is also located at the same region. Mutations 
of CEP290 cause Joubert syndrome (a rare genetic disorder that is characterised by the 
absence or underdevelopment of the cerebellar vermis) and nephronophthisis (an autosomal 
recessive disorder that starts as chronic tubulo-interstitial nephritis and progress to end-stage 
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renal failure). Thus, it is not clear whether T21 could be a splice variant of CEP290. DNA 
sequencing revealed a 694bp sequence with truncated 5′ and 3′ ends (Miles et al, 2007).  
 Expression 
T21 is expressed in various cancer tissue types, but is silenced in normal tissues, with the 
exception of testis and foetal brain. T21 protein levels remain relatively constant throughout 
the cell cycle. Several forms of cancer have been associated with antibodies against this 
protein. Antibodies against T21 have been detected in 50% of prostate cancer patients, but 
not in normal individuals (Miles et al, 2012). 
 Function 
Using in silico analysis, relevant motifs in T21 gene products were identified, suggesting it 
to be a transcription factor. However, the localization of the protein in the cell cytoplasm 
due to the presence of SPAN-X domain suggests that T21 not only acts as a transcription 
factor, but also participates in the transcription process. 
1.4.1.4  The importance of expression of C/T antigens in placenta              
Cancer/testis (C/T) antigens have been detected in placenta along with their presence in 
foetal and adult germ cells. Studies of these genes are scarce in placenta, mostly being related 
to mRNA expression; and protein expression studies are yet to be fully carried out. Jungbluth 
et al studied the protein levels of C/T antigens in 50 placental samples from different 
gestational stages and showed a pattern of protein expression that varied for different 
antigens (Jungbluth et al, 2007). No immunity was detected for placental stages older than 
32 weeks. C/T antigens were mostly expressed in trophoblast cells which resemble cancer 
cells, and which are known to express these antigens. However, the expressions of C/T 
antigens in placenta are not exactly the same to its expression in germ cells of testis. Since 
placenta resembles tumour, C/T antigens may help in trophoblast development in a similar 
way to that in tumour formation. The expression of some of the novel genes have been 
studied in placenta. NY-ESO-1 has been seen in cytotrophoblast and syncytotrophoblast of 
the placenta (Scanlan et al, 2002). The origins of these C/T antigens (whether they are foetal, 
maternal or common) are not known (Gnjatic et al, 2006). HAGE was found to be expressed 
in placental samples, but the level of expression was shown to be lower than that in testis 
(Mathieu et al, 2010).  
1.4.2 Expression of 5-HT receptor subtypes 
5-hydroxytryptamine (5-HT), commonly referred to as serotonin, was first identified by 
Rapport in 1949 (Martin, 1994). Serotonin is a monoamine hormone and acts a 
neurotransmitter in brain. On the other hand, functions of 5-HT are not limited to the brain, 
and is also linked to responses in the gut, immune system activation and vaso-activation. 
The effects of 5-HT on blood vessels and its cardiovascular gastrointestinal responses have 
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been extensively studied. Almost 99% of 5-HT are synthesized in the enterochromaffin cells 
(enteroendocrine cells lining the lumen of digestive tract) (Mylecharane, 2009). The majority 
of this (90%) is stored in the same cells while the remaining 9% is carried by blood platelets. 
A small amount (around 1%) of serotonin is synthesized and stored in the neurons. The free 
5-HT in the plasma ranges between 15-120 nM. During vascular injury, the platelets release 
serotonin at the site of injury. 5-HT can also activate the RhoA and ERK pathways 
(Matsusaka and Wakabayashi, 2005). The many aspects of 5-HT are correlated with its 
interaction with different serotonin receptor subtypes (Section 1.4.2.2) and the different 
actions of 5-HT can be brought about only by its interactions with the different 5-HT 
receptors. Therefore, the study of 5-HT receptors has been a target at both academic and 
pharmaceutical level.  
 
1.4.2.1 Characteristic of 5-HT receptors 
The 5-HT receptors are G-protein coupled receptors which span the transmembrane. Except 
for 5-HT3 receptor subtype which is a ligand-gated ion channel. The general structure of 5-
HT receptors is represented in Figure 1.15 below. The receptor consists of seven α-helices 
which span the transmembrane (Kroeze and Roth, 2006). These helices form three 
intercellular loops and three extracellular loops with an extracellular amino (N) terminal and 
an intracellular carboxyl (C) terminal. The transmembrane is known to bind 5-HT and the 
intracellular domains link the receptors to various actions. The functions of the extracellular 
domains are not defined. A review by Raymond et al (2001) mentions the presence of 
cysteine residues on the extracellular domain which form disulphide bonds to confirm the 
structure of the receptors.  
 
 
Figure 1.14: General structure of 5-HT receptors. 
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The G-protein coupled 5-HT receptor has seven α-helices which span the transmembrane 
beginning with an extracellular amino (N) terminal and an intracellular carboxyl (C) terminal 
in the cytoplasm. [Figure adapted from CNS Forum] 
 
1.4.2.2 Different 5-HT receptor subtypes and their functions 
The classification of 5-HT receptors began when Gaddum and Picarelli in 1957 found that 
the guinea pig ileum was partly blocked by morphine (M) and dibenzyline (D). They 
classified the receptors into M and D respectively. Since then, the 5-HT receptors have been 
studied and classified by various researchers and given different nomenclatures.  
The Serotonin Club Receptor Nomenclature Committee proposed a system of nomenclature 
based on operation, structure and transduction information. These rules were then 
incorporated into the International Union of Basic and Clinical Pharmacology (IUPHAR). 
The nomenclature of 5-HT receptors followed in this study is incorporated from the 
IUPHAR database. According to this classification, 5-HT receptors form seven families and 
some of them divide into subunits. It is difficult to characterise the functions of each 5-HT 
receptor subtypes. Each receptor has a specific mode of action relying on the proteins they 
interact with. That is why the structure and functions of these 5-HT receptors are specified 
in detail below. 
1.4.2.3 5-HT receptors of interest 
As a result of the multiple interactions of 5-HT receptors and their functions, it was difficult 
to select just a few receptors of interest. Since there is limited availability of data for the 
status of 5-HT receptors in human placenta, additional investigations are essential. Therefore 
all seven families of 5-HT receptors were investigated, at least at the mRNA expressions. 
Table 1.2 gives a short overview of the functions mediated via the receptors.  
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Table 1.2: 5-HT receptors and their functions, which are of interest in the comparative 
study in NT and PE placentae. 
 
[Adopted from Barnes and Sharp, 1999] 
 
These receptors are further discussed in depth below. 
 
 5-HT1 receptors 
There is a high homology of amino acids in the members of the 5-HT1 receptor family. The 
5-HT1 receptors have the general seven transmembrane spanning regions which couple to 
G-proteins (Figure 1.15). There is negative coupling of adenylate cyclase to all of them via 
G-protein.  
o 5-HT1A receptor 
The 5-HT1A receptor has been fully characterised and sequenced. It is a 422-amino acid 
introns-less sequence located on chromosome 5 (5q11.2-q13) (Barnes and Sharp, 1999). 
Functions mediated via 5-HT1A receptor:  
At the cellular level, 5-HT1A receptor couples negatively to adenylate cyclase via G-Proteins 
(αi). Alterations in intracellular Ca2+ and activation of phospholipase C have also been 
reported in 5-HT1A receptor transfected cell lines. 5-HT1A receptor activation causes 
hyperpolarisation through the opening of coupled K+ channels.  
The release of 5-HT is hindered by 5-HT1A receptor activation and mediates the influence 
of 5-HT on both noradrenergic and cholinergic pathways. 5-HT1A receptor activation, on the 
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other hand, increases the release of acetylcholine. Studies on both animal and human 5-HT1A 
receptor have concluded that 5-HT1A receptor activation increases the release of hormones 
such as adrenocorticotropic hormone (ACTH), corticosteroids, prolactin and growth 
hormones.  
 
o 5-HT1B receptor 
The gene encoding the human 5-HT1B receptor is located in chromosome 6 (6q13) (Barnes 
and Sharp, 1999). It has been estimated that the 5-HT1B receptor may be synthesised in 
certain locations in the brain and then transported to different regions by cell bodies.  
Functions mediated via 5-HT1B receptor:  
The 5-HT1B receptor couples negatively to adenylate cyclase in transfected cell lines 
conditioned with forskolin. The 5-HT1B receptor activation inhibits glutamate release, thus 
inhibiting depolarisation of synaptic nerves. At the nerve terminals, 5-HT1B receptor acts as 
an autoreceptor, which inhibits the release of 5-HT. As mentioned before, it is speculated 
that in some regions of the brain, the 5-HT1B receptor is transported to nerve terminals to act 
as a heteroreceptor. Upon activation, these receptors inhibit the release of acetylcholine 
(Barnes and Sharp, 1999).  
 
o 5-HT1D receptor 
It is still a challenge to distinguish between the 5-HT1B receptor and the 5-HT1D receptor 
due to their sequence homology. In humans, these two receptors are located on different 
chromosomes (1p34.3-36.3 for 5-HT1D receptor and 6p13 for 5-HT1B receptor). When 
compared to other 5-HT receptor subtypes, the expression level of 5-HT1D receptor is 
relatively low.  
Functions mediated via 5-HT1D receptor:  
Although it was found that 5-HT1D receptor coupled negatively to adenylate cyclase in 
transfected cells, the same could not be attributed to native tissues (Hamblin and Metcalf, 
1991). In fact, the secondary response for 5-HT1D receptor cannot be confirmed at native 
forms. Also, due to the close homology of 5-HT1B and 5-HT1D receptor and their ligand 
binding, it is difficult to attribute definite functions to 5-HT1D receptors.  
 
o 5-HT1E receptor 
The gene encoding the 5-HT1E receptor is located on chromosome 6q14-q15. It is intron-
less and encodes a 365 amino acid sequence.  
Functions mediated via 5-HT1E receptor:  
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A moderate inhibition by forskolin conditioned adenylate cyclase via 5-HT1E receptor has 
been reported. However, very little is known about the mechanisms mediated via this 
receptor. 
 
o 5-HT1F receptor 
The 5-HT1F receptor is located on chromosome 3p12. It has the general structure of 5-HT 
receptors with seven transmembrane spanning regions. The physiological responses 
mediated via 5-HT1F receptor are unclear.  
 
 5-HT2 receptor 
The 5-HT2 receptor comprises three subtypes: 5-HT2A, 2B and 2C. Unlike 5-HT1 receptors 
which are intron-less, the 5-HT2 receptors have introns in their coding sequence (two introns 
for 5-HT2A and 2B; three introns for 5-HT2C). These exons couple to phospholipase C and 
transport intercellular calcium ions (Ca2+).  
 
o 5-HT2A receptor 
The 5-HT2A receptor encoding gene is located on chromosome 13q14-q21 and consists of 
sites for phosphorylation, glycosylation and palmitoylation. 
Functions mediated via the 5-HT2A receptor:  
The 5-HT2A receptor mediates secondary messenger responses by activating phospholipase 
C through G-protein coupling. This leads to increase in intercellular Ca2+ and inositol 
phosphates. The activation of 5-HT2A receptor also mediates neuron depolarisation and 
inhibits noradrenaline release, but increases the secretion of ACTH, cortisol and prolactin.  
o 5-HT2B receptor 
The 5-HT2B receptor gene is located on 2q36.3-2q37.1, encoding 481 amino acids sequence.  
Functions mediated via 5-HT2B receptor:  
5-HT2B receptor activation mediates signal transductions like the other two members of the 
family and stimulates phosphatidyl inositol hydrolysis. 5-HT2B receptor knockout studies in 
mouse by Choi et al (1997) have revealed mitogenic effects of 5-HT that are mediated via 
5-HT2B receptors. 
 
o 5-HT2C receptor 
Amongst all the other 5-HT receptor subtypes, only 5-HT2C receptor is X-linked, located at 
Xq24. Multiple isoforms of 5-HT2C receptor have been reported due to mRNA editing and 
thus each isoform may have different functional consequences.  
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Functions mediated via 5-HT2C receptor:  
At the cellular level, 5-HT2C receptor activation increases phosphatidyl inositol hydrolysis. 
It also mediates depolarisation of neurons and inhibits release of noradrenaline and 
dopamine.  
 
 5-HT3 receptor 
5-HT3 is the only ligand-gated receptor in the 5-HT receptor family. It is encoded by two 
genes, 5-HT3A and 5-HT3B, located in the same locus 11q23.1 (Bockaert et al, 2010). These 
share high homology at the channel domains with the other Cys-Cys loop ligand gated 
channels like nicotinic, glycine and gamma-aminobutyric acid (GABAA) receptors. Unlike 
the G-protein coupled receptors, both the N-terminal and C-terminals of 5-HT3 are located 
outside the cell membrane and contain four transmembrane spanning regions. 5-HT binds to 
the extracellular domain to open the channel, which becomes permeable to Na+ and K+ (See 
Figure 1.16, Panel A).  The native form of 5-HT3 is pentameric (Figure 1.16, Panel B). Only 
the 5-HT3A subunit (α subunit) is functional and the 5-HT3B (β subunit) binds to 5-HT3A to 
form channels resembling the native forms. Clones similar to 5-HT3C, D and E have also been 
reported, but are not functional (Niesler et al, 2007).  
  
 
 
 
 
Figure 1.15: Structure of ligand gated 5-HT3 receptor. 
 
[A] Two α subunits of 5-HT3 aligned close to one another with their extracellular N and C-
terminals and four transmembrane regions. The transmembrane region II of the subunits 
forms the channel for the gates. [B] Both α and β subunits form a pentameric channel. The 
core is 3nm in diameter. Once the 5-HT ligand binds to the N-terminal extracellular domain, 
the channel opens up for ion exchange. [Figure adapted from Nagradova, 2010 and Rammes 
et al, 2004] 
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Functions mediated via 5-HT3 receptor:  
The activation of 5-HT3 receptor opens the cation channels and the exchange of ions leads 
to depolarisation of the neurons. The activation of 5-HT3 receptor also increases the release 
of some neurochemicals like 5-HT, ACTH, GABA, Cholecystokinin (CCK) and dopamine, 
but decreases acetylcholine release.  
 
 5-HT4 receptor 
The 5-HT4 receptor is encoded by a highly fragmented gene (at least five introns) located 
on chromosome 5 (5q31-q33) (Hannon and Hoyer, 2008). Due to the complexity of the gene, 
various splice variants have been identified. Most of the variants have a consensus sequence 
on the transmembrane region with an N-terminal glycosylation region and transmembrane 
and C-terminal phosphorylation regions. The expression of these isoforms has been found 
to be tissue-specific.  
Functions mediated via 5-HT4 receptor:  
The 5-HT4 receptor binds positively to adenylate cyclase. It is proposed that the 5-HT4 
receptor couples to potassium and voltage-gated channels. 5-HT4 receptor activation 
stimulates the release of 5-HT, acetylcholine and dopamine.  
 
 5-ht5 receptor 
5-ht5 is the least understood receptor therefore it retains the small letter nomenclature as 
recommended by IUPHAR. Also, there is no evidence for expression of native 5-HT5 
receptor. Two subtypes have been identified: 5-ht5A and 5B. The 5-ht5A gene is located on 
chromosome 7 (7q36.1) and encodes a protein of 357 amino acids in length with consensus 
sequences predictive of phosphorylation and glycosylation. The 5-ht5B subtype is located on 
chromosome 2 (2q11-13). However, due to the presence of stop codons in the sequence, a 
functional protein cannot be expressed from the 5-ht5B subtype.  
Functions mediated via 5-ht5 receptor:  
There is no data available for the functional role of 5-ht5 in native cells and tissues. 
Therefore, the predictive functions are based on investigations using transfected cells and 
knock out models. In cells transfected with recombinant 5-ht5A, it has been reported that the 
receptor coupled negatively to cAMP via G proteins to inhibit forskolin-stimulated 
production (Francken et al, 1998). Similarly, it was predicted that 5-ht5A could couple to 
potassium channels. 
 
 5-HT6 receptor 
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The 5-HT6 receptor is 440 amino acids long and its gene is located on chromosome 1 (1p35-
36). The gene consists of two introns and consensus sequences (on N-terminal for 
glycosylation and on C-terminal for phosphorylation).  
Functions mediated via 5-HT6 receptor:  
The 5-HT6 receptor binds positively to adenylate cyclase like 5-HT4 and 7. It also stimulates 
the intercellular accumulation of cAMP.  
 
 5-HT7 receptor 
The gene for the 5-HT7 receptor is located on chromosome 10 (10q21-24). The sequence 
consists of two introns. The first intron is located on the intracellular loops and the splice 
variants does not encode functional proteins. The second intron lies on the C-terminal and 
gives rise to four functional splice variants (5-HT7A, B, C and D). Human tissues can express 
only three variants 5-HT7A (448 a.a.), 5-HT7B (435 a.a.)  and 5-HT7D (479 a.a.). They have 
the general G-protein coupled receptor structure (Figure 1.15). 
Functions mediated via 5-HT7 receptor:  
Due to the variation in the phosphorylation site for each variant their functional role differs. 
In general, all the variants are capable of coupling and activating adenylate cyclase.  
 
1.4.2.4 Importance of expression of 5-HT receptors in placenta 
Researchers have pointed out that 5-HT and its receptors may have a fundamental role in 
placental development and pregnancy maintenance (Oufkir et al, 2010). Bolte et al (2001) 
showed that 5-HT influences the early extravillous trophoblast (EVT) and endothelial layer 
of the spiral arteries via 5-HT1B or 5-HT2A receptors. 5-HT induces several physiological 
effects, including vasoconstriction or vasodilation, depending upon which member of the 5-
HT receptor family it interacts with (See Section 1.4.1.2). Several studies have reported 5-
HT-mediated constriction of placental veins and the myometrium; specifically implicating 
5-HT1 and 5-HT2 receptor (Cruz et al, 1998; Cordeaux et al, 2008; Ugun-Klusek et al, 
2011). It is worth noting that circulating 5-HT is increased in PE (Cruz et al, 1998). Here, 5-
HT is thought to be involved in PE because of its vasoconstrictory effects resulting in 
compromised blood flow to the placenta. The increased level of 5-HT seen in PE placenta 
could be due to low levels of its metabolising enzyme, monoamine oxidase (MAO) 
(Sivasubramaniam et al, 2002). Thus, the high levels of 5-HT in PE may lead to extensive 
vasocontriction and as a result limit the maternal blood supply into the placental circulation, 
causing it to be at a more hypoxic state.  
Chapter 1: Introduction 
 
45 
 
Due to ethical constraints, it is impossible to study the status and the changes of 5-HT 
receptor expression in response to increased 5-HT during early stages of human pregnancy. 
A few studies have looked at the expression profiles of 5-HT receptors in vitro using term 
choriocarcinoma cell lines such as JEG3, JAR and BeWo (Sonier et al, 2005). However, 
there is not enough information on (a) the effects of 5-HT on early trophoblast (EVT) 
invasion and (b) the changes in the expression profiles of different 5-HT receptors produced 
by increased 5-HT during this invasion.  
1.4.3 Hypoxia and its relationship to invasion 
Oxygen is a vital molecule for the survival of multicellular organisms. The oxygen demand 
varies from organ to organ and depends mostly on their respective function. Hypoxia 
promotes cell survival in both placenta and tumour through many pathways as shown in 
Figure 1.17.  
 
Figure 1.16: HIFα-related pathways under normal and hypoxic conditions. 
 
In normoxic conditions the HIFα subunit undergoes degradation by PHD and pVHL. Under 
hypoxic conditions, HIFα escapes the hydroxylation and enters the nucleus of the cells. 
There, the HIFα and β subunits form a complex, which binds to the HRE regions of the genes 
to be regulated initiating various effects in the cells.  [Figure adapted from Taddei et al, 
2013 and Zhang and Zen, 2014] 
 
Under hypoxic conditions, a range of transcription factors known as hypoxia-inducible 
factors (HIFs) are key regulators of cell survival. HIF is composed of three α subunits 
(HIF1α, 2α and 3α) and one β subunit (HIF1β); and their expression increases during 
hypoxic conditions (Ji, 2014; Zhang and Zen, 2014). In normoxic conditions, the HIFα 
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subunits are hydroxylated by a proly hydroxylase domain protein (PHD) and are recognised 
by von Hippel–Lindau protein (pVHL). The α subunit undergoes ubiquitination and 
degradation. However, when the oxygen levels fall, PHD loses its activity and HIFα becomes 
more stable. HIF1α then enters the nucleus where it binds to the β subunit to form a fully 
functioning transcription complex. All the genes targeted by HIF complex have hypoxia 
response elements (HRE) in their promoters. The binding of HIF complex onto this HRE 
activates the transcription of various genes involved in metabolism, signalling, proliferation, 
invasion, migration, apoptosis and angiogenesis.  
1.4.3.1 Hypoxia during normal placentation 
Although a hypoxic state is detrimental for most organs, placenta, like tumour cells, has the 
capacity to survive at extreme hypoxic conditions. In fact, the hypoxic condition during early 
placental development is crucial for embryogenesis. As discussed earlier in Section 1.1.1.3, 
the EVT cells form a plug on the spiral arteries during the first trimester (10th week) (Figure 
1.5). As a result of this, the blood supply along with its oxygen is cut off and a hypoxic 
environment is created. This hypoxic environment created by the EVT plug protects the 
developing embryo (and the primitive villi) when the levels of anti-oxidising enzymes (such 
as mitochondrial superoxide dismutase, glutathione peroxidase and reductase) are limited in 
foetoplacental unit (Hutter et al, 2010). The STB cells start secreting these enzymes only 
from 9-10th week. At the end of the 10th week, the plug disrupts and there is influx of 
maternal blood into the IVS. Hence, there is a significant increase in oxygen level during the 
second trimester in comparison to the first trimester. Burton and Jaunaiux (2001) recorded 
the oxygen tensions in 30 women who underwent pregnancy termination at 7-16 weeks due 
to psychosocial conditions. It was recorded that the peripheral oxygen tension in the maternal 
arteries was constant throughout. However the pO2 concentrations in decidua increased from 
64.3 mmHg (7-10 weeks) to 73.2 mmHg (11-16 weeks). Likewise, there was a two-fold 
increase of pO2 in the IVS, from 25.6 mmHg (2-3% O2) to 56.2 mmHg (~8% O2). 
The HIF pathway plays a crucial part in placental development. The genes regulated by HIF 
are classified as (a) those whose expression would help to maintain the energy levels for 
trophoblast under hypoxic conditions and (b) those which would lead to differentiation and 
invasion of trophoblasts. HIFα and β subunits, under hypoxic conditions, regulate the 
expression of these genes. The functional complex of HIF stimulates the Warburg 
metabolism by which oxygen use to produce ATP at the end of glycolysis is avoided. It is 
worth noting that HIF-knockout mice resulted in severe placental damage (Fryer and Simon, 
2006).  
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The effects of hypoxia on trophoblast differentiation and invasion remain, however, 
debatable. Seminal studies confirmed that trophoblasts proliferate under hypoxic conditions 
and differentiate to become invasive at high oxygen levels (Caniggia et al, 2000; Esterman 
et al, 1997; Kilburn et al, 2000; Genbacev et al, 1996). Conversely, another group of 
investigators noticed that hypoxic conditioning improved trophoblast differentiation and 
invasion (Graham et al, 2000; James et al, 2006). These disputes may be due to the different 
experimental designs and trophoblast samples used and also because of the complex network 
of pathways connected to hypoxia.  
Hypoxia-induced autophagy has also been determined to maintain the EVT functions and 
induce invasion (Saito and Nakashima, 2013). Autophagy is a process where the cells 
undergo self-digestion when the nutrient and energy supply is limited. The proteins and 
cytoplasmic contents of the dying cells accumulate in autophagosomes for degradation. The 
breakdown of these autophagosomes generates ATP to maintain the energy supply of the 
trophoblast (and tumour) cells even under low nutrient conditions.  
Oxygen levels are also very important in the remodelling of spiral arteries (Cartwright et al, 
2007). The iCTB cells are in a hypoxic state when they invade the placental decidua. Thus, 
they cannot produce pro-apoptotic factors [e.g. TNF-related apoptosis-inducing-ligand 
(TRAIL)], which could be detrimental to the surrounding cells. When the iCTB reaches the 
spiral arteries, it receives oxygen from the maternal blood which triggers the pro-apoptotic 
factors to express. These factors will induce apoptosis to the vessel cell lining the spiral 
arteries and help in the remodelling to enhance the blood supply (see also Section 1.1.1.2). 
 
 Hypoxia and PE 
Kingdom and Kaufmann have classified hypoxia in pregnancy into three categories: 
(a) Pre-placental hypoxia: the mother and foetus are in an hypoxic state (high altitude)  
(b) Utero-placental hypoxia: the oxygen level in the mother is normal, but the level in 
the foetus is reduced (e.g. PE)  
(c) Post-placental hypoxia: hypoxia occurs only in the foetus  
The utero-placental hypoxic conditions (in PE) are discussed in detail as follows. 
As seen in Figure 1.10 and Section 1.1.5, in PE, the iCTB and eCTB do not completely 
remodel the spiral arteries. As a result of this, the diameter of the arteries is reduced leading 
to insufficient flow of maternal blood into the IVS. Consequently, the oxygen levels are 
lower even in the second trimester. There has been no direct measurement of oxygen tension 
recorded in vivo during PE. Due to the narrow arteries, there is reduced blood flow into the 
placental lobules, but the foetal blood keeps on extracting the oxygen in the IVS. When the 
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maternal blood flow is restored, there is a sharp increase in oxygen tension. This fluctuation 
in the oxygen tension indicates an ischaemia / reperfusion kind of injury (H/R injury) (Hung 
and Burton, 2006; Cartwright et al, 2007). The formation of free radicals during H/R injury 
is detrimental to placenta. There are very little to no oxygen molecules available to receive 
the free electrons from the respiratory chain. The accumulation of electrons forms 
superoxide, which leak to any oxygen available around them. However, if oxygen supply is 
restored before the cells die, then there is elevated production of superoxide.   
1.4.3.2 Hypoxia in cancer 
The rapid proliferation of tumour cells demands a profuse supply of blood with oxygen and 
nutrients. Tumours develop their own vasculature from the existing host blood vessels. This 
vascular formation cannot keep pace with the tumour cell proliferation resulting in primitive 
leaky vessels, as a result of which a hypoxic and highly acidic tumour microenvironment is 
created. The partial pressure of oxygen (pO2) measured at the tumour microenvironment 
(TME) is around 2 mm Hg (0.3%) to 15 mm Hg (2.1%) depending on the tumour type (Byrne 
et al, 2014). Hypoxia plays a particularly important role in solid tumours. In hypoxic 
conditions, tumour cells become quiescent and secrete factors, which increase both vessel 
formation and survival rate of the tumour. If hypoxia is prolonged, tumour cells undergo 
apoptosis like normal cells. The tumour cell death through prolonged hypoxia have been 
investigated for cancer therapy (Alarcon et al, 2004; Byrne et al, 2014).  
HIF up-regulates the expression of growth factors like VEGF and cytokines to enhance 
angiogenesis and lymphoangiogenesis (Figure 1.17). Hypoxia also plays a major role in the 
transition of epithelial cells to a mesenchymal state [epithelial-mesenchymal transition 
(EMT)] (Brahimi-Horn et al, 2011). EMT cells have stem-like properties and can invade 
surrounding tissues giving rise to tumour cells. Furthermore tumour cells, like early 
trophoblasts, follow Warburg metabolism under hypoxic conditions. NADPH levels are also 
elevated due to the anabolism of the pentose phosphate pathway (PPP), which leads to the 
synthesis of DNA and ribose to overcome the oxidative stress. As stated in Section 1.1.1, 
hypoxia also maintains the energy supply by generating ATP through autophagy.  
Due to all the above mechanisms, tumour cells flourish better under hypoxic conditions. In 
fact hypoxia, a process which should be killing the cells, is actually enhancing their growth. 
Studies on both in vitro cell culture (Chinese Hamster cells) and in vivo tumour SCCVII 
carcinoma radiated under normal and hypoxic conditions have reported differences in cell 
survival (Nordsmark et al, 2014). Tumour cells under hypoxic conditions were shown to 
survive much higher doses of radiation. Hypoxia reduces the response of tumour cells to 
Chapter 1: Introduction 
 
49 
 
radiotherapy. Therefore understanding the hypoxic regulation of the genes is the prime target 
for cancer therapy.   
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1.5 Aims and hypothesis 
Literature review and preliminary results indicated differential gene expression patterns in 
normal and PE placentae. 5-HT have also been demonstrated to be involved in proliferation, 
migration and invasion of various cells. Increased 5-HT levels correlates to PE and activation 
of various signalling pathways through 5-HT receptors.  Furthermore due to resemblance of 
placental cells to tumour, C/T antigens are also expressed in placenta.  
Therefore, it was hypothesised: 
 That the expression patterns of 5-HT receptors and C/T antigens in normal and PE 
placentae are different.  
 The expression patterns also differ at different gestational stages. Thus, the first 
trimester placentae demonstrate differences in 5-HT receptors and C/T antigens 
when compared to normal and PE placentae. 
 5-HT is hypothesised to influence the behaviour of trophoblast cells; such as viability, 
proliferation, migration and invasion. Since trophoblast cells are habituated to low 
oxygen levels, the effects of 5-HT on these cells would also alter under hypoxic 
conditions. 
 These changes in cell behaviour under 5-HT influence is mediated by altered 
expression of 5-HT receptors and C/T antigens.  
 
This study aims to: 
 Establish the status and the regional expressions of (a) all 5-HT receptor subtypes 
and (b) C/T antigens in pre-eclamptic (PE) placentae in comparison with 
normotensive (NT).  
 Analyse the expression of 5-HT receptors and C/T antigens in the placentae from 
first trimester pregnancies. 
 Investigate the effects of 5-HT on the cell behaviour of transformed early first 
trimester placental cells in relation to choriocarcinoma (cancer) cell lines under 
normoxic and hypoxic environment. 
 Elucidate the effects of 5-HT on the expressions of C/T antigens in placental cell 
lines under normal and hypoxic conditions. 
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2.1 Buffers and solutions 
 
Table 2.1: Buffers and Solution 
Reagent Recipe 
PBS 1X 10 Phosphate Buffered-Saline tablets (Fisher Scientific) in 1 litre 
ddH2O 
PBS-Tween20 (PBS-T) 1 litre 1X PBS, 5ml Tween 20 
TBS 10X 24.23g Trizma HCl, 80.06g NaCl, 1 litre ddH2O, pH 7.6 
TBS-Tween20 (TBS-T) 1 litre 1X TBS, 5ml Tween20 
Running Buffer 5X 15 g Tris Base, 72 g Glycine, 5.0 g SDS, 1 litre ddH2O, pH 8.3. 
Transfer Buffer 10X 60.4g Tris Base, 288g Glycine, 1.8 litres ddH2O. Methanol added to 
1X transfer buffer before use. 
TAE Buffer 50X 
242 g Tris Base, 57.1ml Acetic Acid, 100 ml 0.5M EDTA, 1 litre 
ddH2O, pH to 8.5 
Laemmli Buffer 4X 200mM Tris-HCl pH6.8, 400mM DTT, 0.8% w/v SDS, 0.4%  w/v 
Bromophenol blue, 40% v/v glycerol, 5% v/v β- mercaptoethanol 
Antibody Buffer 3% BSA, TBS-T, 0.02% Sodium Azide 
 
2.2 Antibodies 
Primary antibodies Catalogue Number 
and Supplier 
Antibody dilutions 
CT Antigens   
Rabbit Anti-CAGE1          
   
HPA029830 Sigma  IHC (1:200); IF (1:200); 
WB (1:1000) 
Rabbit Anti-FATE1          
   
HPA034604 Sigma IHC (1:350); IF (1:350); 
WB (1:1000) 
Rabbit Anti-GAGE1 H0002543-B01P 
Novus 
IHC (1:300); WB 
(1:500) 
Rabbit Anti-GAGEE1 (PAGE5)                           
   
sc-138503 Santa 
cruz  
IHC (1:250); IF (1:250); 
WB (1:500) 
Rabbit Anti-MAGEA1        
   
AB21472 abcam IHC (1:100); IF (1:100); 
WB (1:500) 
Rabbit Anti-MAGEA4       
   
LF-MA10178 
AbFrontier  
IHC (1:100); IF (1:100); 
WB (1:1000) 
Rabbit Anti-PASD1  HPA011122 Sigma  IHC (1:250); IF (1:250); 
WB (1:500-Not 
detected) 
5-HT Receptors   
Rabbit Anti-Serotonin 5-HT1B Receptor
  
Sigma (IHC), abcam 
(WB) 
IHC (1:200); IF (1:200); 
WB (1:500) 
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Rabbit Anti-Serotonin 5-HT2B Receptor
   
Sigma (IHC), 
biorbyt (WB) 
IHC (1:200); IF (1:200); 
WB (1:500-Not 
detected) 
Controls   
Rabbit Anti-ACTB  
(loading control for WB)   
AV40173 Sigma WB (1:1000) 
Mouse Anti-Vimentin  
(positive control for IHC) 
NCL-L-VIM-572 
Leica 
IHC (1:400); IF (1:400) 
Secondary Antibodies  Catalogue Number 
and Supplier 
 
Goat Anti-Rabbit Human IgG 
peroxidase conjugated 
A0545 Sigma WB (1:10,000) 
Donkey Anti-Rabbit Human IgG H+L 
(HRP) conjugated 
ab6802 abcam WB (1:3000) 
Fluorescein Anti-Rabbit IgG 
(H+L)                                 
Vector Laboratories, 
Inc 
WB (1:1000) 
Biotinylated Anti-Mouse/Rabbit IgG 
provided with VECTASTAIN Elite 
ABC Kit 
PK-6200 
Vector Laboratories, 
Inc 
IHC (1:10,000) 
 
IHC-Immunohistochemistry; WB-Western blotting; IF- immunofluorescence 
 
 
2.3 Human placental collection 
Human placental tissue samples were previously collected by the Director of Studies (Dr. 
Sivasubramaniam) in accordance with the ethical approval by the Nottingham City Hospital 
Ethical Committee and stored at -80°C. Some of them were further preserved by 
paraformaldehyde fixation and embedded in paraffin for immunostaining protocols (see 
Section 2.9.1). The Ethical approval was extended to suit this study by the Health Research 
Authority – NRES Committee North East (REC: 12/NE/0112; See Appendix A.1); their 
demographic details are given in Section 3.2.1. First trimester placental explants and protein 
lysates were kindly provided by Prof. Berthold Huppertz, Medical University of Graz, 
Austria. These samples were collected under the local ethical guidance of the Medical 
University of Graz and stored at -80°C until further experimentation. Demographical details 
are given in Section 4.2.1. 
 
2.4 Total RNA extraction  
Total RNA was extracted from the placental samples using commercially available RNeasy® 
Plus Mini RNA extraction kit (Qiagen) to prepare cDNA templates for PCR amplification 
(Section 2.6.2). The samples were homogenized in liquid nitrogen and weighed in pre-cooled 
centrifuge tubes. Then 600µl of RLT buffer plus 6µl β-mercaptoethanol (Sigma Aldrich) 
was added to the sample. This homogenized lysate was transferred into a QIAshredder® 
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(Qiagen) and centrifuged at maximum speed (15,000 x g) for 2 minutes in microcentrifuge 
(Microcentaur Sanyo).  The supernatant was transferred into a gDNA eliminator spin 
column. The column was centrifuged again at 10,000 x g for 30 seconds. The supernatant 
was mixed with 600µl 70% v/v ethanol (Fisher Scientific). This mixture was transferred to 
an RNeasy spin column placed in a collection tube. Centrifugation was repeated at 10,000 x 
g for 15 seconds. RNeasy spin column was retained and 700µl RW1 buffer was added and 
centrifuged again at 10,000 x g for 15 seconds. This was followed by 2x 500µl RPE buffer 
washes. Lastly the column was treated with 50µl RNase-free Millipore water and centrifuged 
at 10,000 x g for 1 minute. The supernatant was collected and stored at -80°C.  
Due to the limited availability of first term placental samples, an AllPrep RNA/Protein 
Extraction kit® (Qiagen) was used. The kit allowed the simultaneous extraction of RNA and 
protein from same sample. The fresh first term placental samples were homogenised in APL 
buffer supplied in the kit and centrifuged in an All Prep column for 1 minute at ≥8,000 x g. 
The flow through was pipetted onto a Protein Cleanup spin column and centrifuged for 3 
minutes at 240 x g. This flow through contains the protein and was further purified using 
ice-cold acetone (Fisher Scientific). The concentrations of purified protein samples were 
then estimated using the BCA assay, as detailed in Section 2.7.2. The AllPrep column was 
treated exactly as RNeasy spin column above. For quality control purposes, extracted RNA 
samples were electrophoresed in 1% w/v agarose gel (BIOzym group) to fractionate the two 
RNA subunits, 28S and 18S. New England, BioLabs® Inc 1kb ladder was used to identify 
the two subunits. The RNA samples extracted were also quantified using a Nanodrop® 
spectrophotometer.  
 
2.5 cDNA template preparation by reverse transcription 
A reverse transcription reaction was carried out using extracted RNA samples. 
SuperScript™ II Reverse Transcriptase kit (Invitrogen™) was used for this reaction. A 20µl 
reaction volume was prepared. The following 20µl reaction volume was used for total RNA 
concentrations of 10pg-5µg. The reaction mix contained the appropriate volume of RNA 
extracted and nuclease-free water, 1 µl Oligo (dT) 15 Primer (Promega), 1µl dNTP 
(Promega) and 1µl RNAsin (Promega) and heated to 65°C for 5 minutes followed by chilling 
on ice. 4µl of 5X First-Strand Buffer and 2µl of 0.1M DTT was added to the reaction and 
incubated at 42°C for 2 minutes. After this incubation, 1µl of SuperScript™ II Reverse 
Transcriptase was added and allowed to incubate at 42°C for 50 minutes. cDNA was also 
produced from commercially available human testis and brain total RNA (Clontech) as 
controls. This was used as a positive control in qRT-PCR. The cDNA produced was stored 
at -4°C. 
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2.6 Gene expression study 
2.6.1 Primer designing and optimising  
Coding sequences (CDS) for the genes of interest were selected from National Centre for 
Biotechnology Information (NCBI) website (www7). CDS were used to design the primers 
using Primer 3® Input version 4 (www8) and primer properties were checked by Integrated 
DNA Tool (www9). Common nucleotide regions for the genes with variants were selected 
using the ClustalW2 (www10). These common regions were then used to design the primers. 
The primer sequences were then checked for their specificity using BLAST (www11) and 
finalised.  
Primers were selected according to the following primer designing guidelines: 
1) Sequence: 
a) The following were avoided: (i) 3 or more runs of G or C at 3´ end, (ii) a T at the 3´ 
end, (iii) mismatches at the 3´end and (d) complementary sequences. 
b) 3´ end should end in G or C or CG or GC. This will increase the efficiency of priming. 
2) Length: 18-30 nucleotides 
3) GC Content: 40-60% 
4) Melting Temperature (Tms) : 55-80˚C 
5) Primer Concentration: 0.1 and 0.5µM 
6) Product size is less than 200 bps 
The primer sequences with their annealing temperatures are given in Table 3.2. The 
annealing temperatures for the primers were first calculated using the following equations: 
 
𝑻𝑻𝒎𝒎 = 4 ( 𝐺𝐺 + 𝐶𝐶) + 2 (𝐴𝐴 + 𝑇𝑇) 
𝑻𝑻𝑨𝑨 = 𝑇𝑇𝑚𝑚 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 + 𝑇𝑇𝑚𝑚 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐹𝐹𝑅𝑅𝑅𝑅2 − 5℃  
 
 
Where Tm is melting temperature for the primers, TA is the annealing temperature for the 
gene of interest.  
 
2.6.2 Gene amplification using conventional PCR and gradient PCR 
Genes of interest were amplified using the primers designed in Section 2.6.1 by conventional 
TECHNE Thermocycler TC3000 (Bibby Scientific Ltd.). PCR Master Mix from Promega 
was used for the reaction mixture. The reaction mixture was prepared according to company 
guidelines.  
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• Reaction Mixture for 25µl 
Components    Volume  Final Concentration 
PCR Master Mix, 2X    12.5µl    1X 
Upstream primer, 10µM   0.25–2.5µl   0.1–1.0µM 
Downstream primer, 10µM   0.25–2.5µl   0.1–1.0µM 
DNA template    1–5µl    <250ng 
Nuclease-Free Water to   25µl    N.A. 
• General program followed for PCR was as follows: 
o  Initial Denaturation at 95°C for 2 minutes 
 Denaturation at 95°C for 30 seconds 
 Annealing at X°C for 30 seconds   x 40 cycles 
 Extension at 72°C for 30 seconds  
o  Final Extension at 72°C for 2 minutes 
Note: Where X°C is the TA calculated in Section 2.6.1.  
TECHNE 3Prime temperature gradient PCR (Geneflow Ltd.) was also used to amplify 
genes for which the calculated TA showed low/no products from genomic DNA. The PCR 
product sizes were then analysed on 1.5% w/v agarose gel using a 100bp ladder from New 
England Biolabs® Inc.  
 
2.6.3 Agarose gel electrophoresis 
The desired percentage of agarose gel was prepared in fresh 1X TAE buffer (1.5% and 1% 
w/v agarose gels were used to analyse PCR products and to detect the integrity of the RNA 
samples respectively). GelRed™ nucleic acid stain (Biotium Inc.) was used as a detection 
dye in the gel. The gel was electrophoresed at 50 Volts for 15 minutes followed by 80 volts 
for 30 minutes which were then imaged on the Gel Doc (InGenius, Syngene) under UV light. 
   
2.6.4 Confirmation of the PCR products by sequencing 
The PCR products were cleaned using Wizard Genomic DNA Purification kit (Promega) 
according to manufacturers’ guidelines. An equal volume of membrane binding solution was 
mixed with the PCR products. The mixture was then transferred into a minicolumn assembly 
and incubated for 1 minute at room temperature. The minicolumn was centrifuged at 16,000 
x g for 1 minute; washed twice with membrane wash solution and centrifuged again at 16,000 
x g for 1 minute. Purified DNA was eluted out from the column using nuclease-free water. 
The products were then sent for sequencing to the Functional Genomics, Proteomics and 
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Metabolomics Facility in University of Birmingham for confirmation. The sequences were 
analysed using SnapGene software for accuracy. 
 
2.6.5 Relative expression of genes of interest by Real-Time quantitative PCR 
Genes of interest were also amplified by the Corbett quantitative PCR (qPCR) thermo 
cycler (Corbett Lifesciences).  A reaction mixture of 12.5µl was prepared containing 6.75µl 
SYBR green mix (Biorad Laboratories, Inc.), 4.25µl millipore water, 0.5µl Forward Primer, 
0.5µl Reverse Primer and 0.5µl cDNA template. The primer concentration was made to 10 
pM/µl. All the reactions were prepared in duplicates. Their calculated annealing 
temperatures are given in Table 3.2. The melting curve for the genes were analysed after the 
reaction using Rotor Gene-6000 Series 1.7 software and the delta Ct values (2-∆∆Ct) were 
calculated. 2-∆∆Ct is a method to calculate relative quantitative expressions by comparing Ct 
values (Livak and Schmittgen, 2001). The amount of target is normalised to endogenous 
reference gene (house-keeling gene) and relative to calibrator (positive control). The house-
keeping genes used in this study are GAPDH, HPRT1 and TBP1; primers for these can be 
found in Table 3.2. Calibrator for C/T antigen expression was testis and for 5-HT receptor 
was brain. All real time PCR experiments were performed twice. 
2.7 Protein expression studies 
2.7.1 Tissue lysate preparation for protein analysis 
Placental samples were homogenised in liquid nitrogen and transferred into centrifuge tubes. 
RIPA buffer (10 ml) (Sigma Aldrich) was added to approximately 1g tissue powder for lysis. 
Protease inhibitor cocktail (Roche) 0.2% v/v and 1mM Na3VO4 (Sigma Aldrich) were added 
to the samples. Samples were vortexed on ice for 40 minutes. After incubation, the tubes 
were centrifuged at 27,000 x g for 20 minutes at 4°C (Harrier 15/80 refrigerated centrifuge, 
Sanyo). The supernatant (i.e. the native form of the tissue lysate) was collected and stored at 
-80°C. 
 
2.7.2 Estimation of protein concentration by Bicinchoninic Acid (BCA) Assay 
The Bicinchoninic Acid (BCA) assay (Sigma Aldrich) was performed according to the 
manufacturers’ guidelines to estimate the protein concentrations in the tissue lysates 
prepared in Section 2.7.1. The BCA working reagent was prepared by mixing 50 parts of 
reagent A (BCA) with 1 part of reagent B (4% w/v Copper (II) sulphate solution; Sigma 
Aldrich). BSA (Bovine Serum Albumin) (Fisher Scientific), in concentrations of 0.2, 0.4, 
0.6, 0.8 and 1 mg/ml was used to obtain a standard curve. The placental tissue lysates, BSA 
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standards and blank (RIPA buffer) were loaded into a 96 well plate and mixed with 8 parts 
of BCA working reagent. The plates were sealed and incubated at 37°C for 30 minutes and 
cooled down for 5 minutes. Finally, the absorbance was read at 570nm by using a microplate 
reader (Biochrom Asys UVM340) and concentrations were calculated from the standard 
curve.  
 
2.7.3 Protein separation by SDS-PAGE 
Protein samples were denatured for SDS-PAGE separation by adding Laemmli Buffer (4X) 
at 70-80˚C for 10 minutes on a heating block. Equal concentrations of the protein samples 
were loaded into 10% or 12.5% w/v SDS-PAGE along with molecular weight markers 
(Biorad Laboratories, Inc.). ProtoGel® 30% w/v, ProtoGel® 4X Resolving and 
ProtoGel® stacking buffers were used to prepare SDS-PAGE gels according to 
manufacturers’ guidelines (National diagnostics). The SDS-PAGE was run for 50 volts for 
15 minutes followed by 80 volts for 90 minutes in running buffer. Finally, they were 
visualised by staining with Coomassie Brilliant Blue (BioRad Laboratories, Inc.).  
 
2.7.4 Protein analysis by immunoblotting 
Immunoblotting was carried out by transferring separated proteins from SDS-PAGE onto 
0.2µm nitrocellulose paper (Sigma Aldrich) by wet-transfer over-night in cold room. The 
nitrocellulose membrane was incubated in blocking solution (3% w/v BSA in TBS-
Tween20) for 1 hour. After incubation, the membrane was washed three times with Millipore 
water followed by TBS-Tween20 wash. The membrane was then incubated in primary 
antibody, at dilutions 1:500-1:1000, overnight on a shaker at 4oC. Following incubation the 
membrane was washed and incubated in secondary antibody (1:10,000 dilution) for 1-2 
hours. Following this incubation the membrane was washed by TBS-Tween20, three times 
for 5 minutes each, to remove excess secondary antibody and developed using RapidStep™ 
ECL Reagent (Calbiochem®) or Westar Supernova for weak signal (Cyanagen Srl). 
The image capture was carried out by using a Gel Doc, InGenius (Syngene) and  
Gel Doc™ XR+ System (BioRad Laboratories, Inc.). Antibodies were prepared at 
appropriate dilutions using antibody buffer. 
 
2.7.5 Analysis of western blot results 
New GeneSys Image analyser software was used for blots captured by InGenius and Image 
lab software was used for blots captured by the BioRad imaging system. The expression 
levels of the genes of interest were normalised against the house keeping proteins (β-actin). 
After normalisation with β-actin, the expression levels in each sample were compared to the 
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expression levels in positive controls (testis for C/T antigens and brain for 5-HT receptors). 
Human brain and testis protein medley were obtained from Clontech. Thus, the expression 
levels in positive controls are arbitrarily set at 1.  
 
2.8 In vitro cell culture  
2.8.1 Maintenance of cell lines 
All cell lines, specifications and culture media are mentioned in Table 2.2. The growth media 
were supplemented by 10% v/v FBS (foetal bovine serum) (Lonza); 2mM L-Glutamine 
(Lonza) and 25 U/ml penicillin/streptomycin (Lonza). Cells were initially grown in T25 
flasks (Sarstedt); incubated at 37˚C in a humidified atmosphere of 95% v/v air/5% v/v CO2. 
Daily checks were performed and the cell lines were sub-cultured when they reached 70-
95% confluence. 
 
Table 2.2: Cell Lines 
Cell line Cell type Provider Culture media 
TEV-1 Human first-trimester extravillous trophoblast 
Dr Mei Choi Choey 
University of Hong 
Kong, China 
RPMI-1640 
HTR-8/SVneo 
Human first-trimester 
villous trophoblast 
transfected with Simian 
Virus 40 large T antigen 
Dr Charles Graham 
University of 
Kingston, Canada 
RPMI-1640 
JEG3 Human placenta choriocarcinoma ECACC* EMEM 
BeWo Human placenta choriocarcinoma ECACC Ham’s F12 
HT1080 Human fibrosarcoma ECACC EMEM 
*European Collection of Cell Cultures 
Sub-culturing was carried out by first aspirating the growth media and washing with 
respective wash media. Cells were detached from the flasks by adding 2.5% v/v trypsin 
(Lonza). The flask was replaced back into the incubator for 5-10 minutes. An inverted light 
microscope (Motic AE2000, Scientific Laboratory Supplies Ltd.) was used to check 
detachment of the cells; the flasks were gently tapped at the sides to improve detachment. 
Then respective growth media were added to inactivate the trypsin. The cells were collected 
into Sterilin tubes (Sarstedt) and centrifuged at 1,000 x g for 5 minutes in Harrier 15/80 
centrifuge (Sanyo). The supernatant was decanted and the cell pellets were re-suspended in 
1ml of growth media. Viable cells were counted by using 0.4% v/v trypan blue (Sigma 
Aldrich). 100µl of cell suspension was mixed with 300µl trypan blue. A small volume (10µl) 
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of this mix was used to count in a haemocytometer. The cell numbers in four large grids 
were counted to estimate the total cell count using the following calculation. 
 
𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪 𝑵𝑵𝑵𝑵𝒎𝒎𝑵𝑵𝑪𝑪𝑵𝑵𝑵𝑵/𝒎𝒎𝑪𝑪  = 𝐴𝐴𝑅𝑅𝑅𝑅𝐹𝐹𝐹𝐹𝐴𝐴𝑅𝑅 𝑐𝑐𝑅𝑅𝑐𝑐𝑐𝑐 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑅𝑅𝐹𝐹 × 104  × 4 (𝐹𝐹𝑑𝑑𝑐𝑐𝑛𝑛𝑑𝑑𝑑𝑑𝐹𝐹𝑛𝑛 𝑓𝑓𝐹𝐹𝑐𝑐𝑑𝑑𝐹𝐹𝐹𝐹) 
These cells were either bulked up into T75/T175 flasks (Sarstedt), used for further 
experiments or frozen down for future use. 
 
2.8.2 Cryopreservation of cells 
For continuous supply of cell lines, cells were cryopreserved in liquid nitrogen. The cell 
pellet after centrifugation was re-suspended in freezing media (Media 6.4 ml, Penicillin/ 
Streptomycin 0.1 ml, FBS 2.5 ml, DMSO 1.0 ml). The cells with freeze media were then 
transferred to cryovials placed on ice and immediately transferred to -80˚C freezer. The 
following day the cryovials were then transferred into liquid nitrogen for extended storage.  
 
2.8.3 Revival of cryopreserved cells 
Cryovials containing the cells were removed from liquid nitrogen and immediately thawed 
in warm water. The cells were then transferred into Sterilin tubes (Sarstedt) containing 5ml 
of fresh growth media and mixed thoroughly. The tubes were then centrifuged at 1,000 x g 
for 5 minutes. The pellets were then re-suspended in 1ml growth media and grown in T25 
flasks.  The flasks were maintained as in Section 2.8.1. 
 
2.8.4 Determining cell seeding density by MTT Assay 
The correct cell seeding density was determined by performing cell proliferation estimations 
using an MTT assay. MTT assay is based on the reduction of 3-(4,5-dimethylthiazol-2-yl)-
2,5-Diphenyltetrazolium Bromide (MTT) to violet formazan crystals by both mitochondrial 
and extra-mitochondrial dehydrogenases (Cobb, 2013; Liu et al, 1997). Viable and 
proliferating cells contain higher ratios of NADH/NAD ratios which acts as intermediates 
during MTT reduction. Likewise succinate and NADH-linked mitochondrial substrates 
(malate, pyruvate or glutamate) support the MTT reduction (Slater et al, 1963).   Thus the 
formazan formation is the direct representation of viable cells and determines the optimum 
cell seeding density. Different cell densities (serial dilution from 10 to 0.3125x 104) were 
transferred into 24 well plates and grown for 24, 48 and 72 hours. Growth media were 
removed from the wells and 50µl of 5mg/ml MTT solution (Sigma Aldrich) was added to 
the wells, followed by incubation for an hour. After incubation 500µl DMSO (Sigma 
Aldrich) was added to the plates, which were then gently shook in a plate shaker to dissolve 
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the crystals. A small volume of this solution (200 µl) was transferred into a 96 well plate and 
the absorbance was read at 570 nm. This experiment was performed for all the cell lines and 
repeated for three different passage numbers .  
 
2.8.5 Estimation of 5-HT cytotoxicity by MTT Assay 
The cell seeding density determined in Section 2.8.4 (5x104 for placental cell lines and 
2.5x104 for HT1080) was used to grow cells in 96 well plates. In one set of experiments, the 
cells were grown along with different doses of 5-HT (Sigma Aldrich) for 24 and 48 hours 
(i.e. cells were plated in the presence of 5-HT). In another set of experiments, the cells were 
treated with 5-HT after 24 hours of plating for 24 and 48 hours duration (i.e. 5-HT treatment 
was after cell attachment). After treatment, MTT assays were performed, following the same 
principle as in Section 2.8.4. The growth media was removed and 25µl 5mg/ml MTT was 
added to the wells and incubated for an hour. DMSO (250µl) was then added and plates were 
gently shaken in a plate shaker.  Then 200µl of the solution was transferred into a fresh 96 
well plate for reading and absorbance was read at 570 nm using a plate reader. This 
experiment was performed for all the cell lines and repeated for three different passage 
numbers.  
 
2.8.6 Estimation of 5-HT cytotoxicity by CytoTox 96® Non-Radioactive 
Cytotoxicity Assay (Promega) 
The CytoTox 96® Non-Radioactive Cytotoxicity assay on the other hand measures the 
release of lactate dehydrogenase (LDH) from the disintegrated membrane of unviable cells 
(Cobb, 2013). The LDH then converts lactate to pyruvate with reduction of NAD+ to 
NADH/H+. The H+ from NADH/H+ is transferred to INT (2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-phenyltetrazolium chloride) which reduces it to a red formazan dye. Thus 
CytoTox 96® Non-Radioactive Cytotoxicity assay represents the cell death exclusively. The 
96 well plates were seeded with 5x104 for placental cell lines and 2.5x104 for HT1080 cells. 
An additional set of wells were plated for Maximum LDH Release (positive) Control. The 
assay was performed according to the manufacturers’ guidelines. After 5-HT treatment, 
Lysis (10X) Solution was added to the maximum LDH release control wells. 45 minutes 
later, the plates were centrifuged at 250 x g for 4 minutes. After centrifugation 50µl of the 
supernatant from each well was mixed with 50µl of substrate mix and incubated for 30 
minutes on a shaker, protected from light. After 30 minutes of incubation the reaction was 
stopped by adding 50 µl of stop solution.  The absorbance was read at 490 nm. This 
experiment was performed for all the cell lines and repeated for two passage numbers for 
each cell line for 24 and 48 hours.  
Chapter 2: Materials and methods 
 
62 
 
 
The sensitivity of the assays are often cell and drug dependent and can show variations 
(Fotakis and Timbrell, 2006).  Hence both MTT and CytoTox 96® Non-Radioactive 
Cytotoxicity assay were performed in this study. 
 
2.8.7 Estimation of 5-HT on cell proliferation by 3H thymidine incorporation 
A proliferation assay was performed to analyse the effect of 5-HT on the DNA synthesis of 
the cells. The increase in DNA synthesis as a result of 5-HT treatment was measured by 
adding [3H] Thymidine. The plates were seeded with 5x104 for placental cell lines and 
2.5x104 for HT1080 cells, and treated with 5-HT after 24 hours of cell recovery. The cells 
were incubated with [3H] Thymidine (1µ Ci per well) for 18 hours before termination of the 
assay. The cells were harvested onto a 96 well UniFilter GF/C plate after the incubation 
period using a Filtermate Harvester (Packard). These plates were allowed to dry at room 
temperature before addition of Microscint O to assist in cell counting. The newly synthesised 
DNA was measured using TopCount NxtYM (Packard). Furthermore, the effect of 5-HT on 
cell proliferation recovery were also examined. The cells were treated with 10μg/ml of 5-
fluorouracil (5-FU) (Sigma Aldrich) for 24 hours to inhibit proliferation. 5-FU is a 
pyrimidine analogue with a fluoride atom attached to the base of pyrimidine ring. 5-FU is 
metabolised to Fluorodeoxyuridine monophosphate (FdUMP) and Fluorouridine 
triphosphate (FUTP) (Wyatt and Wilson, 2009). The first metabolite FdUMP inhibits the 
activity of the enzyme thymidylate synthase (TS). TS in normal conditions converts uracil 
to thymine by the addition of a methyl group at the 5th carbon position. Inhibition of TS 
causes nucleotide imbalance in the cells eventually blocking the DNA synthesis. 
Furthermore FdUMP is converted to Fluorodeoxyuridine triphosphate (FdUTP) which gets 
incorporated into the DNA triggering additional damage. Second metabolite Fluorouridine 
triphosphate (FUTP) is incorporated into RNA leading to translation impairments.   
2.8.8 RNA extraction and protein fractionation  
After the confirmation of the 5-HT doses to be used, the cells were treated with 5-HT and 
extracted for gene expression and protein analysis. RNA extraction was followed as in 
Section 2.4. Similarly cell lysate were prepared as in Section 2.7.1. 
2.8.9 Determination of cell migration by wound healing assay 
An investigation on effects of 5HT on human aortic endothelial cells by Matsusaka and 
Wakabayashi in 2005 have highlighted 5HT as inducer for migration. As mentioned in 
Section 1.1.1, trophoblast migration and invasion are the key steps in regulating the 
formation of placenta. Also tumour cell migration and its regulation are crucial to control 
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tumour metastasis. This raised interests in investigating the effect of 5-HT on trophoblast 
and choriocarcinoma cell migration. Therefore a wound healing assay often known as 
scratch assay was performed using fluorescent (confocal; Leica) microscopy after staining 
with a plasma membrane (FM1-43FX) fluorescent stain (Molecular Probes™). 96 well 
black/clear imaging plates (BD Falcon) were coated with 50μl of 0.01% w/v poly-l-lysine 
(Sigma Aldrich) and incubated for an hour at room temperature to make the surface adherent. 
Excess poly-l-lysine was removed prior to plating. Cells were plated with optimum cell 
densities (5x104 for placental cell lines and 2.5x104 for HT1080 cells) obtained from 
MTT/LDH assays (see Sections 2.8.5 and 2.8.6) and allowed to grow until confluent. Upon 
confluency cells were treated with 10μg/ml of 5-fluorouracil (5-FU) (Sigma Aldrich) for 24 
hours to inhibit proliferation. The cells were stained for 15 minutes before scratching using 
10μM FM1-43FX fluorescent stain. Then a straight scratch was made on the monolayer 
using a two microlitre pipette tip. The wells were washed gently with 1X DPBS (Lonza) to 
remove the debris after the scratch. The plates were then cultured with serum free media 
(SFM) (media with 1% w/v L-glutamine and 1% v/v penicillin/streptomycin) containing 
different doses of 5-HT (and untreated control). The scratches were imaged at 30 minutes 
intervals under the confocal microscope for 48 hours. This experiment was performed in 
duplicates for all the cell lines and repeated twice. 
o Calculating cell migration 
The migration assays were analysed by using WimScratch automated analysis by Wimasis 
Quantitative Image Analysis (www12). This software detects the edge of the scratch and 
measures the gap area. The analysed results include graphic representation of the assay; for 
summary file and image readout see Appendix A.2. 
2.8.10 Invasion Assay 
It is also known that the formation of placenta and tumour requires the cells to both migrate 
as well as invade simultaneously. It was apparent to investigate the effect of 5-HT on cell 
invasion after confirming its effect on migration. Thus, an invasion assay was performed by 
using BD Falcon™ BioCoat tumour invasion systems (BD Falcon) with FluoroBlok™ 96 
well insert plates (8µm pore size) coated with BD matrigel Matrix. This was compared with 
migration of cells through uncoated BD Falcon™ FluoroBlok™ 96 well insert plates. The 
assay was performed according to the manufacturers’ guidelines. The protocol followed was 
as follows: 
• Rehydration: BD Falcon™ BioCoat tumour invasion systems was removed 
from -20˚C freezer and allowed to stand at room temperature. Once the plates reached room 
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temperature the apical chambers were filled with 75µl warm media and allowed to rehydrate 
for 2 hours at 37˚C at 5% v/v CO2.  
• Pre-staining the cells: The cells were grown to 70% confluency and collected 
after trypsinisation. Collected cells were incubated with 10µM CellTrace™ CFSE dye 
(Molecular Probes®) for 15 minutes. After incubation the cells were centrifuged and re-
suspended in warm media.  
• Cell suspension: Cell density of 2x104 cells were prepared in SFM.   
• Assay set-up: After rehydration of BD Falcon™ BioCoat tumor invasion plates 
the media from the apical chambers was removed and replaced with 50µl of cell suspension. 
Similarly 50µl of cell suspension was also added to the apical chambers of the BD Falcon™ 
FluoroBlok™ 96 well insert migration plates.  The bottom chambers were filled with growth 
media containing 5% v/v FBS, which acts as a chemo-attractant. The apical as well as the 
bottom chambers were treated with different concentrations of 5-HT (See Table 2.3 and 
Figure 2.1 for illustration of the assay plate set up). 
 
Table 2.3: Treatment of invasion assay plates 
CONDITION TREATMENT 
APICAL CHAMBER LOWER CHAMBER 
1mM  
5-HT 
Cells in 
SFM 
1mM  
5-HT 
Growth 
Media SFM 
NORMAL 
20% 02 
-VE CONTROL - 50.0 µL - - 200 µL 
+VE CONTROL - 50.0 µL - 200 µL - 
10µM 5-HT 0.5 µL 49.5 µL 2 µL 198 µL - 
20µM 5-HT 1.0 µL 49.0 µL 4 µL 196 µL - 
30µM 5-HT 1.5 µL 48.5 µL 6 µL 194 µL - 
40µM 5-HT 2.0 µL 48.0 µL 8 µL 192 µL - 
HYPOXIC 
2% 02 
-VE CONTROL - 50.0 µL - - 200 µL 
+VE CONTROL - 50.0 µL - 200 µL - 
20µM 5-HT 1 µL 49.0 µL 4 µL 196 µL - 
40µM 5-HT 2 µL 48.0 µL 8 µL 192 µL - 
60µM 5-HT 3 µL 47.0 µL 12 µL 188 µL - 
80µM 5-HT 4 µL 46.0 µL 16 µL 184 µL - 
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Figure 2.1: Diagrammatic representation of the Invasion Assay. 
 
 
• Image capture: The images of the plates at time zero were immediately taken 
with a top plate imaging system using ImmunoSpot® analyser [Cellular Technology Ltd. 
(CTL)]. CFSE has an excitation/emission of 492/517nm. The plates were then incubated at 
37˚C at 5% v/v CO2 and images taken at 48 hours. At the end of the assay, the membranes 
were removed from the inserts and mounted on slides. These were further imaged using a 
fluorescent microscope (Olympus BX51) with Olympus camera.  
• Cell counting: The images scanned by the CTL analyser were counted using the 
CTL software. The images taken by Olympus were analysed and counted using the Image J 
software. The cell counts by the two methods were then compared.  
• Calculating percentage invasion: This was calculated by taking the migration 
plate to have 100% of cells coming through the membrane. Since not all cells will pass 
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through the matrigel matrix, the percentage invasion is calculated as a fraction of the 
migration.  
 
The equation is as follows: 
𝐼𝐼𝑛𝑛𝑅𝑅𝐹𝐹𝑅𝑅𝑑𝑑𝐹𝐹𝑛𝑛 % = 𝑁𝑁𝑛𝑛𝑛𝑛𝑛𝑛𝑅𝑅𝐹𝐹 𝐹𝐹𝑓𝑓 𝑐𝑐𝑅𝑅𝑐𝑐𝑐𝑐𝑅𝑅 𝑑𝑑𝑛𝑛𝑅𝑅𝐹𝐹𝐹𝐹𝑅𝑅𝐹𝐹
𝑁𝑁𝑛𝑛𝑛𝑛𝑛𝑛𝑅𝑅𝐹𝐹 𝐹𝐹𝑓𝑓 𝑐𝑐𝑅𝑅𝑐𝑐𝑐𝑐𝑅𝑅 𝑛𝑛𝑑𝑑𝐴𝐴𝐹𝐹𝐹𝐹𝑑𝑑𝑅𝑅𝐹𝐹 × 100 
 
2.9 Staining protocol 
In order to analyse the human placental sections the following staining protocols were 
performed. 
2.9.1 Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) was performed to investigate the localisation of the proteins 
of interest in the tissue sections. The paraffin embedded sections were taken at 5µm thickness 
and mounted on poly-l-lysine coated slides (Thermo Scientific). The sections were baked at 
60ºC for 1 hour.  
• Deparaffinising: The sections were deparaffinised in xylene (Fisher Scientific) 
twice for 10 minutes and 2 minutes respectively.  
• Hydration: The sections were hydrated through an alcohol gradient as follows: 
 2x in Absolute alcohol for 2 minutes each 
 2x in 95% v/v ethanol for 2 minutes each 
 1x in 75% v/v ethanol for 2 minutes 
• Blocking endogenous peroxide: The sections were then immersed in 3% v/v 
hydrogen peroxide (H2O2) (Fisher Scientific) in methanol for 30 minutes. Followed by wash 
with distilled water.  
• Heat induced Epitope Retrieval (HIER): HIER involved unmasking the 
epitopes in the tissue sections by immersing the sections in retrieval buffers (10mM Tris-
1mM EDTA buffer, pH 9 or 10mM Citrate Buffer, pH 6) and microwaving at high 
temperature for 20 minutes. This was followed by wash with PBS. 
• Blocking: The sections were blocked for unspecific binding with horse serum 
for 30 minutes or longer.  
NOTE: Negative controls were left in blocking solution until remaining slides were 
incubated in primary antibodies.   
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• Primary antibody incubation: After blocking the sections were incubated in 
primary antibody, at dilutions of 1:200-1:500, for 1 hour at room temperature. This was 
followed by washing with PBS 3 x 5 minutes each.  
NOTE: The sections were stained for the expression of vimentin to check for loss of signal 
due to long-term fixation (Dabbs 2006).  
• Secondary antibody incubation: The sections were then incubated in 
biotinylated secondary antibody (1:10,000 dilution) for 1 hour at room temperature followed 
by brief wash with PBS. 
• Avidin/Biotinylated enzyme Complex (ABC): The sections were developed in 
ABC reagent for 30 minutes at room temperature. The sections were briefly washed with 
water. The ABC reagent from Vectastain® was prepared according to manufacturers’ 
guidelines.  
• 3,3'-Diaminobenzidine (DAB) : DAB substrate from Vectastain® was prepared 
according to manufacturers’ guidelines and added to the sections until brown staining was 
observed, followed by a brief wash with water. In presence of antibody conjugated to 
peroxidase enzyme and peroxide the DAB is oxidised to give brown colour.   
• Counterstain: The slides were counter-stained using Gills Haemotoxylin for 
15-30 seconds. Followed by wash with water and 1% w/v Di-potassium tetraborate (blueing 
agent) for few seconds.  
• Dehydration:  The sections were dehydrated through an alcohol gradient as 
follows: 
 1x in 75% v/v ethanol for 2 minutes 
 2x in 95% v/v ethanol for 2 minutes each 
 2x in Absolute alcohol for 2 minutes each 
Followed by soaking in xylene for 3x5 minutes.  
• Mounting: The sections were mounted with coverslip using Entellen®. 
 
2.9.2 Visualisation and semi-quantification of IH 
The slides were visualised at 200X and 1000X magnification and images were captured 
using an Olympus camera DP73. The images captured were taken approximately at the same 
locations in comparative slides. Slides prepared from the consecutive tissue sections were 
compared. The staining in the images were then semi-quantified using a point scale immuno-
reactivity scoring (IRS) system (as shown in Table 2.4). These scorings were carried out 
compared to the positive staining for vimentin IRS (Scored as 3) and negative stain 
(secondary antibody only; 0) in the same sample. Multiple images of the slides were scored 
independently by three observers.  
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Their individual scores were then compared and tallied for final scores. The most frequently 
repeated score between the three scorers (mode) was taken as the final score for the gene of 
interest in overall pool of samples (NT, PE or FT). A weighted kappa statistical analysis was 
also performed with the scores provided individually by the three scorers to analyse the inter-
observer error. The values for the kappa were interpreted as mentioned by Viera and Garrett 
(2005). If the values were: < 0, there was less chances of agreement; 0.01–0.20, indicated 
slight agreement; 0.21– 0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, 
substantial agreement and 0.81–0.99, practically perfect agreement. 
 
Table 2.4:  IRS for semi-quantification of IHC slides. 
Immunoreactivity score (IRS) Staining Intensity 
0 No or Very Low Positive Staining 
1 Low Positive Staining 
2 Medium Positive Staining 
3 High Positive Staining 
 
2.9.3 Haemotoxylin and Eosin (H&E) Staining 
To study the structural features of the various placental tissue types, haemotoxylin and eosin 
(H&E) staining was performed. The deparaffinisation and hydration steps were repeated as 
in Section 2.9.1. The tissue was then stained in Gills Haematoxlylin for 2 minutes. The 
excess stain was removed under running tap water and followed by a quick dip in 1% w/v 
Di-potassium tetraborate (blueing agent). The slides were then rinsed and counter stained in 
1% v/v Eosin (Fisher Scientific). Excess stain was rinsed and followed by dehydration and 
mounting as in Section 2.9.1.  
 
2.9.4 Immunocytochemistry staining 
Immunocytochemistry protocol from abcam® was observed to investigate the localisation of 
the antibodies of interest in the cell lines studied. The cells were first grown on GG-18-PLL 
(neuVitro), poly-l-lysine coated coverslips. The coverslips were then rinsed with 1X DPBS 
and air dried. The general procedure followed for immunocytochemistry staining is given 
below: 
• Fixation: The cells were fixed in either ice cold acetone for 5 minutes, methanol 
for 10 minutes or in 4% w/v paraformaldehyde in PBS pH 7.4 for 15 minutes at room 
temperature, followed by washing twice in PBS.  
• Permeabilisation: For staining intracellular proteins the cells fixed with 
paraformaldehyde and methanol were permeabilised in 0.25% v/v Triton X-100 in PBS for 
Chapter 2: Materials and methods 
 
69 
 
10 minutes. This was followed by washes in PBS for 3 x 5 minutes. The permeabilisation 
step was not required for acetone fixed cells and for detection of membrane proteins. 
• Blocking: The cover slips were then incubated in 1% w/v BSA in PBST for 30 
minutes-1 hour. For paraformaldehyde-fixed coverslips, 0.3M Glycine was added to the 
blocking buffer. 
• Primary Antibody Incubation: The coverslips were then incubated in primary 
antibody diluted in 1% w/v BSA in PBST for 1 hour at room temperature or overnight at 
4ºC in a humidified dark chamber. After incubation the coverslips are washed again in PBS 
3 x 5 minutes. 
• Secondary Antibody Incubation: The coverslips were then incubated in 
secondary antibody diluted in 1% w/v BSA in PBST for 1 hour at room temperature in dark 
followed by 3 x 5 minutes wash with PBS.  
• Counter staining: The coverslips, if required, were counter-stained with 
VECTASHIELD® HardSet™ mounting medium with DAPI.  
Once dried, the edges of the coverslips were sealed with colourless nail varnish to avoid it 
from moving while taking images. The images were captured using an Olympus camera at 
different magnifications (Objective magnification: 10, 20, 40 and 100X).  
 
2.10 Hypoxic conditioning 
Placenta can be considered hypoxic only when compared to other organ environments, in 
which the metabolic demand for oxygen is much higher, but the supply is low. Interestingly, 
studies using isolated trophoblast from term placenta have indicated that these cells are 
tolerant to prolonged periods of hypoxia (Esterman et al, 1997). Therefore the in vitro 
experiments were repeated at hypoxic conditions (2% v/v O2, 5% v/v CO2 balanced by 
nitrogen) using modular incubator chambers MIC-101. The cells were pre-conditioned with 
hypoxic conditions before the experiments for 24 hours. The modular incubator chambers 
maintained a hypoxic environment with no fluctuations. For confocal imaging of the wound 
healing assay at hypoxic conditions, the entire microscopic stage was kept under hypoxic 
conditions (see Figure 2.2). Hypoxia was monitored by an O2 sensor throughout the 
experiment.  
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Figure 2.2: Confocal Imaging of wound healing assay at hypoxic conditions.  
 
The bold red arrow heads indicate the flow of gas through the system. 
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Term placental study 
Comparative expression analysis in 
Normotensive and Pre-eclamptic Placentae
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3.1 Introduction 
Despite the fact that between 2-3% of pregnancies are affected by pre-eclampsia (PE) and 
result in approximately 15% of these babies being born prematurely, the aetiology of this 
syndrome is not well established. Conversely, several causative factors have been identified, 
including genetic predisposition, reduced invasion of the trophoblast cells (during placental 
development), ethnicity, parity etc. A number of genetic differences have been identified 
between pre-eclamptic and normal placental tissues. Differential gene expression techniques 
such as microarray have identified several candidate genes involved in signalling pathways 
(Centlow et al, 2008, 2010; Enquobahrie et al, 2008). A limited number of studies have also 
investigated differential protein expression in PE (Centlow et al, 2009). However, it is 
difficult to identify mutant or ameliorated protein(s) expression involved in the progression 
of PE because the human genome has in excess of 25,000 genes. Due to splicing events these 
genes can then give rise to over 1,000,000 proteins, which can undergo post-translational 
modifications such as phosphorylation, glycosylation etc. Proteomics chip technology would 
be an ideal way to study altered or mutant protein expression. This technology is still in its 
infancy and thus does not have the power to fully identify pre-eclamptic proteins. Therefore 
the protein detections are carried out by conventional methods like 1-D and 2-D gel analysis.  
Several circulating factors, such as 5-hydroxytryptamine (5-HT; serotonin), have been 
reported to increase in PE pregnancies (Cruz et al, 1998). Here, 5-HT is thought to be 
involved in PE because of its vasoconstrictory effects resulting in compromised blood flow 
to the placenta. The increased level of 5-HT seen in PE placenta could be due to low levels 
of its metabolising enzyme, monoamine oxidase (MAO) (Sivasubramaniam et al, 2002). 5-
HT induces several physiological effects, including vasoconstriction or vasodilation, 
depending upon which member of the 5-HT receptor family it interacts with (See Section 
1.4.1.2). Several studies have reported 5-HT-mediated constriction of placental veins and 
the myometrium; specifically implicating 5-HT1 and 5-HT2 receptor (Cruz et al, 1998; 
Cordeaux et al, 2008; Ugun-Klusek et al, 2011). Whilst these studies have focused mainly 
on 5-HT1 and 5-HT2 receptors the involvement of other 5-HT receptor subtypes in PE 
placentae is not fully understood. Therefore the first aim of this chapter was to investigate 
the differential expression of various members of the 5-HT receptor family during normal 
and PE placental development.  
Cancer testis (C/T) antigens are a large family of tumour-associated antigens, whose function 
is unknown. They are usually only found in human tumours, with the exception of healthy 
testis and placental tissue.  In 2007, Jungbluth and co-workers used immunohistochemistry, 
to show the cellular localisation of MAGE family, GAGE and NY-ESO-1 antigens in 50 
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placental samples ranging between weeks 5 to 42. From the few studies that have been 
carried out, these antigens are known to be involved in invasion, tumorigenesis, and 
apoptosis (Olesen et al, 2011; Sang et al, 2011; Gjerstorff et al, 2006). Furthermore, a few 
microarray (and other) studies have shown differences in expression of some of C/T antigens 
in PE placentae where the invasion is shallow (Founds et al, 2009; Old, 2001). However 
there are no detailed studies on the status of C/T antigens in PE placentae. Therefore, the 
second aim of this chapter was to comparatively analyse the expressions of C/T antigens 
between normal (NT) and PE placentae.  
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3.2  Results 
Initially using NT and PE placentae, the mRNA expressions of 5-HT receptors together with 
all know C/T antigens were compared to identify the receptors and antigens that show a 
highly significant change in PE placentae.  Then the faithful translation of these identified 
protein were compared semi-quantitatively by Western blotting and qualitatively by 
immunohistochemistry. By this way, the study only focussed on the proteins that are 
differentially expressed in PE placentae. It is a well-known fact that the human brain express 
all the know 5-HT receptors (Mendelsohn and Paxinos, 1991). Therefore, human brain was 
used as a positive control for 5-HT receptor comparisons. Likewise, C/T antigens are 
abundantly expressed in human testis (Simpson et al, 2005), hence human testis was used as 
the positive control for C/T expression analysis.  
3.2.1 Human placental samples 
The demographic details of NT and PE samples are given in Table 3.1 (Ethical approval 
REC: 12/NE/0112). Individual patient data can be found in the Appendix A.3.  
Table 3.1: Demographic details of the pre-eclamptic patients and normotensive 
subjects 
 
The details are expressed as mean ± SD, N/D= none detected, n=number of women in 
each group.  § Mann – Whitney U test. 
 
Parameter Normotensive 
(n=13) 
Pre-eclamptic 
(n=12) 
P value § 
Maternal age (years) 34.2 ± 1.4  
(28-41) 
28.5 ± 2.2  
(19-39) 
0.075 
Gestational age (weeks) 38.9 ± 0.1 
(38.4-39.3) 
37.5 ± 0.7 
(33-39.4) 
0.036 
Systolic blood pressure 
(mmHg) 
122.2 ± 3.5 
(109-140) 
153.8 ± 3.4  
(140-168) 
<0.0001 
Diastolic blood pressure 
(mmHg) 
70.6 ± 3.4  
(60-90) 
98.5 ± 1.9  
(91.5-108) 
<0.0001 
Protein in urine 
(g / lt) 
N/D 1.149 ± 0.328  
(g / 24 hour) N/D 2.687 ± 0.852  
Placental weight (g) 657.4 ± 37.3  
(527-855) 
506.3 ± 35.8  
(360-620) 
0.015 
Mode of delivery    
Parity 1.9 ± 0.3 (1-4) 0.3 ± 0.3 (0-2) 0.005 
Gestational Weight (Kg) 3.4 ± 0.1 
(3.03-4.24) 
2.6 ± 0.2  
(1.66-3.59) 
0.015 
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3.2.2 Histology of Normotensive (NT) and Pre-eclamptic (PE) placentae 
The histological differences between NT and PE placental sections were studied using 
haematoxylin and eosin staining as mentioned in Section 2.9.3. The sections were analysed 
and graded by Mr Roy Stewart (histopathologist) and the director of study (placentologist) 
at Nottingham Trent University. The staining patterns were reproducible for the different 
sample sections within the two groups (NT and PE) and only representative data is given 
below. In NT sections regular villous system were observed with a single outer layer of 
syncytiotrophoblast cells (See Figure 3.1.A). The cytotrophoblast cells were scattered into 
the maternal decidua and also lining the sprial arteries. Some of the syncytiotrophoblast cells 
undergo apoptosis and form blebs called syncytial knots that disintegrate and are removed 
by circulating blood. The number of syncytial knots in PE sections were found to be higher 
than in NT (See Figure 3.1.B) suggesting increased apoptosis in PE placentae. There were 
distinctive fibrinoid depositions observed in PE sections. The villous capillaries of PE 
sections are lined with necrotic fibrinoid and is filled with plaques. In PE cytotrophoblast 
cells also showed vacuolation and cytomegaly (not shown in figure).  
 
 
Figure 3.1: Histological differences between NT and PE placentae. 
 
 
[A] NT placental section showing the villous system with a single syncytiotrophoblast outer 
layer (arrow head) and an inner cytotrophoblast cell (dotted circle) network. [B] Fibrinoid 
(F) deposits are seen in PE sections. Atheromatous plaque (AP) is formed in the villous 
capillaries. Fibrinoid necrosis (FN) is also observed lining the capillaries. FV- Floating villi; 
Black Arrow- Syncytial knot; (A-B: H&E staining; Magnification: X200). 
 
3.2.3 Gene expression studies 
The varying expression patterns of 5-HT receptor subtypes and C/T antigens of interest in 
NT and PE placental samples were studied. Total RNA was extracted and reverse transcribed 
according to the protocol in Section 2.4 and 2.5. The purity and integrity of RNA samples 
was high because the absorbance ratio of 260/280nm ranged from 1.9-2.3 and after 
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separation on a 1% w/v agarose gel, two clear bands corresponding to 18S and 28S were 
evident. 
Primers for the genes of interests were designed in accordance with Section 2.6.1. 
Conventional and gradient PCR were performed using the primer sets. Optimised annealing 
temperatures and sequence details of C/T antigens and 5-HT receptors together with 
housekeeping genes are summarised in Table 3.2. Human testis and brain cDNA templates 
were used as positive controls to optimise the TA for C/T antigens and 5-HT receptors 
respectively. Primer dimers and product dimers were eliminated by amending the TA. The 
accession numbers for target genes are listed in Appendix A.4. All PCR products were 
confirmed by DNA sequencing carried out by Source Bioscience (Nottingham) Ltd. 
Examples of DNA product confirmation gels and sequencing can be found in Appendix A.5. 
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Table 3.2: Primer Sequences and annealing temperatures (TA) 
GENES PRIMER DIRECTION SEQUENCES (5´-3´) 
PRIMER 
LENGTH 
(Nucleotides) 
TA 
HOUSE KEEPING GENES 
GAPDH Forward ACCACCAACTGCTTAGCACC 20 58°C Reverse CCATCCACAGTCTTCTGGGT 20 
HPRT1 Forward TGACACTGGCAAAACAATGCA 21 55°C Reverse GGTCCTTTTCACCAGCAAGCT 21 
TBP1 Forward TGCACAGGAGCCAAGAGTGAA 21 56°C Reverse CACATCACAGCTCCCCACCA 20 
GENES OF INTEREST 
5-HT Receptors 
5-HT1A 
Forward GAGCTTTCTACATCCCGCTG 20 
58˚C Reverse CCCGACTCTCCATTCACACT 20 
5-HT1B 
Forward CTCCCGGATTTTGAAACAGA 20 
55˚C Reverse TGATCCCTAGGGTCTTGGTG 20 
5-HT1D 
Forward GAGGGAAGGCTCTCTGGTCT 20 58˚C Reverse CACGGACAACTGGGAGAGAT 20 
5-HT1E 
Forward TCCACCTCAGACCCTACCAC 20 
55˚C Reverse GGCAGCCAGGATAAAATGAA 20 
5-HT2A 
Forward AGCTTCCTCCCTCAGAGTTCTTT 23 58˚C Reverse GGGCACCACATCACCACAAA 20 
5-HT2B 
Forward GAACGTTTTGGCGATTTCAT 20 53˚C Reverse AACCATGTTAGGCGTTGAGG 20 
5-HT2C 
Forward ATGGTGAACCTGAGGAATGC 20 
55.8˚C Reverse AATTTGAAGCGTCCACCATC 20 
5-HT3 
Forward ACTGCCTGTAGCCTCGACAT 20 57˚C Reverse AACTCCCACTCTCCCTGGTT 20 
5-HT4 
Forward GGTTTCGGGTCAGTGGAGAAG 21 
57˚C Reverse AGATCCGCAAAAGCAAGAGA 20 
5-HT5A 
Forward CTGTGTGGGCTCTTCGTGT 19 
55.6˚C Reverse GCTGTTTGGCAGAGTCCTTC 20 
5-HT6 
Forward GGGCATGTTCTTTGTGACCT 20 56˚C Reverse GGGGTTCATGGTGCTGTTAC 20 
5-HT7 
Forward CCTCCATCACCTTACCTCCA 20 
59˚C Reverse TGTGTTTGGCAGCACTCTTC 20 
C/T Antigens 
BUC11 Forward CTTGCCACCTCCCAGTAAAA 20 58°C Reverse CTTGGTTTCCAGCTCTTTGC  20 
CAGE1 Forward GGTTGCAAGGAGTGAAGAGC 20 56˚C Reverse CAATCCGGGAGCAGATTAGA 20 
FATE1 Forward CGCAGACTAGCCTGGAAGAG 20 58˚C Reverse ATGATCAGGGTCTCCCTGTG 20 
GAGE1 Forward CTCAAGTCTCCTCAAGGCTGT 21 59˚C Reverse GGGATAGGTACCTGGAGCTG 20 
GAGE C1/ 
PAGE 4 
Forward CCACCAACTGACAATCAGGA 20 
56˚C Reverse CGCTCACTCCGAGTCTTTTC 20 
GAGE E1/ 
PAGE5 
Forward GCACCTAGTGGGGAGATCAA 20 56˚C Reverse TGACATCAGGACCATCTCCA 20 
HAGE Forward GGAGATCGGCCATTGATAGA 20 64.5°C Reverse GGATTGGGGATAGGTCGTTT 20 
MAGE A1 Forward GTCAACAGATCCTCCCCAGA 20 55˚C Reverse GGAGCAGAAAACCAACCAAA 20 
MAGE A3 Forward CTCCAGCAACCAAGAAGAGG 20 55˚C Reverse CAGCATTTCTGCCTTTGTGA 20 
MAGE A4 Forward TCCTTGTTCCGAGAAGCACT 20 55˚C Reverse CAGCATTTCTGCCTTTGTGA 20 
NY-ESO-1 Forward GGCTGAATGGATGCTGCAGA 20 64°C Reverse CTGGAGACAGGAGCTGATGGA 21 
PASD1 Forward GCAAGTGCTCAGCCATTACA 20 56˚C Reverse GCTGCTTCTGAAGGTGATCC 20 
T128 Forward GACGTTCAAGGTCTCCAAGG 20 57°C Reverse TAGTCGCTGGCGTTCTTTCT 20 
T21 Forward CAAAGAATGAAATCATAGCACAGG 24 59˚C Reverse TTCTGTTCTGCCTGGCTTCT 20 
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3.2.3.1 Relative mRNA expression of 5-HT receptors in NT and PE 
Real-time PCR was used to determine expression levels of the various 5-HT receptor 
transcripts in normal (NT) and PE placenta. The 2-∆∆Ct values were calculated as described 
in Section 2.6.5. Scatter-plots (Figure 3.2) show that in general all the NT and PE placentae 
tested expressed most of the 5-HT receptor subtypes.  However, NT and PE samples showed 
high variability of expression. Expression levels for 5-HT3 and 5-HT4 receptors transcripts 
in both NT and PE were negligible and therefore no further analysis performed.  
 5-HT1 Receptor Subtypes: 
Relative expression of 5-HT1 receptors is shown in Figure 3.2. There was no significant 
difference in the levels of 5-HT1A receptor mRNA expression between NT and PE samples. 
However, expression of the other receptor subtypes, 5-HT1B, 1D and 1E, were significantly 
different (p<0.05). The expression patterns of individual subtypes are reported below:   
• 5-HT1A Receptor: 
5-HT1A receptor mRNA expression was higher in PE when compared to NT placentae 
(Figure 3.2). Yet, the data were highly variable and therefore not statistically significant. 
Few samples that show expression were high, but most of the samples (NT as well as PE) 
aligned at the x-axis showing negligible levels of expression.  
 
• 5-HT1B Receptor: 
Relative mRNA levels of expression for the 5-HT1B receptor was significantly reduced in 
PE compared to NT placentae (p<0.05). Therefore, the protein expression and localisation 
of 5-HT1B receptor were investigated further (See Sections 3.2.3.2 and 3.2.3.3). 
• 5-HT1D Receptor: 
Although the data for the 5-HT1D receptor were variable, the relative mRNA expression in 
PE was significantly higher than NT placentae (*p<0.05). The expression in NT samples 
were uniformly distributed, but expression in a few of the PE samples were negligible.  
• 5-HT1E Receptor: 
Overall, mRNA levels for the 5-HT1E receptor was significantly reduced in PE placentae 
(p<0.05). Most of the PE samples showed no expression of this receptor, whereas NT 
placenta had a maximum reading of approximately 8. 
 
 5-HT2 Receptor subtypes: 
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Only one of the three 5-HT2 receptor subtypes studied showed a significant difference in 
mRNA expression in NT compared to PE placental tissue; 5-HT2B (p<0.001) (Figure 3.2). 
These expression patterns are elaborated individually below. 
• 5-HT2A Receptor: 
There were no changes in mRNA expression of the 5-HT2A receptor in NT compared to PE 
samples.  
• 5-HT2B Receptor: 
Maximum levels of mRNA for the 5-HT1B receptor were approximately 8,300 in NT 
placental tissues. However, in PE placental tissues, they were significantly reduced to 700 
(p<0.001) and represented a 12-fold decrease in the expression of 5-HT2B in PE placenta 
(See Figure 3.2). Further analysis for protein estimation and localisation were carried out on 
this receptor subtype due to this significant reduction in its levels of mRNA. 
  
• 5-HT2C Receptor: 
There was a slight down-regulation in mRNA expression for the 5-HT2C receptor in PE when 
compared to NT which was not statistically significant. The mRNA expression of 5-HT2C 
receptor was the lowest among the other 5-HT2 receptor subtypes, as well as other members 
of 5-HT receptor family (See Figure 3.2).  
 
 5-HT3 and 5-HT4 Receptors: 
Levels of mRNA expressions for the 5-HT3 and 5-HT4 receptor subtypes were negligible in 
placental samples. Therefore no further analysis was performed. (Data not shown)  
 5-HT5A Receptor: 
The relative mRNA expression of 5-HT5A receptor in placental tissues were very low to 
negligible. Only three PE samples showed elevated levels, but due to high variability in 
samples it was not statistically different to NT. 
 5-HT6 Receptor: 
The level of mRNA expression for the 5-HT6 receptor was comparable to 5-HT1B receptor 
(See Figure 3.2). The expression was lower in PE when compared to NT, but this difference 
was not statistically significant.  
 5-HT7 Receptor: 
Expression levels were similar between NT and PE placentae, although PE samples showed 
slightly higher expression compared to NT (See Figure 3.2).  
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Figure 3.2: Expression levels of 5-HT Receptor transcripts in NT and PE placentae. 
 
Statistical significance was determined using the Mann – Whitney U test (n = 12-13; *p<0.05; ***p<0.001). The error bars (SEM) are represented 
with brown lines. Values are arbitrary units relative to expressions in brain (positive control; not shown in figure) set to 1.  Therefore the scales 
(y-axis) vary with expression levels in placental samples relative to brain.  
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3.2.3.1.1 Collective expression analysis of 5-HT receptor subtypes  
A major problem with studying gene expression of the 5-HT family of receptors is 
determining whether a change in the expression profile of a particular subunit is real. That 
is, if a low expressing subtype is altered it may be considered insignificant in relation to an 
abundantly expressed family member. For this reason, a tissue that expresses all 5-HT 
transcripts, the brain, was chosen to normalise expression levels against. So since expression 
levels of individual transcripts were ultimately compared to their counter parts in the brain, 
it is possible to determine whether the alteration in expression in placental tissue is due to 
pre-eclamptic conditions per se.   
Since the relative mRNA expression of 5-HT1B and 5-HT2B receptors mRNA levels were 
significantly reduced in PE placentae, further protein expression studies were conducted 
only on these receptors. Although the 5-HT1D and 5-HT1E receptor mRNA levels are also 
significantly reduced in PE placentae, their expression was generally low in placentae, they 
were not explored in protein expression analysis. 
 
3.2.3.2 Protein expression of 5-HT receptors 
The expression of 5-HT1B and 5-HT2B receptors was investigated in NT and PE samples 
using western blot analysis to check the consistency between mRNA and protein 
expressions; see Section 2.7 for methods. Levels of protein expression were first normalised 
against β-actin levels and then levels of 5-HT1B or 2B in human brain tissue. The scatter-
plots for the relative protein expression of 5-HT1BR is represented in Figure 3.3 below. The 
β-actin for the same blot confirmed equal loading of the samples (70µg) and were used as 
internal controls for normalisation. The loading amount was reduced for positive control 
(brain) to avoid over-saturation of the blot. Brain samples (20µg) are separated by dotted 
lines in the blot. Examples of wholes blots can be found in Appendix A.6.  
Unfortunately the antibody available for immunoblotting of 5-HT2BR (biorbyt) were unable 
to detect proteins in placental samples as well as positive control (brain), even at the highest 
concentrations.  
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Figure 3.3: The expression of 5-HT1BR protein in NT and PE placentae. 
 
5-HT1B receptor expression was normalised to both an internal control (β-actin) and a 
positive control (5-HT1B levels in human brain). Scatter-plots are derived from 12-13 
samples and relative expressions were determined from two independent blots. Mann – 
Whitney U test was performed. The error bars (SEM) are represented with brown lines. 
Below are representative Western blots showing the band detected by the anti- 5-HT1B and 
β-actin antibodies. 
 
 5-HT1BR 
The anti-5-HT1B receptor antibody recognised a single band that migrated at approximately 
33kDa in 10% w/v SDS-PAGE gel. This is slightly less than the predicted molecular weight 
which was 47kDa. Among all the placental samples, only few samples (five NT and four 
PE) showed expression of 5-HT1BR receptor at protein level. Furthermore the level of 
expression in PE was found to be slightly lower when compared to NT after analysis of the 
bands. However, this difference in expression was not significant. Overall the placental 
samples expressed lower 5-HT1BR when compared to levels in the brain.  
3.2.3.3 Cellular localisation of the 5-HT1BR and 5-HT2BR 
The status and cellular localisation of 5-HT1B and 2B receptors was investigated by 
immunohistochemistry (IHC). The brown staining with 3,3'-Diaminobenzidine 
(DAB) substrate were considered as immuno-positive and scored according to the intensity 
of staining (See Section 2.9.1). The scoring was carried out blindly by three different scorers 
(two trained histopathologists and the author) and the final IRS can be found in Table 3.3. 
The Fleiss’ Kappa Statistics performed on this IRS data provided a kappa value of 0.47 
suggesting a moderate level of attribute agreement between the scorers. The values for the 
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kappa were interpreted as mentioned by Viera and Garrett (2005). If the values were less 
than 0, there was less chances of agreement; 0.01–0.20, indicated slight agreement; 0.21– 
0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, substantial agreement and 
0.81–0.99, practically perfect agreement.  
Table 3.3: Immuno-reactivity score (IRS) of 5-HT1BR and 5-HT2BR in NT and PE 
5-HT 
RECEPTORS 
NT (n=5) PE (n=5) P VALUE SIGNIFICANCE 
5-HT1BR 3 ± 0.3 3 ± 0.4 > 0.9999 ns 
5-HT2BR 3 ± 0.2 3 ± 0.2 > 0.9999 ns 
 
The intensity of staining was represented by the mode (the most frequently repeated score) 
±SEM of the IRS from 5 individual samples in each group.  Unpaired t-test was then 
performed on the IRS modes of NT and PE (ns=no significance). 
 
 5-HT1BR 
The location of 5-HT1BR can be observed from compiled images for NT and PE tissues 
(Figure 3.4 and 3.5 respectively). Distinct staining was observed around the CTB and STB 
layer in NT tissues (thin arrows) suggesting immuno-positivity for the receptor. In addition, 
the CTB and STB layer of the placental villi (represented by *) showed intense staining. The 
5-HT receptor in PE tissues showed immuno-reactivity at similar locations when compared 
to NT. The IRS scores showed no statistical difference in staining between NT and PE 
samples (Table 3.3).  
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Figure 3.4: 5-HT1B Receptor localisation in NT placentae, determined by 
immunohistochemistry. 
 
 
5-HT1BR reactivity for each sample was scored against immuno-reactivity for Vimentin (+ve) and 
secondary (2nd) Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Circled area 
= EVT cells; Asterisk (*) = placental villi. Objective magnification: 20X (Scale bar=100µm); 
100X (Scale bar= 20µm). 
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Figure 3.5: 5-HT1B Receptor localisation in PE placentae determined by 
immunohistochemistry. 
Five placental samples for each NT and PE groups are represented here. 5-HT1BR reactivity for each 
sample was scored against immuno-reactivity for Vimentin (+ve) and secondary (2nd) Ab only (-ve) 
for the same sample. Thin arrows = CTB and STB layers; Circled area = EVT cells surrounding the 
arteries; Asterisk (*) = placental villi. Objective magnification: 20X (Scale bar=100µm); 100X 
(Scale bar= 20µm). 
 
 5-HT2BR 
Both NT and PE tissues showed high immuno-reactivity for 5-HT2BR (Figure 3.6 and 3.7 
respectively). The STB, CTB layers (thin arrow) and the lining of the spiral arteries (arrow 
head) were distinctly stained. The stromal cells (double arrow) surrounding the spiral arteries 
showed immuno-positivity in NT (image 5). The villi sections (*) were intensely stained in 
NT tissues when compared to PE. The STB layer in PE showed even deeper staining than 
the CTB layer. Focal positivity was observed in decidual sections of PE placenta (image 5) 
with staining concentrated around the syncytial knot (+ in Figure 3.7). The IRS confirmed 
no significant differences in staining between NT and PE tissues (Table 3.3).   
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Figure 3.6: 5-HT2B Receptor localisation in NT placentae determined by 
immunohistochemistry. 
 
 
5-HT2BR reactivity for each sample was scored against immuno-reactivity for Vimentin (+ve) and 
secondary (2nd) Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads 
= the lining of the spiral arteries; Circled area = EVT cells surrounding the spiral arteries; Asterisk = 
placental villi; Plus = syncytial knots. Objective magnification: 20X (Scale bar=100µm); 100X 
(Scale bar= 20µm). 
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Figure 3.7: 5-HT2B Receptor localisation in NT placentae determined by 
immunohistochemistry. 
 
 
5-HT2BR reactivity for each sample was scored against immuno-reactivity for Vimentin (+ve) and 
secondary (2nd) Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads 
= the lining of the spiral arteries; Circled area = EVT cells surrounding the spiral arteries; Asterisk = 
placental villi; Plus = syncytial knots. Objective magnification: 20X (Scale bar=100µm); 100X 
(Scale bar= 20µm). 
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3.2.3.4 Relative mRNA expression of C/T antigens in NT and PE placenta 
All C/T antigens studied showed differential expressions patterns in NT and PE 
placentae. Some show increased expression in NT placentae (e.g. CAGE1), whereas others 
show increased expression in PE placentae (e.g. MAGEA1). In contrast, some show very 
low expression in both (e.g. FATE1). However, amongst the 14 C/T antigens studied, seven 
showed statistical significant difference at the mRNA level. The expression of C/T antigens 
were analysed in relation to human testis (as positive control). Unlike the 5-HT receptors 
family, all the C/T antigens studied do not belong to the same family so an overall 
representation of their expressions could not be performed. The scatter plots comparing the 
expression of these genes in NT and PE are provided in Figure 3.6.  
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Figure 3.8: Relative expressions levels for C/T antigens mRNAs   
 
Statistical significance was determined using the Mann – Whitney U test (n = 12-13; *p<0.05; ***p<0.001; ****P<0.0001). The error bars (SEM) 
are represented with brown lines. Values are arbitrary units relative to expression in testis (positive control; not shown in figure) set to 1.  Therefore 
the scales (y axis) vary with expression levels in placental samples relative to testis. 
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The expression patterns for each of the C/T antigens are elaborated below: 
 BUC11  
The majority of placental samples showed lower levels of expression of BUC11 compared 
to human testis. The expression of BUC11 was lower in PE placentae when compared to NT 
(Figure 3.6).  
 
 CAGE1  
Interestingly, mRNA expression for CAGE1 was significantly down-regulated in PE 
compared to NT placentae (p<0.05) (See Figure 3.6).  
 
 FATE1 
Although the level of expression of FATE1 was seen to be lower in all placental samples, 
the expression was significantly lower in PE when compared to NT (p<0.05).  
 
 GAGE Family: 
The relative expression of GAGE family genes was lower in PE placentae when compared 
to NT samples (Figure 3.7). Among the three members of the GAGE family, 
GAGEC1/PAGE4 showed the highest expression in all placental samples. However, it was 
the only member which did not show any significant different in expression between NT and 
PE placentae. On the other hand, whilst GAGE1 and GAGEE1/PAGE5 showed relatively 
lower levels of expressions; they were both significant difference in patterns for NT and PE 
(p<0.05 and p<0.0001).  
 
Figure 3.9: Overall expression patterns of GAGE family members. 
 
NT and PE placental samples are represented in green dots and red squares respectively. 
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 HAGE 
There was no change in mRNA expression for HAGE between NT and PE placentae (Figure 
3.6). 
 
 MAGE Family: 
• MAGEA1 
MAGEA1 was significantly up-regulated in PE placentae compared to NT (p<0.0001; 
Figure 3.6).  
• MAGEA3  
Whilst MAGEA3 appears to have a higher level of expression in NT placenta, the difference 
is not significant. This is probably due to high variability in individual data points (Figure 
3.6). 
• MAGEA4 
The level of expression of MAGEA4 was statistically lower in PE compared to NT placentae 
(p<0.001; Figure 3.6).   
 
The comparative expression patterns of MAGE family members are represented in Figure 
3.8. The MAGEA1 is significantly up-regulated in PE, thus resulting in significant difference 
in expression levels to other MAGE family, MAGEA3 (p<0.05) and MAGEA4 (p<0.01). 
 
Figure 3.10: Overall mRNA expression patterns of MAGE family members. 
 
NT and PE placental samples are represented in green dots and red squares respectively. 
Variances were analysed by Kruskal-Wallis test followed by Dunn’s multiple comparison 
between the three members (*p<0.05; **p<0.01±SEM). 
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Approximately 25% of the PE placenta showed elevated NY-ESO-1 levels compared to NT 
(Figure 3.6) with the rest of the PE samples having similar levels to NT placenta. The level 
of expression was less in all placental samples relative to testis.  
 PASD1  
This mRNA was of low abundance and hardly expressed in placental tissue. Nevertheless, a 
few of the NT samples (~25%) did show relatively high levels of expression when compared 
to PE samples, resulting in statistical significance (p<0.05). The level of PASD1 mRNA 
expression was statistically lower in PE compared to NT placentae (p<0.05; Figure 3.6).  
 T21 
Although two samples in both NT and PE placenta did show high levels of T21 expression, 
generally levels were not elevated (Figure 3.6).  
 T128  
Expression levels for T128 were highly variable in both NT and PE samples suggesting 
factors unrelated to placental development/homeostasis are playing a role in their expression 
(Figure 3.6).  
 
3.2.3.5 Protein expression of C/T antigens 
The scatter-plots for protein expression of C/T antigens are shown in Figure 3.9. Equal 
amounts of placental samples (35-70µg) were loaded, as confirmed by the internal controls 
(β-actin and GAPDH) on the same blots. Only 20µg of the positive control (testis) were 
loaded to avoid over-saturation of the blot. The last lane containing the testis samples are 
separated by dotted lines (See Figure 3.9). Of the seven C/T antigens that show significant 
differences in mRNA expression, only six were checked for protein expressions as there 
were no reliable, commercially available, antibodies against PASD1. The protein 
expressions of the rest, namely CAGE1, FATE, GAGE and MAGE families were compared 
between NT and PE samples.  Examples of whole blots can be found in the Appendix A.6.  
 
 CAGE1 
The anti-CAGE1 antibody yielded three distinct bands in three of the minority of the NT and 
PE placental samples. The molecular weight of these bands were approximately 100, 150 
and 175kDa respectively (indicated by red arrows in Figure 3.9). This molecular weight of 
the bands is within the range (95-230kDa) of detected bands declared by the supplier 
(Sigma). The three visible bands were analysed in all the samples as the positive control also 
displayed these bands, making it difficult to predict the correct band.  The expression levels 
in PE samples were comparatively lower than in NT placentae. Although only 20µg of 
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positive control (testis) was loaded along with 70µg of placental samples, the intensity of 
the band was still stronger in testis.  
 FATE1 
The predicted molecular weight for FATE1 protein declared by the supplier (Sigma) was 
17-28 kDa. The two bands detected for FATE1 in positive control and placental samples 
were within the range of 20kDa to 25kDa (indicated by red arrows in Figure 3.9). Almost all 
the NT samples showed expression of FATE1. On the other hand, only few of the PE samples 
showed expressions of FATE1, but the intensity of the bands was higher when compared to 
NT. 
 GAGE Family 
The two members of GAGE family that were investigated for protein expression showed 
significant differences in expression between NT and PE placentae.  
o GAGE1 
Two bands were observed for GAGE1 immunoblotting in both testis and placental samples 
that migrated between 30-40kDa (indicated by red arrows in Figure 3.9), which is within the 
predicted range of between 25-37kDa. Both the bands were analysed, since these were also 
visible in positive control (testis). Few placental samples showed very close level of 
expressions to that in testis (approximately 0.8). Additionally a significant difference in 
expression was observed between NT and PE placentae (p<0.05). The levels were 
significantly lower in PE when compared to NT, which could be as a result of 6 PE samples 
showing negligible expression.  
o GAGEE1/PAGE5 
GAGEE1 (also known as PAGE5) was one of the few C/T antigens which exhibited very 
intense bands on the immunoblots (Figure 3.9). Therefore, of all the C/T antigens studied, 
GAGEE1/PAGE5 showed the greatest expression in placental samples. As the scatter plot 
shows, GAGEE1/PAGE5 expression is lower in PE placenta (p<0.001). Whilst the expected 
molecular weight of the band was 14kDa, the antibody detected a band at ~22kDa in 
placental samples and testis (positive control).  
 
 
 
 MAGE Family 
 
o MAGEA1 
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The commercially available antibody for MAGEA1 (Abcam) was not able to detect 
MAGEA1 expressions in placental samples, even after increasing loading amounts of 
protein (70-140µg). Since a band was detected in testis (positive control) that migrated at 
~34 kDa, it confirms that this protein was not expressed in the placental tissue studied (data 
not shown).  
 
o MAGEA4 
Almost all the samples showed expression of MAGEA4 protein (See Figure 3.9). The bands 
were detected at 37kDa for placental, as well as testis samples. Interestingly, when the 
expression levels were compared between NT and PE placentae, a significant reduction was 
observed in PE samples (p<0.001). 
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Figure 3.11: C/T antigen protein expression – Comparative scatter plots. 
 
The relative expressions are arbitrary units of the values calculated from two independent 
blots normalised firstly to internal control (β-actin) and secondly to a positive control (human 
testis). Mann – Whitney U test was performed (*p<0.05; ***p<0.001). The error bars (SEM) 
are represented with brown lines.  
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As a result from the protein investigations of these six C/T antigen, three showed 
significantly lower protein levels in PE samples compared to NT. Hence, the protein study 
supports the differential expression patterns of these genes in NT and PE placentae.  
 
3.2.3.6  Cellular localisation of significant C/T antigens 
The expression of C/T antigens in placental samples was also investigated by IHC in order 
to identify their cellular localisation. Most of the C/T antigens showed granular positive 
staining of the cytoplasm with a few exceptions. For example, the GAGE family for which 
both nucleus and cytoplasm were stained. The IRS semi-quantified data between NT and PE 
are shown in Table 3.4. As before (Section 3.2.3.3), the Fleiss’ Kappa Statistics was 
performed on this IRS data and a kappa score of 0.468 was obtained indicating the agreement 
between the scorers were moderate.  
 
Table 3.4: Immuno-reactivity score (IRS) of C/T antigens 
C/T ANTIGENS NT (n=5-6) PE (n=4-5) P VALUE SIGNIFICANCE 
CAGE1 2 ± 0.5 2 ± 0.2 > 0.9999 ns 
FATE1 1 ± 0.6 0 ± 0.2 0.1761 ns 
GAGE1 3 ± 0.4 3 ± 0.0 > 0.9999 ns 
GAGEE1/PAGE5 3 ± 0.1 2 ± 0.5 0.1231 ns 
MAGEA1 3 ± 0.4 1 ± 0.3 0.0094 ** 
MAGEA4 1 ± 0.2 1 ± 0.3 > 0.9999 ns 
PASD1 3 ± 0.2 3 ± 0.4 > 0.9999 ns 
 
The intensity of staining was represented by the mode±SEM of the IRS from 5 individual 
samples in each group.  Unpaired t-test was then performed on the IRS modes of NT and PE 
(ns=no significance). 
 
 
 
 CAGE1 
Moderate immuno-staining was observed for CAGE1 in both NT and PE samples (Figure 
3.12 and 3.13). Staining was visible in the cytoplasm of the cells that were immunopositive. 
The STB and CTB layers of the placental villi were deeply stained for CAGE1 in NT tissues 
(thin arrows). The lining of the spiral arteries also showed similar staining intensities (arrow 
head). The EVT cells, present around the villous columns and in the placental beds, also 
revealed distinct immuno-positivity (encircled). Intense staining was also observed in the 
collagen and fibrous layers surrounding the placental arteries (bold arrows; image 5 of Figure 
3.12).  However, in PE tissues, the staining of CAGE1 was reduced, relatively around the 
placental villi, but was more concentrated on the decidual placental beds.  Various cells, 
including EVT cells, in the placental bed showed moderate immuno-reactivity to CAGE1 
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(PE; image 1 and 4).  The CAGE1 staining intensities for NT and PE showed no significant 
differences (Table 3.4).  
 
Figure 3.12: CAGE1 protein placental localisation in NT placentae determined by 
immunohistochemistry. 
 
CAGE1 reactivity for each sample was scored against immuno-reactivity for Vimentin (+ve) and 2nd 
Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = spiral arteries 
encircled area = villous column; Bold arrows = collagen and fibrous layers surrounding the placental 
arteries; Asterisk = villi. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 
20µm). 
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Figure 3.13: CAGE1 protein placental localisation in PE placentae determined by 
immunohistochemistry. 
 
CAGE1 reactivity for each sample was scored against immuno-reactivity for Vimentin (+ve) and 2nd 
Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = spiral arteries 
encircled area = villous column; Bold arrows = collagen and fibrous layers surrounding the placental 
arteries; Asterisk = villi. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 
20µm). 
 
 FATE1 
Compared to other C/T antigens studied, the overall IRS for FATE1 was very low. In NT 
tissues, granular cytoplasmic staining was observed in the CTB and STB layers (thin 
arrows). The EVT cells of the placental villous column showed more intense staining than 
the remaining tissue sections (encircled in Figure 3.14; NT, image 1). Fibrin and collagen 
layers around the arteries were also immuno-reactive to FATE1 (bold arrows). Interestingly, 
few cells in the stroma of the villi were also stained (double arrows), which were more focal 
in some sections (NT, image5).  Furthermore, the FATE1 staining in PE samples was almost 
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negligible, with only few focal staining of the EVT in the decidua and stroma (Figure 3.15). 
It was not statistically significant (Table 3.4). 
 
Figure 3.14: FATE1 protein placental localisation in NT placentae determined by 
immunohistochemistry. 
 
FATE1 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) and 2nd 
Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; encircled area = villous 
column; Bold arrows = collagen and fibrous layers surrounding the placental arteries; Asterisk = 
villi. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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Figure 3.15: FATE1 protein placental localisation in PE placentae determined by 
immunohistochemistry. 
 
FATE1 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) and 2nd 
Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; encircled area = villous 
column; Bold arrows = collagen and fibrous layers surrounding the placental arteries; Asterisk = 
villi. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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 GAGE Family 
Immunohistochemistry was performed on two members of the GAGE family, GAGE1 
and GAGEE1/PAGE5.  
• GAGE1 
The IRS data for GAGE1 in NT and PE inferred high staining intensity with no significant 
difference between the two groups (Table 3.4). The CTB and STB layers of the placental 
villi (asterisk) as well as the villous tree (thin arrows) were deeply stained in both NT and 
PE tissues (Figure 3.16 and 3.17 respecitvely). Staining was also distinctly visible around 
the inner lining of the spiral arteries in NT tissues (represented with arrow heads in NT, 
image 3). Moreover, the cytoplasm and nucleus of the EVT in the placental beds of NT 
tissues exhibit a higher IRS when compared to the other stained areas of the same tissue 
(NT, images 4 and 5). Conversely, in PE tissues, in addition to staining of the CTB, STB 
and EVT, the fibrin and collagen deposits as well as few stromal cells were stained 
(Represented with bold arrows in PE, image 1). 
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Figure 3.16: GAGE1 localisation in NT placentae determined by 
immunohistochemistry. 
 
GAGE1 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) and 
2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = spiral 
arteries; encircled area = villous column; Bold arrows = collagen and fibrous layers surrounding 
the placental arteries; Asterisk = villi. Objective magnification: 20X (Scale bar=100µm); 
100X (Scale bar= 20µm). 
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Figure 3.17: GAGE1 localisation in PE placentae determined by 
immunohistochemistry. 
 
GAGE1 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) and 
2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = spiral 
arteries; encircled area = villous column; Bold arrows = collagen and fibrous layers surrounding 
the placental arteries; Asterisk = villi. Objective magnification: 20X (Scale bar=100µm); 
100X (Scale bar= 20µm). 
 
 
• GAGEE1/ PAGE5 
Amongst all the C/T antigens investigated for IHC, GAGEE1/PAGE5 IRS exhibited the 
maximum intensity (See Figure 3.18 and 3.19). The entire NT sections were completely 
stained; with higher staining intensities around the spiral arteries (bold arrows).  These 
regions comprised of fibrin, collagen layers and stromal cells (double arrows). The 
immuno-reactivity of the CTB and STB layers were relatively low. Futhermore, the EVT 
cells in the villous column as well as the villi showed moderate staining (encircled). On 
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the other hand, the staining in PE tissues were more dispersed and concentrated at few 
regions on the placental bed. In these regions, the cytoplasm of various cells were 
observed to have granular staining, especially EVT (encircled) and stromal cells (double 
arrows). Although the IRS score was lower for PE staining when compared to NT, the 
difference was not statistically significant (Table 3.4). 
 
 
 
Figure 3.18: GAGEE1 localisation in NT placentae determined by 
immunohistochemistry. 
 
GAGEE1 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) 
and 2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = 
spiral arteries; encircled area = villous column; Bold arrows = collagen and fibrous layers 
surrounding the placental arteries; Asterisk = villi. Objective magnification: 20X (Scale 
bar=100µm); 100X (Scale bar= 20µm). 
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Figure 3.19: GAGEE1 localisation in PE placentae determined by 
immunohistochemistry. 
GAGEE1 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) 
and 2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = 
spiral arteries; encircled area = villous column; Bold arrows = collagen and fibrous layers 
surrounding the placental arteries; Asterisk = villi. Objective magnification: 20X (Scale 
bar=100µm); 100X (Scale bar= 20µm). 
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 MAGE Family 
MAGEA1 and MAGEA4, members of the MAGE family were investigated for their 
localisation in NT and PE tissues by IHC.  
• MAGEA1 
The primary location for MAGEA1 staining in NT tissues was the placental villi (asterisk) 
with intense staining detected in the STB and CTB layers (thin arrows) and a few stromal 
cells (double arrows; Figure 3.20). In PE, IRS for MAGEA1 was observed in the decidual 
regions with more focal staining of the EVT cytoplasm in the placental beds (encircled). 
Patchy staining patterns were also observed in PE decidua (represented by double arrows 
in PE, image 4 of Figure 3.21). Overall, the staining intensity in PE tissues was lower 
when compared to the high staining levels in NT tissues. These were confirmed by the 
IRS data which showed statistically significant differences for MAGEA1 staining in NT 
and PE samples (p<0.01) (Table 3.4).   
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Figure 3.20: MAGEA1 localisation in NT placentae determined by 
immunohistochemistry. 
 
MAGEA1 reactivity for each sample was scored against immune-reactivity for Vimentin 
(+ve) and 2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; 
encircled area = villous column; Asterisk = villi. Objective magnification: 20X (Scale 
bar=100µm); 100X (Scale bar= 20µm). 
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Figure 3.21: MAGEA1 localisation in PE placentae determined by 
immunohistochemistry. 
 
MAGEA1 reactivity for each sample was scored against immune-reactivity for Vimentin 
(+ve) and 2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; 
encircled area = villous column; Asterisk = villi. Objective magnification: 20X (Scale 
bar=100µm); 100X (Scale bar= 20µm). 
 
• MAGEA4 
The staining intensity for MAGEA4 was very weak in both NT and PE tissues, as can be 
seen in Figure 3.22 and 3.23. The staining around the CTB and STB layers were almost 
negligible. A small number of EVT cells in the placental beds showed granular staining 
of the cytoplasm. Weak staining was also observed in the fibrin deposits around the 
placental bed (bold arrow). Overall, there was no significant difference in staining 
intensity of MAGEA4 in NT and PE (Table 3.4).  
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Figure 3.22: MAGEA4 localisation in NT placentae determined by 
immunohistochemistry. 
 
MAGEA4 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) 
and 2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = 
spiral arteries; Bold arrows = collagen and fibrous layers surrounding the placental arteries; 
Asterisk = villi. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 
20µm). 
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Figure 3.23: MAGEA4 localisation in PE placentae determined by 
immunohistochemistry. 
 
MAGEA4 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) 
and 2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = 
spiral arteries; Bold arrows = collagen and fibrous layers surrounding the placental arteries; 
Asterisk = villi. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 
20µm). 
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 PASD1 
NT and PE tissues showed relatively high IRS for PASD1. In NT tissues, the CTB and 
STB layers were distinctly stained (thin arrows in Figure 3.24). The cytoplasmic staining 
of the stromal cells (represented by double arrows; NT, image 3) as well as the EVT cells 
(encircled in NT, image 4) were also stained.  Apart from staining of the CTB and STB 
layers, in PE the decidual sections showed intense staining around the EVT cells (bold 
arrows in PE, image 1, Figure 3.25). The IRS data showed equal intensities of staining in 
NT and PE tissues (Table 3.4). 
 
Figure 3.24: PASD1 localisation in NT placentae determined by 
immunohistochemistry. 
 
PASD1 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) and 
2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = spiral 
arteries; Bold arrows = collagen and fibrous layers surrounding the placental arteries; Asterisk = 
villi. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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Figure 3.25: PASD1 localisation in PE placentae determined by 
immunohistochemistry. 
 
PASD1 reactivity for each sample was scored against immune-reactivity for Vimentin (+ve) and 
2nd Ab only (-ve) for the same sample. Thin arrows = CTB and STB layers; Arrow heads = spiral 
arteries; Bold arrows = collagen and fibrous layers surrounding the placental arteries; Asterisk = 
villi. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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3.3 Discussion 
The aim of this chapter was to determine the levels of mRNA and protein expression of 5-
HT receptors and C/T antigens as well as their cellular locations in NT and PE placentae.  
Although there is no established direct link between 5-HT and the expression of C/T 
antigens, studies have highlighted that 5-HT promotes tumour growth and invasion (Soll et 
al, 2010). In fact the metabolism of 5-HT is affected by cancer chemotherapeutic agents was 
highlighted as early as 1992 (Cubeddu et al, 1992); in which the authors have suggested that 
the change in the 5-HT metabolism might be the cause of drug induced nausea and vomiting 
in cancer patients. Interestingly, breast cancer cells have shown to increase their biosynthetic 
capacity of 5-HT (Pai et al, 2009). It was argued that increased 5-HT, together with the 
changes in the expression of its receptors, would result in rapid proliferation of these cells 
into malignancy. The fact that the homeostatic regulatory mechanisms of 5-HT are changed 
during tumorigenesis, opens a new avenue for identifying the link between 5-HT, its 
receptors and any diagnostic and prognostic tumour markers.  
As explained in Chapter 1, C/T antigens are mainly expressed in tumours; hence they are 
considered as tumour markers. The only two non-tumour tissues that show the expressions 
of C/T antigens are testis and placentae. Interestingly in PE, where the trophoblastic invasion 
is found to be low, the circulating level of 5-HT is increased (Bolte et al, 2001; 2001a; 
Sivasubramaniam et al, 2002; Salas, 2007). Also this increase affects the expression of 5-
HT2A receptors in chorionic arteries and veins (Ugun-Klusek et al, 2011). Trophoblast and 
tumour invasion share common characteristics and they both express C/T antigens. Together 
with the fact that invasion is low in PE, coupled with an increase in 5-HT, it is interesting to 
compare the expressions of (a) 5-HT receptors and (b) C/T antigens between NT and PE 
placentae. Therefore, the chapter compared the levels of mRNA and protein expression of 
5-HT receptors and C/T antigens as well as their cellular locations in NT and PE placentae. 
This is then linked to (a) their status in first trimester trophoblast (Chapter 4) and (b) the in 
vitro effects of 5-HT on its receptors and C/T antigens using placental origin cell lines in 
(Chapters 5 and 6). 
Since gene transcription does not guarantee faithful translation, the expression of both 
mRNA and protein in NT and PE placentae were studied. In addition, identification of any 
mRNA that was up-regulated, but not translated, is suggestive of another role in cell 
function, for example control of gene expression. 
The summary of results for this chapter can be found in Table 3.5 below.  
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 5-HT 
There are 13 known members of the 5-HT receptors family which is split into 7 main classes; 
5-HT1-7. The 5-HT1F receptor has only been identified by comparative studies in the human 
genome and was therefore excluded from this study. Both mRNA and protein levels for 5-
HT1BR were decreased in PE placentae compared to NT tissue, although only mRNA levels 
were significant (p<0.05). On the other hand, there was no overall alteration in 5-HT1BR 
cellular distribution. Interestingly, 5-HT2BR mRNA levels were significantly decreased in 
PE tissue (p<0.001) to such a level that no protein was detected on immunoblots. This 
appears to contradict the immunohistochemistry data that clearly shows 5-HT2BR protein in 
PE placenta. The reduction of 5-HT2BR mRNA confirms previous study carried out by the 
author and co-workers using placental arteries and veins (Ugun-Klusek et al, 2011).  
Table 3.5: Overall correlation amongst mRNA, protein expression and IRS in PE in 
comparison to NT placentae. 
 
 The mRNA and protein expressions of C/T antigens which were in agreement are encircled 
in red. (-) down regulated; (+) upregulated; = - No change (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001); ns= no significance; ND= Not detected. 
C&F- Collagen & fibrin; CTB- Cytotrophoblast; D-Decidua; DS-Decidual stroma; EVT-
Extravillous trophoblast; SA-Spiral arteries; STB- Syncytiotrophoblast. 
 
 
 C/T antigens 
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The result for FATE1 is unexpected because even though the mRNA levels in PE tissue were 
significantly reduced its protein levels were actually elevated. Although the reasons for this 
inverse correlation is not clear, one explanation could be that high levels of the protein have 
shown to down regulate mRNA transcription as a compensatory effect. Another reason could 
be due to the half-life of some transcripts being extremely low and hence any mRNA 
expressed has already been degraded. The converse argument can be made for studies 
showing relatively high levels of mRNA compared to their protein counterpart; some 
transcripts have extremely long half-lives. In fact, Schwanhausser et al (2013) argued there 
is a poor correlation between some mRNAs and proteins, especially amongst those factors 
involved in the regulation of cell division and differentiation. They have suggested that the 
correlation between transcript and protein levels can be as little as 40% for factors/antigens 
that have regulatory functions (Vogel and Matcote, 2012; Guo et al, 2008). Since FATE1 is 
proposed to have steroidogenic factor 1 (SF-1, a protein that controls sexual development in 
the embryo and in tumorigenesis) binding sites in its promoter region. (Olesen et al, 2011) 
Although the functions of FATE1 in placenta are yet to be understood, this would seem a 
reasonable explanation for its differing transcript and protein expression profiles. 
However, in some cases (such as CAGE1 and GAGE1), there were more than one protein 
bands visible on the blots. Since these bands were also consistently shown in positive 
controls, the intensities of all these bands were comparatively analysed. Although this may 
be a limitation of this study, it was unfeasible, within the study period, to extensively analyse 
whether these extra bands actually represent the original protein. This is one of the very few 
studies that used CT antigen specific antibodies in Western blots.  In fact to author’s 
knowledge, this is the first study that comparatively analysed the expression of CT antigens 
between NT and PE placentae. Since all the antibodies used were polyclonal in nature, these 
additional, but faint, bands may be due to non-specific binding. 
CAGE1, GAGE1, GAGEE1/PAGE5 and MAGEA4 levels of both mRNA and protein 
expression were decreased in PE samples; although there appears to be no alteration in their 
cellular expression. Most of these C/T antigens are localised in CTB and STB layers of both 
NT and PE placentae. The cytoplasm of these cells showed granular staining. In human 
placentae, the cytotrophoblast layer function as stem cells for syncytiotrophoblasts. They 
continually differentiate into syncytiotrophoblasts during villous development. Since these 
cells are capable of invading uterine spiral arteries and involved vascular remodelling, they 
are believed to be “pseudo-malignant” (Sounderajan and Rao, 2004). 
The expression of C/T antigens by these cells is an indication of their similarity to invading 
tumour cells. The fact that CTB cells continuously express these tumour markers even at 
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term suggests that they retain their proliferative capacity throughout the pregnancy. This 
agrees with the theory “placenta can be regarded as a physiological counterpart of highly 
invasive tumours” recently summarised by Novakovic and Saffery (2013).   
The GAGE family is expressed primarily in germ cells, such as primary spermatocytes and 
oocytes (Gjerstorff et al, 2006). Since proteins for members of this family are found in the 
nucleus their role in germ cell regulation through apoptosis has been speculated. Since the 
IHC results (Figure 3.12) clearly shows the expression of GAGE1 in the nucleus, as well as 
the cytoplasm, of trophoblast cells this would suggest a nuclear role in the placenta. The IHC 
staining intensity was very high for GAGEE1/PAGE5 making it difficult to differentiate 
between nuclear and cytoplasmic staining. It has also been reported that the expression levels 
of GAGE family varied with the developmental stage of the germ cells. Although in oocytes, 
it has been shown that expression levels did not change during the maturation phase 
(Gjerstorff et al, 2006). On the other hand, expression levels of GAGE decreases during 
maturation of spermatocytes. Thus, it was important to study the expression of the GAGE 
family in first trimester placental tissues in order to understand expression patterns in 
trophoblast cells (this is given in Chapter 4).  
MAGEA1 had a similar profile to 5-HT1BR; no protein levels were detected even though 
mRNA expression were identified. This could be due to the fate of the proteins after 
extraction and processing. Therefore, care should be taken to extrapolate the data from the 
immunoblots. It is also worth noting that the IRS for MAGEA1 was reported to be 
significantly reduced in PE when compared to NT. Thus, the extremely significant increase 
in the mRNA expression of MAGEA1 could be a compensatory effect for the low levels of 
the protein which were almost undetectable in immunoblots. Although MAGEA1 is reported 
to be involved in cell differentiation during spermatogenesis (Monte et al, 2006), its function 
in placenta is not clear. 
MAGEA4 is a member of the MAGE family that was also suggested to induce apoptosis by 
both p-53 dependent and independent pathways (Sang et al, 2011). So it is intriguing as to 
why four of the C/T antigen genes studied (GAGE1, GAGEE1/PAGE5 and MAGEA4) that 
are involved in apoptosis, were significantly reduced in PE placentae. These results 
contradict reports that indicate increased apoptosis rates during PE (Ishihara et al, 2002), 
and suggest a different function for these genes during placental development. This would 
be confirmed by functional studies using cell lines (Section 7.4: Future studies). 
Even though the IRS scores from IHC is only semi-quantitative, it was very valuable to 
identify the cellular localisation between the two placental types (NT and PE). Staining for 
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most of the receptors/antigens were localised around the CTB/STB layers, placental villi and 
the lining of the spiral arteries in NT tissues. These regions contain cells that constantly 
undergo differentiation and division. Also the STB layers are undergoing constant apoptosis 
by forming syncytial knots. However in PE tissues the staining was frequently between low 
to moderate intensity around these areas. There were few exceptions like PASD1 which 
showed strong staining around the CTB/STB layers and placental villi. On the contrary the 
staining was more concentrated in the EVT as well as fibrin and collagen layers in the 
placental beds of PE which do not undergo further differentiation. Although it has been 
suggested that PASD1 acts as a transcription factor its definite function is still not known. 
 
Conclusions: 
The collective data from mRNA, protein and IHC studies suggest the expression patterns of 
many C/T antigens and at least two 5-HT receptors are altered in PE placentae. Since 
placental invasion resembles tumorigenesis, and the fact that expression of the putative 
tumour marker antigens are altered in PE placentae, which has low invasion it may be an 
interesting avenue to explore. Therefore it is important to study the functions of these 
antigens during placental development (see Section 7.4: Future Studies).  
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4.1 Introduction 
Due to the interesting data on the expression of C/T antigens observed in Chapter 3, it was 
decided to compare the status of common 5-HT receptors and C/T antigens in the first 
trimester (FT) and full term placentae. The development of FT placenta is summarised in 
Section 1.1.2.1. During the first trimester only two villous types are formed (Huppertz, 
2008); (a) mesenchymal villi: rich in mesenchymal cells and weakly organised stroma and 
(b) immature intermediated villi: mesenchymal cells are organised in a mesh with placental 
macrophages (Hofbauer cells). 
The villous CTB is present as a complete layer under the STB during the FT, behaving as 
stem cells for the outer STB. However, with progress in pregnancy the CTB numbers are 
reduced. The villous tree is then covered only with STB, with few patches of CTB. On the 
35th day p.c., the CTB differentiates into interstitial (extravillous) CTB (invades the decidua) 
and the endovascular CTB (eCTB; remodels the spiral arteries of the uterus) (James et al, 
2005; Gude et al, 2004; Red-Horse et al, 2004).  
The EVT invades the uterus up to the inner third of the myometrium (reviewed by Norwitz 
et al, 2001). This invasion takes place only in the first half of the pregnancy until a fully 
functional placenta is formed. Thus, the two different CTB cells are highly invasive during 
the first trimester and their invasive properties decline with pregnancy progression to full 
term. The invasive properties of the CTB cells earlier in the pregnancy could determine the 
fate of the pregnancy. The unregulated invasion of the CTB leads to complications like 
placental accrete (firm attachment to the myometrium), increta (invasion into the 
myometrium) and percreta (penetrations through the myometrium into the uterine serosa and 
other organs) (reviewed by Norwitz et al, 2001). 
A number of microarray studies using first trimester CTB in comparison with term placentae 
have reported differences in gene expression patterns. Some of the major differences in 
expression in FT are as follows:  
(1) Difference in gene expression between FT and term placentae. 
A 25% difference in gene expression was reported by a microarray study involving 16 
samples from FT and 21 samples from term placentae (Sitras et al, 2012). This study showed 
there was an up-regulation of genes involved in cell proliferation, differentiation, migration 
and angiogenesis in FT. Conversely, in term placentae, an up-regulation of genes involved 
in signal transduction and receptors were reported.  
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(2) Difference in gene expression with gestational age in FT placentae. 
Khan et al (2010; 2004) reported that there were differences in gene expression with 
increasing gestational age (6 to 8 weeks) even within the first trimester. Three distinct 
expression clusters were observed in this study, with genes involved mostly in programmed 
cell development, immunity, adhesion and epithelial-to-mesenchymal transition.  
(3) Difference in gene expression in eCTB and EVT. 
Another microarray study by Apps et al (2011), showed differential expression patterns of 
3000 transcripts in eCTB and EVT differentiated from the CTB stem cells. Most of these 
genes were involved in novel pathways for cell migration, invasion and immune modulation. 
The molecular mechanisms of isolated eCTB and EVT from the FT were also investigated 
by Tarrade et al (2001). 
(4) Difference in gene expression in villous and decidua of the FT. 
A high expression of 75 genes in chorionic villi and 25 genes in decidua of early gestational 
age placentae were reported by a human cDNA microarray study involving 9600 clones 
(Chen et al, 2002). This study reported the importance of expression of genes encoding 
proteins (such as IGFBP-1, 3, 4 and 5) in decidualisation of the uterus for the implantation 
and the invasion of the EVT.  
It has been well investigated that growth factors and cytokines act in an auto-paracrine 
function to maintain the development of the placenta and foetus (Hofmann et al, 1993; Chen 
et al, 1991). Similarly, serotonin (5-HT) in the trophoblast may be involved in placental 
development (Deroy et al, 2013). An immunohistochemical staining of 5-HT and its 
receptors in human placenta reported their localisation in the cytoplasm of the cells (Huang 
et al, 1998). In the study it was reported the STB was immuno-positive for both 5-HT and 
its receptors. The staining intensities in STB were reported to be higher than in CTB, but 
reduced with increasing gestational age for 5-HT only. The CTB, on the other hand, was 
reported to express only the 5-HT receptors. The staining intensities of 5-HT and its 
receptors in maternal decidua were reported to be high. The antibodies used for the detection 
of the 5-HT receptors were specific only for the 5-HT1A receptor but that used for 5-HT2 
receptors detection recognised common epitopes of all the 5-HT2 receptors. Therefore, a 
generalised localisation for the 5-HT2 receptor was reported (significant expression pattern 
observed in Chapter 3) and an antibody recognising a unique epitope of 5-HT2B receptor is 
required for the specific identification of this receptor. The 5-HT2B receptors are reported to 
mediate cell differentiation and it has been reported to be expressed in the maternal 
myometrium (Choi et al, 1997; Kelly and Sharif, 206).  
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Although the expression of C/T antigens have been reported in placenta, only two detailed 
studies could be found to have investigated a subset of the C/T antigens in FT placentae 
(Jungbluth et al, 2007; Khan et al, 2014). Jungbluth et al reported the cellular localisation of 
MAGE-A and C, NY-ESO-1 and GAGE in week 5 to 42 placental samples and the 
importance of gestational age in the expression of C/T antigens. The importance of 
gestational age was also reflected in the expression of CAGE1 in week 6 to 8 samples, in 
which expression increased with progression of gestational age (Khan et al, 2014).  
Keeping in mind all these variations in gene expressions linked to the gestational age of 
placenta, this chapter aimed to investigate, 
• The status of 5-HT receptors and C/T antigens in the first trimester (FT) and normal 
term placentae. 
• The localisation of these receptors and antigens in FT chorionic villi and maternal 
decidua. 
• The expression patterns in FT samples with different gestational age (weeks). 
 
4.2 Results  
This study was performed on the basis of the results obtained from previous Chapter 3, in 
which significant differences in expression of 5-HT receptors and C/T antigens were 
observed between NT and PE placentae. Two 5-HT receptors and seven C/T antigens which 
showed interesting differences in expression between NT and PE were analysed in this 
chapter. Although initially it was intended to perform a complete expression analysis of these 
receptors and antigens, due to limited availability of samples, only mRNA expression and 
cellular localisation studies were possible. The qRT-PCR was performed using brain (5-HT 
receptors) and testis (C/T antigens) as the positive controls as detailed in Section 2.6.5. The 
cellular localisation of these receptors and antigens was investigated by 
immunohistochemical (IHC) staining, as detailed in Sections 2.9.4. 
  
4.2.1 First trimester human placental samples 
The human first trimester placental samples were collected from the Medical University of 
Graz, Austria under the supervision of Dr. Martin Gauster (Institute of Cell Biology, 
Histology and Embryology). The fresh FT placental samples were used for RNA and protein 
extraction simultaneously using the AllPrep RNA/Protein Extraction kit® (Qiagen, UK). Due 
to the small size of the samples, the protein concentrations were not appropriate for Western 
blot detection. The integrity of the RNA samples were analysed by 1% w/v agarose gel 
Chapter 4: First trimester placental study 
 
122 
 
electrophoresis before qRT-PCR investigations. The gestational ages of the samples 
collected are detailed in Table 4.1. The samples are arbitrarily numbered as F1-15.  
The samples collected were between 7 to 11 weeks of gestational age (8.3 ±0.4) (Mean ± 
SEM). As can be seen from Figure 4.1 (Section I), placental villous trees (trophoblast cells) 
are only developed during week 7. The membranous tissue formations start appearing from 
week 8 onwards, along with larger villous trees. Samples for RNA and protein investigations 
were collected only from the villous tree. 
 
Table 4.1: Details of the FT samples collected. 
 
 
The histology of placental villous and decidual regions during FT is shown in Figure 4.1 
(Section II). The immature intermediate villi during FT are represented distinct thick STB 
and CTB layers surrounding the stromal mass (S). A small number of mesenchymal cells 
(represented with arrow heads) and foetal blood vessels with blood cells (enclosed in square) 
can be found in the stroma. The decidual region contained vessels and distinct uterine glands 
with epithelial lining. Spiral arteries were also a common sight, which can be seen in other 
immunohistostaining images (not shown in Figure 4.1).  
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Figure 4.1: Structural features and histology of first trimester placentae. 
 
Section I. Structural features of first trimester placentae. Panel A: Only villous tissue 
was visible in 7 week old placenta. The membrane tissue was visible in 8 week old placenta 
(Panel B) depicting the rapid development of the placenta within one week.  
 
Section II. H&E staining showing the histology of a representative FT sample. [A] FT 
villi section showing an outer uniform STB and inner CTB layers. Mesenchymal cells 
(Arrow head) are scattered in the stroma (S). The box encloses a foetal blood vessel (FV) 
which is enlarged in Panel [B]. [C] Membrane and decidual section of an FT sample, 
showing distinctive uterine glandular epithelium (Bold arrows) and vessels (V). [D] Shows 
the enlarged section of glandular epithelium [the box in Panel C]. Magnification: A, C- 200X 
(Scale bar=100µm); B, D- 1000X (Scale bar= 20µm).  
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4.2.2 Expression analysis of 5-HT receptors 
The relative mRNA expression and cellular localisation of 5-HT1B and 5-HT2B receptors 
were investigated as follows. 
4.2.2.1  Relative mRNA expression of 5-HT receptors 
To check for successful qRT-PCR performance, human brain samples (positive control for 
5-HT receptors; Clontech, UK) were analysed along with FT samples. The relative mRNA 
expression is presented in the form of arbitrary units with positive set to 1 (data not shown). 
Figure 4.2 shows the differential mRNA expression patterns of 5-HT1B and 5-HT2B 
receptors between FT and term placentae. There were no differences in mRNA expressions 
of 5-HT1B receptor observed. The 5-HT2B receptor on the other hand showed a statistically 
significant difference in mRNA expression. The expression of 5-HT2B receptor mRNA was 
dramatically up-regulated in term placentae when compared to FT (p<0.01).  
 
 
Figure 4.2: Comparative mRNA expression  analysis of 5-HTR between FT and term 
placentae. 
 
The mean gestational age (weeks) for FT and Term placentae are 8.3 ±0.4 and 38.9 ±0.1 
respectively (Mean ±SEM). The relative mRNA expressions were compared by Mann-
Whitney U test (±SEM; **p<0.01).  
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4.2.2.2 Cellular localisation of 5-HT receptors 
The status and cellular localisation of 5-HT1B and 5-HT2B receptors were investigated by 
immunohistochemistry (IHC) and scored as previously described in Section 2.9.1. Positive 
3,3'-Diaminobenzidine (DAB) staining was scored according to the intensity of staining. No 
brown stains were visible with just secondary antibody staining, confirming the specificity 
of the antibodies and DAB stain. The Fleiss’ Kappa Statistics performed on this IRS data 
provided a kappa value of 0.55, suggesting a 50% agreement between the scorers. The 
aggregate scores for 5-HT receptor scoring are given in Table 4.2 below.  
 
Table 4.2: Summary of staining intensity of 5-HT receptors 
FT Placentae 5-HT Receptors 
Region Cell type 5-HT1BR 5-HT2BR 
Villous CTB 3±0.0 3±0.4 
STB 3±0.4 3±0.4 
Mesenchymal cells 2±0.8 0±0.3 
Decidua Uterine epithelium 2±0.4 1±0.5 
Decidual stromal cell 2±0.5 2±0.5 
Spiral arteries 2±0.4 2±0.4 
Staining intensity: 0-negative; 1-low; 2-moderate; 3-high (Mode±SD). 
 
 5-HT1B Receptor: 
The STB (thin arrows) and CTB (bold arrows) layers of the placental villous tissue showed 
intense staining for 5-HT1B receptor when compared to the stromal region (See Figure 4.3, 
Panel F1-5). The staining was mostly cytoplasmic and granular. The primary villi, which 
show dense CTB and STB layers, are intense in staining (represented with * in Figure 4.3, 
Panel F4). A number of mesenchymal cells in the stroma were also stained. The decidual 
regions also showed immuno-positivity to 5-HT1B receptors (See Figure 4.3, Panel D1-3). 
However, the staining was more specific to the epithelial lining of the uterine glands 
(enclosed in box), spiral arteries (arrow heads) and the stromal cells of the decidua. Overall, 
the staining was high (score 3) in villous regions and moderate (score 2) in decidual regions 
(See Table 4.2). 
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Figure 4.3: Localisation of 5-HT1B Receptor in FT placentae. 
 
5-HT1B receptor localisation is shown on the right (at both 20X and 100X magnification), 
whilst the negative (no primary Ab) control images are shown in the left hand panels and the 
positive control (vimentin) images are in the centre. Panel F1-5 show images for placental 
villous sections from 5 representative FT samples. Panel D1-D3 represents the decidual 
sections from 3 representative FT samples. Thin arrows: STB; Bold arrows: CTB; *: primary 
placental villi; Arrow head: Spiral arteries; Uterine glandular epithelium enclosed in box. 
Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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 5-HT2B Receptor: 
Similar to 5-HT1B receptors, both the STB (thin arrows) and the CTB (bold arrows) showed 
high staining intensities (score of 3) for 5-HT2B receptor in the villous sections (See Figure 
4.4, Panel F1-5; Table 4.2). Staining was also visible around the syncytial sprouting 
(represented with +) in the mesenchymal villi (rich in mesenchymal cells) (Figure 4.4, Panel 
F1). However, unlike the 5-HT1B receptor, the mesenchymal cells were negative for 5-HT2B 
receptor staining. The staining of 5-HT2B receptor in the maternal decidual regions were 
concentrated around the spiral arteries (arrow heads), epithelial cell lining of the 
glands/vessels (enclosed in box) and the stromal cells (see Figure 4.4, Panel D1-3). The 
staining appeared more granular in the epithelial cells lining the glands which are usually 
secretory in behaviour. The staining intensity was generally high (score 3) in villous sections 
and moderate (score 2) in decidua (See Table 4.2). 
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Figure 4.4: Localisation of 5-HT2B Receptor. 
 
5-HT2B receptor localisation is shown on the right (at both 20X and 100X magnification), whilst 
the negative (no primary Ab) control images are shown in the left hand panels and the positive 
control (vimentin) images are in the centre. Panel F1-5 show images for placental villous 
sections from FT. Panel D1-D3 represents the decidual sections from FT as well. Thins arrows- 
STB; Bold arrows- CTB; + Syncytial knot; Arrow head- Spiral arteries; Uterine glandular 
epithelium enclosed in box. Objective magnification: 20X (Scale bar=100µm); 100X (Scale 
bar= 20µm). 
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4.2.3 Expression analysis of C/T antigens 
Seven C/T antigens (CAGE1, FATE1, GAGE family (GAGE1 and GAGEE1/PAGE5), 
MAGE family (MAGEA1 and MAGEA4) and PASD1 were investigated as follows.  
4.2.3.1 Relative mRNA expression of C/T antigens 
The mRNA expression of C/T antigens in FT was investigated along with expression in 
human testis (positive control; data not shown). The relative mRNA expression is calculated 
by normalising sample expression to the positive control (set to an arbitrary value of 1). With 
the exception of CAGE1 and GAGE1, statistically significant differences in expression were 
observed between FT and term placentae for C/T antigens (See Figure 4.5). Further details 
are given below: 
 
 CAGE1 
In general, the mRNA expression of CAGE1 was low in six out of 11 FT samples (Figure 
4.5). The other five FT samples show higher expression. In contrast, most term samples show 
a very low expression of CAGE1 mRNA. Although not significant, mRNA expression in 
term samples showed a trend towards being lower than in FT placentae. 
 
 FATE1 
There were three distinguishable groups of mRNA expression seen amongst the FT group. 
Five out of 11 samples show negligible expression. Three samples showed moderate 
expression and a further 3 samples had relatively high expression.  In term placentae, half of 
the samples showed negligible expression. Therefore, a significant up-regulation in FATE1 
mRNA expression was observed in FT placentae compared to term placentae (p<0.05). 
 
 GAGE Family: 
In accordance with Chapter 3, only two of the GAGE family members were investigated in 
FT placentae. These were GAGE1 and GAGEE1 (PAGE5).  
• GAGE1 
Two distinct groups were seen in GAGE1 mRNA expression in FT placentae. One group 
included samples with lower expression closely resembling the expression in term placentae 
and the second showed much higher mRNA expressions than term samples. Due to this 
scattered distribution of expression in FT samples, there was no significant difference found 
between the two groups.  
 
• GAGEE1 
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The mRNA expression of GAGEE1, also known as PAGE5, in FT samples was more 
consistent. Therefore, a highly significant down-regulation of expression was observed in 
FT placentae when compared to term (p<0.01). However, the expression levels of GAGEE1 
was relatively lower when compared to the other member of GAGE family (GAGE1). 
Interestingly, GAGEE1 was the only C/T antigen that showed down-regulation in FT when 
compared to up-regulation of other antigens in FT. 
 
 MAGEA Family: 
MAGEA1 and MAGEA4 were investigated from the MAGE family in FT placentae. 
 
• MAGEA1 
Similar to other C/T antigen expression profiles, clustering into sub-populations was 
observed for MAGEA1 expression amongst different FT placentae. Overall, the FT 
placentae showed a higher mRNA expression than the term placental group; showing a 
significant up-regulation of MAGEA1 mRNA expression in the FT vs term placental groups 
(p<0.05).  
 
• MAGEA4 
MAGEA4 showed similar expression patterns to MAGEA1. Compared to the term placental 
group, the mRNA expression in FT placentae showed significant up-regulation (p<0.05).  
 
 PASD1 
The mRNA expression of PASD1 was almost negligible in term placentae. On the other 
hand, in FT two distinct groups were observed: five samples showed negligible mRNA 
expression, similar to term placentae; the remaining samples showed a scattered pattern of 
mRNA expression. Overall, there was a statistically significant up-regulation of PASD1 
mRNA expression in FT, relative to term placentae (p<0.05).  
 
Overall, apart from GAGEE1, the mRNA expression of the remaining C/T antigens were 
up-regulated in FT placentae, illustrating differences in expression patterns between 
different pregnancy stages (see Discussion).   
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Figure 4.5: Comparative mRNA expression  analysis of C/T antigen between FT and 
term placentae. 
 
The mean gestational age (weeks) for FT and Term placentae are 8.3 ±0.4 and 38.9 ±0.1 
respectively (Mean ±SEM). Relative mRNA expression compared by Mann-Whitney U test 
(±SEM; *p<0.05; **p<0.01).  
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4.2.3.2 Cellular localisation of C/T antigens 
 
The cellular localisation of C/T antigens were investigated as explained previously in this 
chapter (for 5-HT receptors). The aggregate scoring for C/T antigens are given in Table 4.3 
below.  
 
Table 4.3: Summary of staining intensity of C/T antigens 
FT Placentae C/T antigens 
Region Cell type CAGE1 FATE1 GAGE1 GAGEE1 MAGEA1 MAGEA4 PASD1 
Villous 
CTB 2±0.5 3±0.4 2±0.6 3±0.0 3±0.0 2±0.7 2±0.6 
STB 2±0.5 3±0.5 2±0.6 2±0.9 3±0.4 2±0.5 2±0.6 
Mesenchymal 
cells 0±0.5 2±0.7 0±0.4 0±0.9 0±0.4 0 0±0.5 
Decidua 
Uterine 
epithelium 2±0.6 2±0.6 2±0.5 3±0.0 3±0.0 3±1.1 3±0.0 
Decidual 
stromal cell 0±0.6 2±0.6 1±0.6 2±0.6 0±1.2 1±0.6 2±0.6 
Spiral arteries 1±0.5 1±0.6 2±0.0 3±0.0 N/A 1±0.0 1±0.6 
 
Staining intensity: 0-negative; 1-low; 2-moderate; 3-high (Mode±SD). N/A- not available 
 
 
 CAGE1 
Cytoplasmic regions of the STB (thin arrow) and CTB (bold arrow) in the placental villi 
were moderately (score 2) stained with CAGE1 (Figure 4.6, Panel F1-5; Table 4.3). The 
staining in the stromal mesenchymal cells was negligible. The epithelial lining the uterine 
glands (enclosed in box) and the lining of spiral arteries (arrow heads) of the decidua were 
moderate to low in CAGE1 staining (Figure 4.6, Panel D1-3). The surrounding stromal cells 
showed no positive CAGE1 staining.  
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Figure 4.6: Localisation of CAGE1. 
 
CAGE1 localisation is shown on the right (at both 20X and 100X magnification), whilst 
the negative (no primary Ab) control images are shown in the left hand panels and the 
positive control (vimentin) images are in the centre. Panel F1-5 show images for placental 
villous sections from FT. Panel D1-D3 represents the decidual sections from FT as well. 
Thin arrows- STB; Bold arrows- CTB; Uterine glandular epithelium enclosed in box. 
Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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 FATE1 
The trophoblast cells (CTB and STB) of the placental villi were highly stained for FATE1 
(See Figure 4.7, Panel F1-5). Although in most of the samples the staining appeared to be 
mostly cytoplasmic, under higher magnification staining also visible in the nuclear region in 
some samples (Figure 4.7, Panel F2). The few mesenchymal cells within the stromal layer 
were also positive to FATE1.   The staining in the maternal endometrium was localised 
around decidualised regions and spiral arteries (Figure 4.7, Panel D1). Moderate staining 
was also observed in the epithelial linings and in the stromal cells of decidua. The staining 
was higher in villous than in maternal sections. 
Chapter 4: First trimester placental study 
 
135 
 
 
Figure 4.7: Localisation of FATE1. 
 
FATE1 localisation is shown on the right (at both 20X and 100X magnification), whilst the 
negative (no primary Ab) control images are shown in the left hand panels and the positive 
control (vimentin) images are in the centre. Panel F1-5 show images for placental villous 
sections from FT. Panel D1-D3 represents the decidual sections from FT as well. Thin arrows- 
STB; Bold arrows- CTB; Arrow head- Spiral arteries; Uterine glandular epithelium enclosed in 
box. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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 GAGE family 
The cellular localisation of two members of the GAGE family, namely GAGE1 and 
GAGEE1, was investigated. Both the placental villi and maternal decidua showed immuno-
positivity for these two antigens (Figure 4.8 and 4.9). The staining intensities of the 
trophoblast cells (CTB and STB) were moderate (score 2) for GAGE1. However, the 
GAGEE1 antibody showed high staining intensity in the CTB (score 3) and moderate in STB 
(score 2) (Figure 4.9, Panel F1). The mesenchymal cells were negative for both antigens. 
The staining in maternal decidua was concentrated in the inner lining of the spiral arteries 
and glands. The staining of the stromal cells in the decidua was low for GAGE1 and 
moderate for GAGEE1. In general, the staining intensity of GAGEE1 was higher than 
GAGE1 in both placental villi and decidua. 
Chapter 4: First trimester placental study 
 
137 
 
 
 Figure 4.8: Localisation of GAGE1. 
 
GAGE1 localisation is shown on the right (at both 20X and 100X magnification), whilst the 
negative (no primary Ab) control images are shown in the left hand panels and the positive 
control (vimentin) images are in the centre. Panel F1-5 show images for placental villous 
sections from FT. Panel D1-D3 represents the decidual sections from FT as well. Thin arrows- 
STB; Bold arrows- CTB; Arrow head- Spiral arteries; Uterine glandular epithelium enclosed in 
box. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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Figure 4.9: Localisation of GAGEE1. 
 
GAGEE1 localisation is shown on the right (at both 20X and 100X magnification), whilst 
the negative (no primary Ab) control images are shown in the left hand panels and the 
positive control (vimentin) images are in the centre. Panel F1-5 show images for 
placental villous sections from FT. Panel D1-D3 represents the decidual sections from 
FT as well. Bold arrows- CTB; Uterine glandular epithelium enclosed in box. Objective 
magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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 MAGE family 
The cellular localisation of the two members of the MAGE family, MAGEA1 and 
MAGEA4, was investigated. 
 
• MAGEA1 
Intense cytoplasmic staining was observed in the STB and CTB layers of the villi (See Figure 
4.10, Panel F1-5). The syncytial spout (represented by +) of the mesenchymal villi was also 
immuno-positive (Panel F4). However, the mesenchymal cells in the stroma were negative 
for MAGEA1 staining. The epithelial layer lining the glands and vessels in the decidua was 
stained with the same intensity as trophoblast cells (Figure 4.10, Panel D1-3; Table 4.3). No 
staining was found on the decidual stromal cells or the lining of the spiral arteries.  
 
• MAGEA4 
The cellular localisation of MAGEA4 in the placental villi was similar to MAGEA1 (see 
Figure 4.11, Panel F1-5). The intensity of staining was only moderate (score 2) when 
compared to the high (score 3) intensity of MAGEA1 (Table 4.3). In the decidual regions, 
apart from staining of glandular epithelium, low levels of immuno-reactivity for MAGEA4 
were also observed on the lining of the spiral arteries and the surrounding stromal cells 
(Figure 4.11, Panel D1-3). 
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Figure 4.10: Localisation of MAGEA1. 
 
MAGEA1 localisation is shown on the right (at both 20X and 100X magnification), whilst the 
negative (no primary Ab) control images are shown in the left hand panels and the positive control 
(vimentin) images are in the centre. Panel F1-5 show images for placental villous sections from 
FT. Panel D1-D3 represents the decidual sections from FT as well. Thin arrows- STB; Bold 
arrows- CTB; + Syncytial knot; Arrow head- Spiral arteries; Uterine glandular epithelium 
enclosed in box. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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Figure 4.11: Localisation of MAGEA4. 
 
MAGEA4 localisation is shown on the right (at both 20X and 100X magnification), whilst 
the negative (no primary Ab) control images are shown in the left hand panels and the 
positive control (vimentin) images are in the centre. Panel F1-5 show images for placental 
villous sections from FT. Panel D1-D3 represents the decidual sections from FT as well. 
Arrow head- Spiral arteries; Uterine glandular epithelium enclosed in box. Objective 
magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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 PASD1 
Moderate levels of staining for PASD1 were observed in the cytoplasmic region of STB and 
CTB layers of the villous region (Figure 4.12, Panel F1-3 and 5; Table 4.3). However, 
nuclear positivity for PASD1 was observed in the CTB cells (Figure 4.12, Panel 4). The 
mesenchymal cells were negative. The uterine glandular epithelium showed high immuno-
positivity in the decidua (Figure 4.12, Panel D1-D3). The decidual stromal cells and the inner 
lining of the spiral arteries showed moderate to low levels of staining.  
 
 
On the whole, trophoblast (STB and CTB) and epithelial (decidua) cells showed immuno-
positivity for most of the C/T antigens investigated. The staining in the mesenchymal cells 
decidual stromal cells and spiral arteries were antigen-dependent. Although most of the 
staining for the antigens was observed as granular brown stains in the cytoplasm of the cells, 
FATE1 and PASD1 showed nuclear staining, especially in certain of the villous CTB cells. 
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Figure 4.12: Localisation of PASD1. 
 
PASD1 localisation is shown on the right (at both 20X and 100X magnification), whilst the 
negative (no primary Ab) control images are shown in the left hand panels and the positive 
control (vimentin) images are in the centre. Panel F1-5 show images for placental villous 
sections from FT. Panel D1-D3 represents the decidual sections from FT as well. Thin arrows- 
STB; Bold arrows- CTB; Arrow head- Spiral arteries; Uterine glandular epithelium enclosed in 
box. Objective magnification: 20X (Scale bar=100µm); 100X (Scale bar= 20µm). 
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4.2.4 Differential mRNA expression patterns within FT placentae 
Interestingly, there was a heterogeneous distribution of C/T antigen mRNA expression levels 
amongst FT placenta. This may be due to the range in gestational age (7-9 weeks) of the 
samples. Therefore, the FT samples were grouped according to their different gestational 
ages and the expression patterns were investigated within groups (weeks 7, 8 and 9; 
Represented in Table 4.4 below).  
Out of all the receptors and antigens investigated, four C/T antigens showed significant 
differential expression patterns between gestational ages. A significant down-regulation of 
FATE1 and GAGE1 mRNA expressions were observed in week 8 when compared to week 
7 (p<0.05). On the other hand, a significant up-regulation of CAGE1, FATE1 (p<0.01), 
GAGE1 and MAGEA1 mRNA expressions were noticed in week 9. It should be noted that 
these effects are observed only using a small sample size (n=3 in each group).  
 
Table 4.4: Differential mRNA expression patterns between gestational age (weeks). 
 
(-)* Down-regulated in week 8; (+)# up-regulated in week 9; ns= not significant. 
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4.2 Discussion 
The placenta shows a rapid growth during the first trimester (FT) of pregnancy. This rapid 
growth is regulated by various factors like hormone secretion, gene expression and protein 
translation (See Section 1.1.1). These factors regulate the properties and functions of the 
cells involved during placental development. These cells also show variations in their 
functional properties with gestational age (Tarrade et al, 2001). The STB cells are highly 
invasive during the first trimester but their invasive properties reduce towards the end of the 
pregnancy. Differential expression patterns of proteins/factors involved in proliferation and 
invasion have been reported between the FT and term placenta (Sitras et al, 2012). Therefore 
this study was carried out to investigate the expression patterns of the main 5-HT receptors 
and C/T antigens in FT compared to term placentae. Also, the differences during the early 
gestational age (weeks 7 to 9) was studied. The cellular localisation and IHC staining 
intensities of these receptors were compared between villous and decidua of first trimester.  
 5-HT receptors: 
The comparative mRNA expression of the 5-HT receptors differed between FT and term. 
The relative mRNA expression of 5-HT1B receptor was up-regulated in FT when compared 
to term placentae. 5-HT1B receptors have been reported to mediate proliferation of other 
cells (Sibella-Argüelles, 2001; Banasr et al, 2004; Gurbuz et al, 2014). Therefore, it can be 
postulated that the high mRNA expression of 5-HT1B receptor during FT would be an 
indication of 5-HT mediated proliferation of the trophoblast cells. Since invasion is no longer 
a necessity in fully developed term placentae, the expression of 5-HT1B may have reduced.  
The 5-HT2B receptor however, was significantly down-regulated in FT placenta when 
compared to term. The mediation of contraction of chorionic vessels by 5-HT through this 
have been well documented (Cruz et al, 1998; Ugun-Klusek et al, 2011; Cordeaux et al, 
2008). Moreover, studies using tumour-derived cell lines such as breast and hepatocellular 
cancer have confirmed the pro-migratory effects of 5-HT via 5-HT2B receptor subtype (Pai 
and Horseman, 2008; Soll et al, 2012). Therefore, the observed down-regulation of 5-HT2B 
receptor in the FT placentae during the time of high levels of neo-vascularisation is 
surprising.  
As mentioned in Chapter 3, the up/down-regulation of mRNA expression may not be a true 
indicator of changes at the protein level. The mRNA level does not usually predict its protein 
level, nor its activity (Wang et al, 2002; Yang et al, 2003). Therefore, the changes in 5-HT 
receptor mRNA levels in FT can only be taken as a guide to identify the interesting proteins. 
Although attempts were made to carry out immuno-blotting, it was not possible to quantify 
the protein expression due to very limited protein sample availability.   
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Previously, it has been shown that the activation of these two receptors are 5-HT 
concentration-dependent (Soll et al, 2012; Sonier et al, 2002; See also Chapter 5 and 6). A 
review by Moiseiwitsch (2000) has summarised that the migration of neural crest cells 
reduced and differentiation increased in response to higher 5-HT levels. Also, 
immunohistochemical staining of the placenta for 5-HT localisation have shown its presence 
only in first trimester STB, with a decrease observed with gestational age (Huang et al, 
1998). This suggests that the high levels of 5-HT during FT may activate the 5-HT1B receptor 
for migration of trophoblast cells. However, the reduced levels of 5-HT in term placenta may 
have activated the 5-HT2B receptor and induce differentiation of the cells.   Therefore 5-
HT2B receptor might have anti-migratory effects in STB of FT. It is worth noting the mRNA 
expression of 5-HT2B in term placentae is 10000 fold higher than that of 5-HT1B, (Figure 
4.2); which suggests an important role of this receptor subtype in the events related to 
parturition. 
 
 C/T antigens:  
The mRNA expression of C/T antigens were relatively higher in FT than term placentae, 
except for GAGEE1/PAGE5. The function(s) of these C/T antigens in general, and 
particularly in the placenta, are not fully understood. Only two studies to date have reported 
the expression profile of MAGE-A and C, NY-ESO-1, GAGE and CAGE1 (Jungbluth et al, 
2007; Khan et al, 2014). The present study represents the first of its kind to compare many 
identified C/T antigens by both mRNA expression analysis and immunohistochemistry in 
FT, term as well as in PE placentae (Chapter 3). The proposed function of the antigens up-
regulated in FT are as follows: linked to tumorigenesis (FATE1) (Olesen et al, 2011), 
structural protein (CAGE1) (Alsheimer et al, 2005), cell differentiation and signalling 
(MAGEA1) (Monte et al, 2006) and apoptosis (GAGE1 and MAGEA4) (Gjerstorff et al, 
2006; Sang et al, 2011).  Functions such as tumorigenesis, cell differentiation and signalling 
are required for the tumour-like behaviour of the trophoblast (enhanced proliferation, growth 
and invasion), especially during the FT. The high mRNA expression of C/T antigens GAGE1 
and MAGEA4 (which have apoptotic functions) in FT could be due to constant proliferation, 
differentiation and apoptosis cycles within trophoblast cells. This cycle is required for the 
rapid expansion of the villous tree during the FT.   
The STB cells constantly undergo apoptosis and the apoptotic nuclei of these cells are packed 
into syncytial knots which are released into the maternal blood stream (Huppertz, 2008). The 
STB layer is constantly maintained by the differentiation of the CTB which are located below 
the multinucleated STB. Therefore, the increased mRNA expression of GAGE1 and 
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MAGEA4 observed in FT could be an indication of such a proliferation/apoptosis cycle. In 
contrast, the mRNA expression of GAGEE1/PAGE5, which also belongs to the GAGE 
family and shares apoptotic functions, was interestingly the only antigen which was 
significantly lower in FT. This suggests that there may be some other additional functions 
for this antigen. The PASD1 antigen also showed significant differences in mRNA 
expression between FT and term. This antigen has three domains which respond to 
environmental stimuli and the function of PASD1 is thus stimuli-dependent (Campbell et al, 
2011).  
The differential expression of these antigens between FT and term placenta suggests that 
their functions are dependent upon, or changing with, pregnancy progression. If the 
mechanism of control of these changes is known, then it may be possible to demarcate the 
period at which the highly invasive placenta transforms into physiologically functioning 
organ. This might open new avenues for investigating the causes of PE, where the invasion 
is shallow. 
It is worth noting that FT samples consisted of a heterogeneous group, with different 
gestational ages (in weeks). Although the sample numbers were small, this study attempted 
to investigate the difference in the mRNA expressions between: (a) 7 and 8 weeks, (b) 7 and 
9 weeks, and (c) 8 and 9 weeks.  Remarkably, significant differences in mRNA expression 
of four C/T antigens (CAGE1, FATE1, GAGE1 and MAGEA1) were observed with 
different gestational age in FT. The increase in CAGE1 antigen with gestational age (week 
6 to 8) in FT was earlier reported by Khan et al (2014). The expression of FATE1 and 
GAGE1 showed an increase in week 7, but decreased at week 8; followed by an increase at 
week 9. MAGEA1 shows an increase in expression at week 9. These differences in 
expression with gestational age confirm and extend the findings by Khan et al (which also 
used small sample numbers) (2010). On the whole the oscillatory changes in the mRNA 
expressions of these antigens may be linked to some developmental process.  
 
 Cellular localisation of 5-HT receptors and C/T antigens in villous and decidua 
of FT: 
The IHC staining of 5-HT1B and 5-HT2B receptor in this study revealed a cytoplasmic 
localisation in the CTB and STB layers of the villi. This confirms data from an earlier study 
by Huang et al (1998). The staining intensities were comparable for both the receptors in 
villous as well as decidual tissue of first trimester. However, the mesenchymal cells of the 
villi were immuno-positive for 5-HT1B receptor, but negative for 5-HT2B receptor. The 
mesenchymal cells are progenitor cells for several cell types including fibroblast, endothelial 
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cells, smooth muscle cells, myofibroblasts, blood cells and macrophages (Huppertz, 2008). 
The expression of 5-HT1B receptor in mesenchymal cells suggests differentiation was also 
mediated through the activation of the receptor similar to monocyte differentiation (Katoh 
et al, 2006). The expression of these receptors on the decidua of the first trimester were 
localised primarily to the stromal cells of the endometrium, epithelial lining of the uterine 
gland and spiral arteries.  
Although a detailed study on the cellular localisation of MAGE-A and C, NY-ESO-1, GAGE 
was carried out by Jungbluth et al on placental samples from week 3 to 42 (2007), the present 
study localised additional C/T antigens (CAGE1, MAGE-A4, GAGEE1, PASD1) in the 
villous and decidual cells of FT. Furthermore, the antibodies used by Jungbluth’s group were 
all monoclonal antibodies (M3H67, AE1/AE3 and 4H84) produced by their group. Although 
the antibodies used in this study were all commercially available polyclonal antibodies the 
expression patterns were comparable to Jungbluth et al. High staining intensities were 
observed in the trophoblast cells of the villi which is comparable to studies by Jungbluth et 
al. The cytoplasmic regions showed granular staining for most of these antigens except for 
FATE1 and PASD1. FATE1 showed intense cytoplasmic as well as nuclear staining for the 
STB. PASD1 on the other hand stained the cytoplasm and nucleus of the CTB in some of 
the villous samples. Interestingly FATE1 was the only antigen which showed distinct intense 
staining of the mesenchymal cells in the stroma. These cells also have numerous cisternae 
of the rough endoplasmic reticulum. The cellular localisations of these antigens were 
investigated through various online databases. Uniprot suggests that FATE1 is localised in 
the endoplasmic reticulum (Uniprot ID: Q969F0). Structures of cisternae continuous with 
the endoplasmic reticulum and the nucleus have also been reported in the STB (reviewed by 
Jones and Fox, 1991). The FATE1 expression in the endoplasmic reticulum of STB suggests 
a high biosynthetic activity of these cells. Uniprot suggests PASD1 is located in the nucleus, 
but expression was observed in both cytoplasm and nucleus (Uniprot ID: Q8IV76). 
However, the function of PASD1 is predicted to be stimuli-dependent (Campbell et al, 
2011).  
The cellular localisation of the C/T antigens were also investigated in the decidua of FT. The 
uterine glandular epithelium, decidual stromal cells and the spiral arteries were immuno-
positive for the C/T antigens. The intensity of staining was highest in the epithelium followed 
by moderate staining in decidual stromal cells and weak in the spiral arteries for most of the 
antigens. Only the cytoplasm of the cells showed granular staining, even for FATE1 and 
PASD1. The expression of these antigens on the cells of the uterine endometrium can be 
linked to the maintenance of the decidualisation of the endometrium for the implantation of 
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the foetus. The stromal cells in the decidua function to regulate the epithelial cell growth 
(Arnold et al, 2001). The epithelial cells in the uterus determine the fate of the trophoblast 
cell adhesion (Thie et al, 1998). As discussed earlier, the initial attachment of the trophoblast 
onto the uterine epithelium is a critical stage that decides the development of the placenta 
and foetus (reviewed by Norwitz et al, 2001). Although the cellular localisation of the 
antigens were investigated in both the villous and decidua of FT, conclusions cannot be made 
about the expression of these proteins based on the staining intensities alone (due to 
variations in cell morphology). Therefore, further analysis of protein expression, such as 
Western blotting would be necessary to fully investigate their relative expression (See 
Chapter 7).  
 
Conclusion:  
The results from this study suggest that the mRNA expression of the 5-HT receptors and C/T 
antigens were different in FT and term placentae. Variances were also observed with 
gestational age within FT samples. These changes may be linked to the functions of the 5-
HT receptors in the migration/differentiation of trophoblast cells and constriction of the 
placental blood vessels. On the other hand, the functions of the C/T antigens in placenta 
remain unknown. 
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Chapter 5                              
Effect of 5-HT on cell behaviour 
Alterations in cell morphology, viability, 
proliferation, migration and invasion under 
normoxia and hypoxia. 
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5.1 Introduction 
As explained in Chapter 1, placenta ensures the exchange of nutrients and gases to the foetus 
for its healthy development. Due to this critical function it is impossible to carry out in vivo 
studies during the developmental stage of the human placenta. On the contrary, the full term 
placentae are relatively easy to obtain after delivery with consent from the patients. These 
samples can be used to set up placental perfusion studies and be used as ex vivo models to 
study the materno-foetal transport and communication. However, this model is incapable to 
monitor functional changes during the early developmental stages of placenta. Furthermore, 
the placenta is one of the most variable organ in the animal kingdom and are classified by 
various characteristics such as shape, maternal-foetal barrier interface etc. The most 
commonly used classification is based on the histology of the placenta and are divided into 
three main groups: epitheliochordial, endotheliochordial and hemochordial (Furukawa et al, 
2014). Epitheliochordial placenta are the least invasive causing no distruction of the maternal 
uterine layers. Such placentation takes place in horses, swines and ruminants. In 
endotheliochordial placenta, the maternal uterine epithelium and connective tissue disappear 
after implantation but the endothelium is still intact e.g. dogs and cats. The hemocordial is 
third and the highly invasive placentation, where maternal epithelium, connective tissue and 
the endometrium are displaced. The placentation in humans and rodents belong to this group. 
Since rodents and humans belong to the same placentation group, mouse models are 
extensively being used to investigate therapeutic drugs for human placental conditions (pre-
eclampsia) (Faas et al, 1994). However, mouse has a very short gestational period when 
compared to the nine months period in humans. Therefore, mouse models are restricted to 
molecular level of studies (Reviewed by Mess, 2014). Although animal models are required 
for the restricted access to human placenta, investigators have to bare in the mind the 
limitations of the experimental models being used and the unique developmental and 
endocrine functions of the placenta (Redman and Sargent, 2001). The data obtained from 
these models have to be critically reviewed for its applications in humans.   
Human placenta is made of heterogeneous group of cells mainly the trophoblasts, 
mesenchymal, and stromal fibroblasts with surrounding connective tissues. These different 
cell types display varying morphology, function and gene expressions. Therefore to study 
the specific processes in placental development in vitro it is more appropriate to include all 
these different cell types. By this way any cell specific changes can constantly be monitored. 
There are two options for in vitro studies; (a) primary cells from term and/or first trimester 
aborted pregnancies and (b) placental derived cell lines. Primary trophoblast cells isolated 
from term placenta are not suited to study the early developmental stages and the isolated 
cells are appropriate only for short term examination. Likewise, due to ethical constraints, 
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obtaining primary cells from the early trophoblast is difficult. Placental cell lines on the other 
hand partially behave in a similar manner to cells they were derived from the original tissue 
(Novakovic et al, 2011). The use of these placental derived cell lines dates back to 1968 
when Patillo and Gey successfully established BeWo cell line from placental 
choriocarcinoma tissues. Following this, many placenta derived cell lines were established 
(Fogh et al, 1977; Graham et al, 1993; Feng et al, 2005).  Furthermore, these cell lines are 
immortalised by various means and therefore they are useful for long time monitoring. 
However it should be noted that the physiological functions of these cell lines may be altered 
due to their modes of immortalisation. Therefore any in vitro investigations should use as 
many different cell lines as possible to obtain meaningful results.  
Among the four placental cell lines used in this chapter, BeWo and JEG3, were derived from 
gestational choriocarcinoma and the other two transformed (non-tumour) placental cell lines, 
TEV-1 and HTR8/SVneo, were produced by respective immortalisation of first trimester 
EVT using retroviral vector with HPV16 E6/E7 gene (Feng et al, 2005), and SV-40 large T 
antigen (Novakovic et al, 2011).  The origins and functions of the different cell lines are 
summarised in Table 5.1. Both choriocarcinoma as well as EVT cells show invasiveness, 
however the EVT cells invade only after proliferating whereas the choriocarcinoma cells can 
both proliferate and invade at the same time (Frank et al, 1999).  
Therefore, it was evident that there are differences in mechanisms, gene expressions and 
functions between the two groups. Thus, two different groups of cell lines were used in this 
study. A fibrosarcoma-derived cell line which shows epithelial morphology like placental 
cell lines, HT1080, was also used as a positive control for migration and invasion studies 
(Rasheed et al, 1974).  
 
 5-HT- new potential for an old monoamine: 
As mentioned earlier (Chapter 1) increased levels of 5-HT have been reported during 
pregnancy, and especially in pre-eclampsia (Middelkoop et al, 1993; Cruz et al, 1998). 
Increased levels of 5-HT is believed to be coincide with craniofacial and cardiovascular 
development during embryogenesis (Choi et al, 1997). This led to suggestions that 5-HT 
might play some function during placental development.  Previous studies have shown that 
5-HT influences the early extravillous trophoblast (EVT) invasion (Sonier et al, 2005) and 
vasoreactivity of the spiral arteries via 5-HT1B and/or 5-HT2A receptors (Bolte et al, 2001). 
Futhermore, the influence of 5-HT on the contractility of chorionic arteries and veins have 
been reported by many authors  (Cruz et al, 1998; ; Cordeaux et al, 2008; Ugun-Klusek et 
al, 2011).  In fact, 5-HT not only induces cell proliferation, but also activates differentiation 
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of cells such as monocyte and T lymphoblastic cells (Katoh et al, 2006; Argüelles, 2000). 
The most important physiological effect of 5-HT in early embryogenesis is enhancing the 
migration of several cell types to develop into functional organs (Choi et al, 1997; Matsusaka 
and Wakabayashi, 2005).  
On the tumour side, a very early study by Burtin et al (1982) reported a decrease in tumour 
size with direct serotonin injection. Subsequently, several studies have investigated the 
effects of 5-HT and its receptor activation pathways on tumour growth (Manda et al, 1998; 
Soll et al, 2010, 2012; Pai et al, 2009); some authors reporting a decrease in tumour growth 
with 5-HT, whereas others have shown survival of the tumour cells by the influence of 5-
HT. These disparities could be due to the variations in 5-HT doses, cell types used, and the 
origin of the cells. Conversely, very few studies have concentrated on the effects of 5-HT on 
early placental cell lines (Sonier et al, 2005; Klempan et al; 2011). Many reporting the 
production and storage of 5-HT in the placenta and specifically in trophoblast cells have 
been postulated (Deroy et al, 2013; Huang et al, 1998). However, the cell lines investigated 
in these studies originated from placental choriocarcinoma (BeWo and JEG3).  
Thus, it is important to investigate the various physiological effects of 5-HT on transformed 
trophoblast cell lines (TEV-1 and HTR8/SVneo) which have closer resemblance to early 
first trimester trophoblast and thereby explore any new potential for this old monoamine.  
 
 In vitro study under hypoxic conditions: 
As mentioned in Section 1.5 (Chapter 1), hypoxia is a condition that occurs when the demand 
for oxygen is more than the supply. It may be caused due to abnormal inspired oxygen, 
scarce blood supply or the inability of the tissue to extract/utilise oxygen from the blood. 
None of these happen during placental development; in fact in normal pregnancy the blood 
supply for the developing foetus and placenta is increased. Therefore, regarding the placental 
environment as being hypoxic is fundamentally incorrect. It can be considered hypoxic only 
when compared to other organ environments, in which the metabolic demand for oxygen is 
much higher, but the supply is low. Interestingly, studies using isolated trophoblast from 
term placenta have indicated that these cells are tolerant to prolonged periods of hypoxia 
(Esterman et al, 1997). The study also reported changes in cytoplasm during hypoxic 
condition with a reduction in microvilli on the surface of cytotrophoblasts. There were no 
significant differences in trophoblast proliferation in normoxic and hypoxic conditions.  
Several studies have now confirmed that hypoxia inhibits the differentiation of 
cytotrophoblast cells and also has detrimental effects on differentiated syncytiotrophoblast 
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cells which appear during later placental development (Koklanaris et al, 2006; Genbacev et 
al, 1996; Burton and Jaunaiux, 2001). However, whether hypoxia stimulates or reduces the 
trophoblast invasive properties has been a controversial topic (James et al, 2006). One group 
of investigators consider hypoxic conditioning improves the trophoblast invasion (Graham 
et al, 2000), whereas others have made contradictory observations (Genbacev et al, 1996; 
Kilburn et al, 2000). Therefore this topic still remains open for further investigations. 
Additionally, further hypoxic conditions occurring during later stages of pregnancy have 
been considered to cause PE (Hung and Burton, 2006). However, this has not been confirmed 
by direct measurement of the dissolved oxygen in PE.  
Thus, the aim of this chapter was to investigate the effects of 5-HT on transformed early 
trophoblast cell lines and compare them to placental cancerous cell lines (placental 
choriocarcinoma) under normoxic and hypoxic conditions. This first half of the study is 
performed under 20% v/v oxygen (normoxia). The same studies were then performed under 
hypoxic conditions (2% v/v O2). 
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Table 5.1: Features and functions of the different cell lines used in this study. 
 
 
Table adapted from Novakovic et al, 2011
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5.2 Results 
5.2.1 Determination of cell seeding density for each cell line 
Since most of the assays and experiments needed up to 48 hour incubation, it was essential 
to determine the cell seeding densities for each of the cell lines. Moreover, since these cell 
lines are relatively new only a few studies were available for comparative purposes. The 
accurate seeding density was determined by comparing the cell activity at different time 
points. MTT assay was carried out to measure the cell viability and mitochondrial 
dehydrogenase activity of the cells as mentioned in Section 2.8.4. The cell metabolism was 
then used as guide for seeding the suitable cell densities. 
Compared to 24 hours, the cell activity of TEV-1 (2.5 x104) cells showed a 0.33 fold increase 
at 48 hours and 0.72 fold increase at 72 hours (See Figure 5.1, Panel A). However, the 
increase in activity was higher with 5 (x104) cells. A half fold increase was observed at 48 
hours whereas 72 hours showed approximately one fold increase in cell activity (compared 
to 24 hours). The cell activity gradually decreased when the seeding number was increased 
to 10 (x104) cells. Both 48 and 72 hours incubation increased the activity by 0.6 fold. Since 
5 (x104) number of cells showed the maximum activity up to 72 hours this density was used 
as seeding density for TEV-1 for further experimentations. The second transformed 
trophoblast cell line HTR8/SVneo, showed a reduction of activity after 48 hours incubation 
when compared to 24 hours (See Figure 5.1, Panel B). However, the activity increased with 
72 hours of incubation. Cell numbers 0.625 (x104) and 5.0 (x104) showed the half fold 
increase of activity at 72 hours. Seeding with 10.0 (x104) cells, the activity was reduced at 
48 and 72 hours. Although the differences in activity were not significant, 5.0 (x104) was 
selected as the seeding density for further experimentations.   
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Figure 5.1: Cell seeding densities for transformed placental trophoblast cell lines. 
 
Panels A and B represents the fold increase in activity of TEV-1 and HTR8/SVneo 
respectively. Statistical analysis was carried out using ANOVA. The results are a 
representation of the mean values for data for each time point for 3 independent experiments 
performed in triplicates ± SEM; *, p<0.05; **, p<0.01 and ***, p<0.001.  
 
In the case of choriocarcinoma cells BeWo, from Figure 5.2.A, it can be seen that seeding 
with higher cell densities for BeWo (5-10 x104) hindered its activity.  At 72 hours incubation 
there was 0.3 fold reduction in activity with 10(x104) cells. Although there were no 
significant differences in activity, cell seeding densities below 5(x104) were selected for 
further experiments. In case of JEG3 compared to 24 hours incubation, more than 0.7 fold 
increase in cell activity was observed at 48 hours incubation with cell densities of 2.5, 5.0 
and 10(x104) cells (Figure 5.2.B). Interestingly 72 hours showed a highly significant increase 
in   activity (over 2 fold) when compared to 24 hours. Therefore 5.0 (x104) cells were used 
as ideal seeding density for JEG3.  
   
T E V -1
C ell n u m b er  (x 1 0 4 )
F
o
ld
 i
n
cr
ea
se
 i
n
 a
ct
iv
it
y
0 .3 1 2 5 0 .6 2 5 1 .2 5 2 .5 5 .0 1 0 .0  
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
* *
* * *
*
*
* 2 4  H O U R S
4 8  H O U R S
7 2  H O U R S
H T R 8 /S V n e o
C ell n u m b er  (x 1 0 4 )
F
o
ld
 i
n
cr
ea
se
 i
n
 a
ct
iv
it
y
0 .3 1 2 5 0 .6 2 5 1 .2 5 2 .5 5 .0 1 0 .0  
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
2 4  H O U R S
4 8  H O U R S
7 2  H O U R S
A
B
Chapter 5: Effect of 5-HT on cell behaviour 
 
158 
 
 
Figure 5.2: Cell seeding densities for placental choriocarcinoma cell lines. 
 
Panels A and B represents the fold increase in activity of BeWo and JEG3 respectively. 
Statistical analysis was carried out using ANOVA. The results are a representation of the 
mean values for data for each time point for 3 independent experiments performed in 
triplicates ± SEM; *, p<0.05; **, p<0.01 and ***, p<0.001.  
 
HT1080, a fibrosarcoma cell line which is used as a positive control for most of the 
experiments, showed significant increase in activity with cell seeding densities of 2.5 and 
5.0 (x104) cells at 48 and 72 hours as seen from Figure 5.3. Almost one fold increase in 72 
hours incubation was observed when compared to 24 hours. Therefore 2.5 (x104) cell number 
were used for further experimentations.  
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Figure 5.3: Cell seeding densities for fibrosarcoma cell line HT1080. 
 
Statistical analysis was carried out using ANOVA. The results are a representation of the 
mean values for data for each time point for 3 independent experiments performed in 
triplicates ± SEM; *, p<0.05 and **, p<0.01.  
 
 
5.2.2 Effect of 5-HT in in vitro under normoxia 
The effect of 5-HT on cells were investigated under normal oxygen conditions of 20% v/v 
O2 at 37ºC. The cells were maintained at this conditions for further investigations.  
 
5.2.2.1 Effect of 5-HT on cell morphology 
As predicted, H&E staining of cells treated with 5-HT for 24 hours revealed the changes in 
morphology. The 5-HT treated cells showed differences in their morphology. As the 
concentration of the 5-HT treatment increased there were increased numbers of necrotic cells 
with condensed and fragmented nuclei. Interestingly in some cells, such as HTR8/SVneo 
apoptotic blebbing and apoptotic bodies could be clearly seen. The 5-HT treatment also 
induced migration indicated by membrane ruffling, extended lamellipodium and filopodium. 
At higher concentrations (40µM and 80µM) 5-HT was cytotoxic as indicated by apoptotic 
and necrotic cells (cell swelling and disintegrated membranes). The presence of large 
multinucleated giant cells (which had anaplastic features) can also be seen at these high 
doses.  It was noticed the cell numbers per field were lower at 80µM 5-HT treatment. Please 
refer to Figures 5.4 to 5.6 for further details on individual cell lines. Thus the cytotoxic 
effects of 5-HT could be observed by studying the morphological features of the cells.   
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 Figure 5.4: H & E staining for transformed trophoblast cell lines after 24 hours of 5-HT treatment. 
Section I. and II. Shows images for TEV-1 and HTR8/SVneo cells respectively. Panel A represents control cells and Panels B-F represents 5-HT treated 
cells (10-80µM 5-HT respectively). The mitotic cells undergoing division with two daughter chromatin structures were seen in all panels (indicated by black 
arrows). The red arrows points to cells undergoing apoptosis with characteristic features like blebs on the cell surfaces. These increase in number at higher 
5-HT concentrations. The cells treated with 5-HT also induced formation of extended structures, membrane ruffles and lamellipodium indicated in green 
arrows. The yellow arrows show large anaplastic cells with undistinguished features (Sections I and II, Panel E). Necrotic cells were also seen with 
disintegrated membranes and faded nucleus (Brown arrows). Scale bar= 100µm. Images taken at 200X magnification.  
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Figure 5.5: H & E staining for placental choriocarcinoma cell lines after 24 hours of 5-HT treatment. 
 
Section I. and II. Shows images for BeWo and JEG3 cells respectively. Panel A represents control cells and Panels B-F represents 5-HT treated 
cells (10-80µM 5-HT respectively). The nucleus and the chromatin structures were clearly distinguished (deep blue). The cytoplasmic 
surroundings formed uniform sheets (pink) with disruptions at higher 5-HT concentrations (Panel D-F). The black arrows indicate cells 
undergoing mitotic divisions with condensed chromatin structures in control as well as treated cells. These features increased with 5-HT treatment 
when compared to control. Disintegrated cell debris after apoptosis were more frequent at Panel F (represented by red arrows). The yellow arrow 
points to giant anaplastic cells with no distinctive features at Panel F. Scale bar= 100µm. Images taken at 200X magnification.  
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Figure 5.6: H & E staining for HT1080 after 24 hours of 5-HT treatment. 
 
Panels A= Control, B, C, D, E, F= 10, 20, 30, 40, 80µM 5-HT treatments respectively. There 
were more extended features from the cells and mitotic cells in Panel C and D (green and 
black arrows respectively). A spike formation was seen on cells undergoing apoptosis 
indicated by red arrows (Panel D, E and F). The cell pointed by yellow arrow in Panel F 
varies from any of the other cells in the population thus distinguished as an anaplastic cell. 
Scale bar= 100µm. Images taken at 200X magnification.  
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5.2.2.2 Effect of 5-HT on cell viability and toxicity 
To investigate the effect of 5-HT on viability or cytotoxicity of the cells, MTT and CytoTox 
96® Non-Radioactive Cytotoxicity assays were performed respectively. These two assays 
are mostly the first choice of cell viability and cytotoxicity assays because of straight forward 
protocols, speed and requirement of non-radioactive reagents. The effect of 5-HT were 
investigated on (a) plating cells along with 5-HT- to investigate any immediate effects of 5-
HT on vulnerable cells and well as on cell attachment (b) treating cells after 24 hours of 
recovery- to investigate effects on already viable and adherent cells. The data are represented 
as percentage in comparison to Control (no treatment) for both assays.  
 
 Plating cells along with 5-HT 
The cells were seeded into plates with different doses of 5-HT to check if there were 
immediate effects of 5-HT on cell viability and adherence.  
 
• Effect of 5-HT on transformed trophoblast cells 
The transformed trophoblast cell lines, TEV-1 and HTR8/SVneo, both show an increase in 
cell viability when treated with 5-HT.   
In TEV-1, 30µM 5-HT treatment for 24 hours showed over 50% increase in cell viability 
when compared to control (no treatment - See Figure 5.7, Panel A). However, the viability 
reduced at higher doses of 5-HT (40 and 80 µM), also viability at 48 hours was lower than 
at 24 hours. From Figure 5.7, Panel B it can be seen that there were no significant changes 
in cell toxicity with 5-HT when compared to control.  
HTR8/SVneo cells also showed similar results with 30µM 5-HT treatment showing 50% 
increase in cell viability and 8% decrease in cell toxicity when compared to control (Figure 
5.7, Panel C and D). However, unlike TEV-1, 5-HT treatment for 48 hours in HTR/SVneo 
showed higher viability in comparison with 24 hours duration. Overall, 30µM 5-HT 
treatment increased the viability of the transformed trophoblast cells with the least cytotoxic 
effect.  
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Figure 5.7: Dose-response curve for transformed trophoblast cell lines treated with 5-
HT. 
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *p<0.05. 
 
• Effect of 5-HT on placental choriocarcinoma cells 
The effect of 5-HT on placental choriocarcinoma cell lines showed similar results to 
transformed trophoblast cell lines. A 77% increase in cell viability was observed in 30µM 
5-HT treated BeWo cells when compared to control (See Figure 5.8, Panel A). The viability 
of the cells reduced with increasing dose concentration and duration. However no conclusive 
results could be inferred for 5-HT toxicity to the cells (See Panel B of Figure 5.8). No 
significant changes were observed with 5-HT treatment in JEG3 cells (See Figure 5.8, Panel 
C and D).  
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Figure 5.8: Dose-response curve for placental choriocarcinoma cell lines treated with 
5-HT. 
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; **, p<0.01.  
 
• Effect of 5-HT on fibrosarcoma cells 
5-HT treatment (20 and 30µM) of fibrosarcoma HT1080 cell line enhanced cell viability at 
48 hours (approximately 30%); compared to control (See Figure 5.9, Panel A). However, 
similar to the placental derived cell lines (stated above), a bell shaped curved was observed 
in HT1080. From Figure 5.9, Panel B it can be seen that 30 µM 5-HT treated cells showed 
significantly reduced LDH release when compared to the control.   
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Figure 5.9: Dose-response curve for fibrosarcoma cell line HT1080 treated with 5-HT. 
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *, p<0.05. 
 
In summary, seeding the cells along with 5-HT improved the viability of the cells. However, 
higher doses of 5-HT were toxic to the cells and showed increased LDH release. The 20 and 
30µM 5-HT were optimal concentrations for further investigations.  
 
 5-HT treatment after 24 hours of recovery 
The five cell lines used in this study are all adherent cells. Therefore, a trypsinisation step is 
required before the cells are ready for seeding. This causes stress to the cells and reduces the 
metabolic activity of the cells. Most cells require 24 hours of recovery from stress to function 
as viable cells again. Therefore, to investigate the effect of 5-HT on viable cells different 
doses of 5-HT were added to cells after 24 hours of seeding.   
• Effect of 5-HT on transformed trophoblast cells 
An 82% increase in cell viability was observed in 30µM 5-HT treated TEV-1 cells when 
compared to control for 24 hours of treatment (See Figure 5.10, Panel A). This increase is 
higher than cells seeded along with 5-HT. It may be due to more viable cells after 24 hours 
of seeding. Likewise, for 48 hours of treatment, 30µM 5-HT shows higher viability of cells, 
although this effect was not significant. No conclusive results could be drawn from LDH 
assay (See Figure 5.10, Panel B).  
In Figure 5.10, Panel C, an increase of 27% and 17% in viability was observed with 
HT8/SVneo cells treated with 30µM 5-HT for 24 and 48 hours respectively. The 
HTR8/SVneo cells treated with 5-HT for 24 hours showed lower release of LDH when 
compared to control (See Figure 5.10, Panel D). 
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Figure 5.10: Dose-response curve for transformed trophoblast cell lines treated with 5-
HT after 24 hours of recovery. 
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *p<0.05. 
 
• Effect of 5-HT on placental choriocarcinoma cells 
The increase in BeWo cell viability by 20µM 5-HT was 30% and 56% for 24 and 48 hours 
respectively when compared to control. Moreover, the 48 hours treatment showed higher 
cell viability when compared to 24 hours. The second choriocarcinoma cell line JEG3 also 
showed similar pattern of cell viability with 5-HT treatment as represented in Figure 5.11, 
Panel C. However, only the 24 hour treatment exhibited an increase in cell viability when 
compared to control. In contrast, at 48 hours of treatment the viability of the cells reduced 
in comparison to control. No conclusive results were drawn from the LDH assay.  
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Figure 5.11: Dose-response curve for placental choriocarcinoma cell lines treated with 
5-HT after 24 hours of recovery. 
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *, P<0.05. 
 
 
• Effect of 5-HT on fibrosarcoma cells 
The fibrosarcoma cell line HT1080 treated with 30µM 5-HT exhibited an approximately 
30% increase in cell viability at 24 hours treatment (See Figure 5.12, Panel A). The toxicity 
of 5-HT on HT1080 cells could not be inferred from LDH assay (Refer to Figure 5.12, Panel 
B). Lower doses of 5-HT were less toxic to the cells leading to lower levels of LDH release.  
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Figure 5.12: Dose-response curve for fibrosarcoma cell line HT1080 treated with 5-HT 
after 24 hours of recovery. 
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *p<0.05. 
 
The effects of 5-HT after 24 hours of seeding were almost similar to the cells seeded along 
with 5-HT. Therefore, for further investigations, the cells were allowed to recover for 24 
hours before treatment with 5-HT.   
 
5.2.2.3 Effect of 5-HT on cell proliferation 
In order to prove the data obtained from MTT and LDH assays are due to cell proliferation 
(not from increased metabolic activity), a tritium labelled (3H) thymidine incorporation 
method was performed, as explained in Section 2.2.6.7. Furthermore, the effect of 5-HT on 
cell proliferation recovery were also examined. The cells were treated with 5-Fluoro-Uracil 
(5-FU) for 24 hours before 5-HT treatment. 5-FU is a pyrimidine analogue with a fluoride 
atom attached to the base of pyrimidine ring causing nucleotide imbalance and thus blocking 
DNA synthesis (Section 2.8.7). 
• Effect of 5-HT on transformed trophoblast cell proliferation 
There was no significant effect of 5-HT on TEV-1 proliferation at both 24 and 48 hours 
treatment (See Figure 5.16, Panel A). Furthermore, 5-HT had no recovery effect on the TEV-
1 cells inhibited with 5-FU. On the other hand, in HTR8/SVneo, 5-HT treatment further 
reduced the proliferation of 5-FU inhibited cells at 24 hours. A significant decrease of 32% 
was observed in 80µM 5-HT treatment when compared to controls.  
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Overall, no significant increase in cell proliferation of transformed trophoblast cell lines 
were observed with 5-HT treatment. Moreover, the proliferation was further reduced in 5-
FU inhibited cells confirming no recovery effects with 5-HT.  
 
 
Figure 5.13: 3H incorporation in transformed trophoblast cell lines treated with 5-HT. 
Statistical analysis was carried out using two-way ANOVA (Tukey’s multiple comparisons 
test). The results are a representation of the mean values for data from a single experiment 
performed in triplicates ± SEM; *, P<0.05. 
 
• Effect of 5-HT on placental choriocarcinoma cell proliferation 
5-HT treatment showed a remarkably different pattern in placental choriocarcinoma cell 
proliferation. As seen from Figure 5.17 (Panel A) the 5-HT treatment had no significant 
effect on BeWo proliferation at 24 hours incubation. On the contrary, BeWo cells previously 
treated with 5-FU, when incubated again with 5-HT for 24 hours, showed an increase in 
proliferation. The 30µM 5-HT showed 25% increase in BeWo proliferation while a 
significant increase of 80% was observed with 80µM 5-HT for 24 hours (p<0.05).   
The second choriocarcinoma cell line, JEG3 also showed similar results to BeWo for 5-HT 
treatment in proliferation (See Figure 5.17, Panel B). Interestingly, a significant increase in 
cell proliferation (112%) was observed with 80µM 5-HT after 5-FU inhibition. At 48 hours, 
again there was no significant effect of 5-HT on cell proliferation.  
Therefore, for placental choriocarcinoma cell lines 5-HT treatment for 24 hours significantly 
improved the proliferation of the cells inhibited with 5-FU. These results were contrary to 
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transformed trophoblast cell lines which showed further decrease in proliferation with 5-HT 
treatment on 5-FU inhibited cells. 
 
     
 
Figure 5.14: 3H incorporation in placental choriocarcinoma cell lines treated with 5-
HT. 
Statistical analysis was carried out using two-way ANOVA (Tukey’s multiple comparisons 
test). The results are a representation of the mean values for data from a single experiment 
performed in triplicates ± SEM; *, P<0.05. 
 
 
• Effect of 5-HT on fibrosarcoma proliferation 
In cell line HT1080, 5-HT showed no significant effect on cell proliferation at 24 as well as 
48 hours treatment (See Figure 5.15).  
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Figure 5.15: 3H incorporation in fibrosarcoma cell line treated with 5-HT. 
 
Statistical analysis was carried out using two-way ANOVA (Tukey’s multiple comparisons 
test). The results are a representation of the mean values for data from a single experiment 
performed in triplicate ± SEM. Untreated controls are given as unshaded bars in respective 
time point. 
 
In general, the effect of 5-HT on cell proliferation was cell line dependent. 5-HT increased 
proliferation of transformed trophoblast cell lines, however it was unable to recover the cells 
from 5-FU inhibited proliferation.  On the other hand, 5-HT reduced the proliferation of 
placental choriocarcinoma cells, but improved the proliferation of 5-FU treated cells.  
 
5.2.2.4 Effect of 5-HT on cell migration  
As mentioned in Section 1.1.1 trophoblast migration and invasion are the key steps in 
regulating the formation of placenta. Similarly tumour cell migration and its regulation are 
crucial to control tumour metastasis. This raised interests in investigating the effect of 5-HT 
on trophoblast and choriocarcinoma cell migration. Therefore, a wound healing assay (often 
known as scratch assay) was performed due to simplicity and reliability of the method. The 
scratch assay was performed as described in Section 2.8.9. The WimScratch image analyser 
by Wimasis was used for all the confocal images to calculate the wound closure (%). Due 
to the differences in scratch area (at time 0) the results are not conclusive with un-aided 
visual analysis therefore Wimasis was used. Examples of the summary of cell migration 
image analysis data (to show how the calculations were made) are given in Figure 5.16. The 
experiment was performed twice in triplicates each and two-way ANOVA was performed 
on the data sets. The wound closure (percentage) was used to plot the graphs taking time 0 
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as 0% closure, thus no migrating cells. Post-hoc Dunnett’s test was performed to compare 
the control to treated cells. 
 
Figure 5.16: Example of Wimasis  quantitation image. 
 
Accurate quantitation of wound healing speed can be achieved using the Wimasis® analyser. 
Red-Represents the cells stained with FM143-FX (Images submitted for analysis). Green- 
Represents the area covered by the cells in Wimasis program. Black- Represents the area 
of the scratch. Images taken at 200X magnification.  
 
 Effect of 5-HT on transformed trophoblast cell migration  
The percentage of wound closure (along with the wound healing images of time 24 and 48 
hours) for transformed trophoblast cells are represented in Figure 5.17. 5-HT treated cells 
showed significant differences in cell migration compared to control.  
 
In TEV-1 cells, 20µM and 30µM 5-HT treated cells showed higher wound coverage starting 
from 3 hours (Figure 5.17, Panel A). However, higher concentrations of 5-HT (40µM and 
80µM) reduced the wound healing compared to control. At 10µM 5-HT, TEV-1 cells 
showed similar wound healing rate as control. At 24 hours of incubation it was evident that 
20µM and 30µM 5-HT significantly improved the wound closure, whereas 40µM and 80µM 
significantly reduced it (p<0.05). Almost 100% of wound healing was observed at 48 hours 
with 30µM treatment. This can be clearly seen from the scratch image with total wound 
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coverage with green compared with other treated and control cells. Thus, the TEV-1 wound 
coverage progressively increased with time with 20 and 30µM treatment. 
HTR8/SVneo cells showed wound healing trend to as TEV-1 (Figure 5.17, Panel B). 
However in this cell line even 40µM 5-HT improved the wound coverage along with 20µM 
and 30µM. In fact 40µM 5-HT showed higher rate of wound healing compared to other two 
doses. Significant enhancement of wound healing was observed with these three doses from 
12 hours onwards compared to control. Conversely again 80µM seemed to reduce the wound 
healing, though it was not statistically significant. Unlike TEV-1, in HTR8/SVneo control 
cells the healed area at the end of 48 hours was low (indicated by area in the graphs).  
 175 
 
 
 
 
 
 
 
 
  
 
Figure 5.17: Effect of 5-HT on transformed trophoblast cell migration. 
Panel A: Represents the wound closure (%) and scratch images at 0 and 48 hours for TEV-1 cells. Significant differences in wound covered 
area were observed with 5-HT treated cells when compared to control at 24 and 48 hours (n=2 ±SEM; *p<0.05). Maximum wound coverage 
observed from the scratch with 30µM 5-HT at 48 hours. 
Panel B: Represents the wound closure (%) and scratch images at 0 and 48 hours for HTR8/SVneo cells. Significant differences in wound 
covered area were observed again with 20, 30 and 40µM 5-HT treated cells when compared to control at 24 and 48 hours (n=2 ±SEM; 
*p<0.05). 
The grey shaded area in the graphs represents the wound covered area by control cells. Magnification of images 200X. 
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 Effect of 5-HT on placental choriocarcinoma cell migration 
It was challenging to perform scratch assays on choriocarcinoma cell lines due to the 
syncytial morphology of the cells. The 40µM 5-HT treated BeWo cells showed more wound 
coverage when compared to control from the very beginning of the assay (Figure 5.18, Panel 
A). At the end both 30µM and 40µM 5-HT showed significant improvement of wound 
coverage when compared to control and other 5-HT treated cells (p<0.05). While 20µM 
treatment showed negligible difference to control, both 10µM and 80µM showed reduced 
wound coverage.  
In JEG3 only 20µM 5-HT treatment showed significantly (p<0.05) higher wound coverage 
all throughout the assay when compared to control (Figure 5.18, Panel B). The remaining 
doses of 5-HT actually reduced the wound coverage with minimum wound coverage 
observed for 80µM treatment.  
The images for the scratch for both the cell lines shows only few cells migrating as clumps 
into the scratch area. Due to this, only 25% wound healing was observed in these cells even 
after 48 hours. This was lower when compared to transformed trophoblast cell lines (TEV-
1 and HTR8/SVneo). These results for 5-HT effect on placental choriocarcinoma cell lines 
were not as expected. Since these cell lines originate from cancerous sources it was expected 
to show higher speed of migration.  
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Figure 5.18: Effect of 5-HT on placental choriocarcinoma cell migration. 
Panel A: Represents the wound covered area and scratch images at 0 and 48 hours for BeWo cells. Significant differences in wound covered 
area were observed with 30µM and 40µM 5-HT treated cells when compared to control at 48 hours (n=2 ±SEM; *p<0.05). 
Panel B: Represents the wound covered area and scratch images at 0 and 48 hours for JEG3 cells. Significant differences in wound covered 
area were observed only with 20µM 5-HT treated cells when compared to control at 48 hours (n=2 ±SEM; *p<0.05). 
The grey shaded area in the graphs represents the wound covered area by control cells. Magnification of images 200X. 
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 Effect of 5-HT on fibrosarcoma cell migration 
Since HT1080 is a fibrosarcoma derived cell line, it has been used as a positive control for 
migration in this study. HT1080 cells show the fastest rate of wound healing compared to 
the two types of placental cell lines. The scratch area is almost completely covered by these 
cells before 12 hours of the assay, as a consequence of which, images for 12 hours are shown 
instead of 48 hours (See Figure 5.19). Interestingly, all the doses of 5-HT improved the rate 
of wound healing compared to control. Although 80µM 5-HT treatment showed reduced 
wound coverage until 6 hours, at the end of the assay the wound closure was still higher 
compared to control. Highly significant differences in wound coverage were observed with 
30µM at 12 hours (p<0.01). Notice from the graph 10, 20 and 30µM show 100% of wound 
coverage at 24 hours. 
 
 
Figure 5.19: Speed of Migration and Cell-covered area in HT1080. 
 
Significant differences in wound coverage were seen from 6 hours onwards (n=2±SEM; 
*p<0.05, **p<0.01). The wound coverage was approximately 100% even at 12 hours also 
visible from the scratch images. At 48 hours all 5-HT treated cells show higher wound 
coverage compared to control. The grey shaded area in the graphs represents the wound 
covered area by control cells. Magnification of images 200X. 
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5.2.2.5 Effect of 5-HT on cell invasion 
The cell migration assay was followed by invasion assay using BD Falcon™ BioCoat 
tumour invasion plates mentioned in Section 2.8.10. Two methods, CTL and Image J, were 
performed for analysis in order to produce consistent results and to confirm uniform cell 
seeding at the start of the assay. CTL imager scanned images from the top of the insert wells 
at beginning of the assay (t=0) and after 48 hours (t=48) of incubation. At t=0 there were 
equal number of cells seeded into all the wells thus giving similar cell counts. After 48 hours, 
there were still a few cells seen at the upper chamber of the inserts, but these numbers were 
maximum in negative control [as there was no chemo-attractant (FBS) at the bottom 
chambers]. However, the cell numbers decreased in positive (5% v/v FBS in bottom chamber) 
and 5-HT treated wells (5% v/v FBS plus 5-HT in bottom chambers). Therefore, the negative 
control was assumed to have maximum number of non-invaded cells (100%).  
 
Image J was also used for the analysis of migrated cells after 48 hours of incubation. It was 
observed there were high numbers of cells on top of the membrane in negative controls, 
indicating there were very few cells invaded in these wells. Conversely, in positive and 5-
HT treated wells, cells were mostly observed at the lower side of the membrane. The number 
of invaded cells were compared to positive control (100%) which is assumed to have 
maximum number of invaded cells.    
 
Therefore, both non-invaded and invaded cell percentages were compared. Variances were 
analysed using one-way ANOVA and compared against positive control using Dunnett’s 
test.  
 
 Effect of 5-HT on transformed trophoblast cell invasion 
From Figure 5.20 (Panel A) it can be seen that the TEV-1 cells treated with 20 and 30µM 5-
HT showed fewer number of non-invaded cells in the CTL scan, indicating that more cells 
had invaded through the matrigel. However, this reduction of non-invaded cells was not 
significant to control (positive). The percentage of non-invaded cells analysed from CTL 
correlated to the percentage of invaded cells counted by Image J. The positive control 
showed the least number of non-invaded cells in CTL and 100% of invaded cells in Image 
J. The percentage of invaded cells in 5-HT treated wells were lower than positive control. In 
fact, the cells treated with 10, 30 and 40µM 5-HT showed significantly reduced number of 
invaded cells when compared to positive control. Only 20µM 5-HT treated cells showed 
similar number of invaded cells as to positive control.  
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The results from HTR8/SVneo were similar to TEV-1. There was a significant reduction in 
non-invaded cells in 5-HT treated cells as well as positive control when compared to negative 
control (See Figure 5.20, Panel B). Furthermore, the reduction was lower in positive controls 
compared to 5-HT treated cells, indicating that 5-HT treatment did not induce invasion. 
These results correlated to Image J, where 5-HT treated cells showed reduced number of 
invaded cells when compared to positive control with significant reductions in 20 and 40µM 
5-HT treatment. In summary, the results from invasion assay suggested that 5-HT treatment 
reduced the invasion of both, TEV-1 and HTR8/SVneo, transformed trophoblast cell lines. 
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Figure 5.20: Effect of 5-HT on transformed trophoblast cell invasion. 
 
There was a correlation between CTL (I) and Image J (II) analysis.  
Panel A: Represents the invasion of TEV-1 cells with 5-HT treatment. I. There was high percentage of non-invaded cells seen in 10 and 30 µM 5-HT. 
More number of non-invaded cells were seen in CTL scan for negative at 48 hours. II. The 30µM and 40µM 5-HT treatment significantly reduced the % 
invaded cells (n=2±SEM; **p<0.01; *p<0.05). More invaded cells were seen at bottom of membrane in positive. 
 
Panel B: Represents the invasion of HTR8/SVneo cells with 5-HT treatment. I. The 40µM 5-HT showed the highest % non-invaded cells when compared 
to positive and other 5-HT treated cells. II. Significant reduction in % invaded cells were observed in 20 and 40µM 5-HT when compared to positive 
(n=2±SEM; **p<0.01; *p<0.05). More invaded cells were seen on bottom of membrane in positive and 30µM. 
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 Effect of 5-HT on placental choriocarcinoma cell invasion 
The effect of 5-HT on cell invasion was also investigated in choriocarcinoma cell lines, JEG3 
and BeWo. As seen in Figure 5.21 (Panel A), there was a significant reduction in non-
invaded BeWo cells in 30µM 5-HT treatment when compared to control (positive), thereby 
suggesting that 5-HT induced BeWo cell invasion. Remarkably this was also confirmed by 
Image J analysis which showed maximum number of cells invaded in 30µM 5-HT treated 
cells when compared to positive (although not significant). 
 
In JEG3, there was significant reduction of non-invaded cells treated with 5-HT and in 
positive when compared to negative in CTL scans (See Figure 5.21, Panel B). The CTL 
results were interestingly correlated by Image J, showing a significant increase in JEG3 
invasion treated with 20µM 5-HT, and decrease at 40µM 5-HT, when compared to positive.  
In contrast to transformed trophoblast cell lines (TEV-1 and HTR8/SVneo), the placental 
choriocarcinoma cells (BeWo and JEG3) showed increased cell invasion under the influence 
of 5-HT.  
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Figure 5.21: Effect of 5-HT on placental choriocarcinoma cell invasion. 
Panel A: Represents the invasion of BeWo cells with 5-HT treatment. I. There was significant reduction of % non-invaded cells seen in 30 µM 5-HT 
(n=2±SEM; *p<0.05). Fewer cells were seen in CTL scan indicating cell have invaded. II. The 30µM 5-HT treatment increased the % invaded cells. 
More invaded cells were seen at bottom of membrane in 30 and 40µM. 
 
Panel B: Represents the invasion of JEG3 cells with 5-HT treatment. I. The 30µM and 40µM 5-HT showed the highest % non-invaded cells when 
compared to positive and other 5-HT treated cells. II. Interestingly 20 and 30µM 5-HT showed increased % of invaded cells compared to control 
(positive) (n=2±SEM; **p<0.01; *p<0.05).  
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 Effect of 5-HT on fibrosarcoma cell invasion 
The differences in invasion of HT1080 cells treated with 5-HT and the control were not 
statistically significant (See Figure 5.22). However, all 5-HT treated cells showed lower cell 
numbers in CTL (non-invaded) and higher numbers in Image J (invaded) compared to 
control (positive). The 40µM 5-HT exhibited an almost 100 fold increase to control.  
 
Figure 5.22: HT1080 invasion under the influence of 5-HT. 
 
All the 5-HT treated cells showed a non-significant increase cell invasion in HT1080 
(n=2±SEM).  
 
 
Furthermore, HT1080 was used as a positive control to compare the invasion in other cell 
lines, as recommended by the manufacturer. The invasion in transformed trophoblast cell 
lines (TEV-1 and HTR8/SVneo) was reduced by 5-HT and was lower when the invasion by 
HT1080. On the other hand, the 5-HT treatment significantly increased the invasion in 
placental choriocarcinoma cells (BeWo and JEG3) and the percentage of cell invasion was 
similar (BeWo) or higher (JEG3) to that of HT080. 5-HT treatment induced the invasion of 
BeWo and JEG3 cells but reduced the invasion of TEV-1 and HTR8/SVneo cells. Overall 
the effect of 5-HT on cell invasion was cell line dependent. 
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5.2.3 Effect of 5-HT in in vitro under hypoxic conditions 
The 5-HT acts as a regulator to maintain the homeostasis of the epithelial layer of many 
organs e.g. breast, liver, prostate.  Therefore, the effects of 5-HT on the cells were analysed 
under hypoxic conditions in order to determine if the effects were still prevalent under 
hypoxic conditions. Furthermore, the first trimester trophoblast cells are more resistant to 
hypoxic conditions, as has been reported previously (Esterman et al, 1997). Additionally, 
due to increased level of 5-HT found in PE, higher 5-HT doses (20-100μM) were used for 
hypoxic investigations compared to normoxia (10-80μM) in order to better mimic the PE 
conditions. In order to investigate this, the cells were first grown in normoxic conditions 
(20% v/v O2) and trypsinised when confluent (See Section 2.8.1). The trypsinised cells were 
then transferred to hypoxic conditions with 2% v/v O2 and maintained for further 
investigations. 
 
5.2.3.1 Morphological changes due to 5-HT treatment under hypoxia 
The cells were grown under hypoxic conditions for 24 hours and then treated with 5-HT. 
The H&E staining was then performed to observe the morphological changes in these cells. 
The 5-HT treated cells showed more elongated extensions when compared to the control 
cells. However, the cell number per field have reduced at very high doses of 80µM and 
100µM. Moreover, at these concentrations higher numbers of apoptotic cells with blebs and 
necrotic cells were observed. It is known that 5-HT induces the migration of these cell lines 
in normoxic condition, as seen from Section 5.2.2.4. Therefore, the extended features of the 
cells under hypoxic condition could be due to effect of 5-HT on migration. However, features 
like membrane ruffling and filopodium could not be distinctly identified. Please refer to 
Figures 5.23 to 5.25 for further details on individual cell lines.  
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Figure 5.23: H & E staining for 24 hours effect of 5-HT on transformed trophoblast cells under hypoxia. 
 
Section I. and II. Shows images for TEV-1 and HTR8/SVneo cells respectively. Panel A represents control cells and Panels B-F represents 5-HT 
treated cells (20-100µM 5-HT respectively).  
Long extensions from the cells were seen (green arrows in Panels B to E). The mitotic cells undergoing division are indicated by black arrows. Apoptotic 
cells with clear blebbing were observed in most of the 5-HT treated cells (red arrows); also visible at lower doses of 20 and 40µM 5-HT in HTR8/SVneo 
(II. Panels B and C).  The apoptotic cell numbers increased in 80µM and 100µM 5-HT treatment. Necrotic cells with faint structures were seen only in 
HTR8/SVneo (II. Panels C and E; brown arrows). Scale bar= 100µm. Images taken at 200X magnification.  
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Figure 5.24: H & E staining for 24 hours effect of 5-HT on placental choriocarcinoma cells under hypoxia. 
 
Section I. and II. Shows images for BeWo and JEG3 cells respectively. Panel A represents control cells and Panels B-F represents 5-HT treated cells 
(20-100µM 5-HT respectively).  
Cells undergoing mitotic divisions during anaphase with chromosomal division were observed (black arrows).  Cell debris after apoptosis of the cells were 
frequently observed in BeWo cells treated with 80µM and 100µM 5-HT (represented with red arrows in Panel E and F). Also there were large giant 
anaplastic cells observed at higher concentrations of 5-HT represented with yellow arrows in Panel E, Section I. However, these morphological features 
were difficult to be identified in JEG3 cell line. Nonetheless, in 100µM 5-HT treated JEG3 peculiar distortion in the cell chromosome was seen ( ; Panel 
F). This may be due to the combined effect of hypoxia and high dose of 100µM treatment. Scale bar= 100µm. Images taken at 200X magnification. 
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Figure 5.25: H & E staining for 24 hours effect of 5-HT on HT1080 under hypoxia. 
 
Panel A represents control cells and Panels B-F represents 5-HT treated cells (20-100µM 
5-HT respectively). Extended features like lamellipodium indicated with green arrows were 
observed in viable cells in control, 20 and 40µM 5-HT treatment (Panel A, B and C 
respectively). Mitotic cells with condensed chromatin division are indicated with black 
arrows. These features were reduced in higher doses like 60, 80 and 100µM and replaced 
with increased number of apoptotic cells with blebs (red arrows) and necrotic cells (brown 
arrow) (Panel D, E and F respectively). Scale bar= 100µm. Images taken at 200X 
magnification.  
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5.2.3.2 Effect of 5-HT on cell viability and toxicity under hypoxia 
The cell-cycle can be affected by environmental changes, particularly changes in the level 
of oxygen supply (Alarcon et al, 2004). It has been proven that the cell cycle progression is 
hindered during hypoxic conditions.  Hence, the MTT and LDH assay were performed to 
investigate the effects of hypoxic in cell viability and toxicity, and to understand the role of 
5-HT during these changes.  
 
 Plating cells along with 5-HT 
The cells were seeded into plates with different doses of 5-HT and incubated in hypoxic 
chambers for 24 or 48 hours.  
 
• Plating transformed trophoblast cells along with 5-HT 
When TEV-1 cells were treated with 5-HT under hypoxic conditions it was observed that 
the cell viability increased significantly by approximately 25% with 60µM 5-HT treatment 
upon 24 and 48 hours incubation when compared to control (no treatment) (Refer to Figure 
5.26.A). There was no significant effect of higher doses of 5-HT (80 and 100µM) on TEV-
1. Moreover, no conclusive results were obtained from LDH assay on 5-HT toxicity in this 
cell line. 
There was no significant difference in viability of 5-HT treated HTR8/SVneo cells compared 
to control (Refer to Figure 5.26.C). The LDH results confirmed the MTT findings 
concluding the 40 and 60µM 5-HT was least toxic to the cells when compared to other doses 
and control (See Figure 5.26.D).  
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Figure 5.26: Dose-response curve for transformed trophoblast cell lines seeded with 5-
HT under hypoxic conditions.  
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *, p<0.05. 
 
 
• Plating placental choriocarcinoma cells along with 5-HT 
Incubation of BeWo cells with 5-HT for 24 hours showed a significant decrease of 
approximately 16% in cell viability with 80µM 5-HT when compared to control (Refer to 
Figure 5.27.A). The same cell line revealed significant decrease in viability with 20µM (15% 
decrease) and 100µM (approximately 20% decrease) 5-HT treatment for 48 hours. There 
was no significant differences observed in cell toxicity at 24 and 48 hours for BeWo cells 
treated with 5-HT (See Figure 5.27.B). Once again 5-HT had no significant effect on JEG3 
metabolic activity and toxicity (See Figure 5.30.C and D).  
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Figure 5.27: Dose-response curve for placental choriocarcinoma cell lines seeded with 
5-HT under hypoxic condition.  
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *, p<0.05; **, p<0.01.  
 
 
• Plating fibrosarcoma cells along with 5-HT 
In 5-HT treated HT1080, a peak at 40-60µM was observed for metabolic activity (Refer to 
Figure 5.28.A). However, all the 5-HT treated cells showed increase in viability when 
compared to control. The 60µM 5-HT treated cells showed the maximum viability of 
approximately two fold (183%) during 24 hours treatment. The viability, however, decreases 
with the increase in 5-HT dose with the minimum at 100µM 5-HT.  When the cells were 
treated for 48 hours, 40µM 5-HT treatment increased the viability of the cells by 88% when 
compared to control. However, no conclusive results could be drawn from the LDH results 
(See Figure 5.28.B). Therefore, the toxicity of the 5-HT on the HT1080 cells could not be 
estimated.  
 
Chapter 5: Effect of 5-HT on cell behaviour 
 
192 
 
 
Figure 5.28: Dose-response curve for fibrosarcoma cell line HT1080 seeded with 5-HT.  
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *, p<0.05. 
 
Overall, it could be concluded that 40-60µM 5-HT treatment was ideal for all the cell lines 
under hypoxic conditions. 
 
 5-HT treatment after 24 hours of recovery 
The cells that were grown under normoxic conditions (20% v/v O2) were plated and then 
incubated in hypoxic chambers (2% v/v O2) for 24 hours before treatment with 5-HT. Thus, 
the cells would be pre-acclimatised to hypoxic conditions. 
 
• Effect of 5-HT on transformed trophoblast cells 
TEV-1 cells treated with 5-HT showed an increase of 20% cell viability at 60µM treatment, 
however at higher concentrations the viability reduced when compared to control (Refer to 
Figure 5.29.A). The viability of TEV-1 cells was further increased when treated with 60µM 
5-HT for 48 hours under hypoxic incubation (approximately 60% more viable cells than the 
control). The LDH results confirmed the MTT results, but were not statistically significant 
(See Figure 5.29.B).  
Although the second transformed trophoblast cell line, HTR8/SVneo, exhibited an increase 
in cell percentage viability with 5-HT treatment, this effect was not significant (See Figure 
5.29.C). Nonetheless, the LDH results was analysed for the effects of 5-HT as seen in Figure 
5.29.D and not significant changes were observed.  
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Figure 5.29: Dose-response curve for transformed trophoblast cell lines treated with 5-
HT after 24 hours under hypoxic condition.  
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *, p<0.05. 
 
• Effect of 5-HT on placental choriocarcinoma cells 
The effect of 5-HT on BeWo cells is given in Figure 5.30.A. There were no significant 
change in cell viability with 5-HT. The LDH results indicated there was increase in toxicity 
when the cells were treated with 5-HT for 48 hours when compared to control (See Figure 
5.30.B). The 100µM 5-HT treatment showed significantly high release of LDH when 
compared to control showing high toxicity to the cells.  
In the second choriocarcinoma cell line, JEG3, there was an increase of approximately 25% 
in cell viability with 60µM 5-HT treatment for 24 and 48 hours when compared to control 
(See Figure 5.30.C). There were very little differences in results for 24 hours and 48 hours 
of incubation. Increased release of LDH was indicated in 80-100µM 5-HT treated cells for 
24 hours (See Figure 5.30.D). The LDH results are consistent with the MTT results.  
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Figure 5.30: Dose-response curve for placental choriocarcinoma cell lines treated with 
5-HT after 24 hours of hypoxia.  
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *, p<0.05. 
 
 
• Effect of 5-HT on fibrosarcoma cells 
HT1080 cells treated after 24 hours of recovery showed an increase in cell viability as shown 
in Figure 5.31.A. The cells treated with 60µM 5-HT for 24 hours and 48 hours showed an 
increase of approximately 33% and 21% respectively when compared to control. The 
viability reduced with increasing concentration of 5-HT. The LDH released from the cells 
reciprocally corresponded to the MTT assay, but were not statistically significant (See Figure 
5.31.B).  
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Figure 5.31: Dose-response curve for fibrosarcoma cell line HT1080 treated with 5-HT 
after 24 hours of under hypoxic conditions.  
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The results are a representation of the mean values for data from 3 
independent experiments performed in triplicates ± SEM; *, p<0.05. 
 
5.2.3.3 Effect of 5-HT on cell proliferation under hypoxic conditions 
Considering the almost inconclusive MTT/LDH data, the effect of 5-HT on cell proliferation 
was examined after 5-HT treatment by 3H incorporation into the cells (see Sections 2.8.7 
and 5.2.2.3) after 5-HT treatment. Only two doses of 5-HT were examined for proliferation, 
60µM (that indicated maximum percentage increase in viability of the cells from MTT/LDH 
assays) and 100µM (which reduced viability of the cells). The role of 5-HT in the recovery 
of cell proliferation after 5-FU inhibition was also investigated. The cells were plated and 
allowed to recover for 24 hours before 5-FU and 5-HT treatment.  
 
• Effect of 5-HT on transformed trophoblast cell proliferation 
5-HT had no significant effect on the proliferation of TEV-1 and HTR8/SVneo cells even 
after 24 and 48 hours treatment (Refer to Figure 5.32). Furthermore, 5-HT did not induce 
any recovery of cells that were previously inhibited by 5-FU. The proliferation further 
reduced with 24 hours 5-HT treatment and a significant reduction of 56% was observed for 
100µM when compared to control in TEV-1 cells. This reduction was not observed in 
HTR8/SVneo cells.  
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Figure 5.32: 3H incorporation into transformed trophoblast cell lines treated with 5-
HT. 
 
Statistical analysis was carried out using two-way ANOVA (Tukey’s multiple comparisons 
test). The results are a representation of the mean values for data from an experiment 
performed in triplicates ± SEM; **, p<0.01. 
 
• Effect of 5-HT on placental choriocarcinoma cell proliferation 
A significant increase of 85% of proliferation was observed in BeWo treated with 100µM 
for 24 hours when compared to control (See Figure 5.33.A). Apart from this, there were no 
other significant changes in proliferation due to 5-HT in BeWo cells, and 5-HT had no 
capacity to reverse the influence of 5-FU on proliferation.   
In JEG3, the 60μM 5-HT treatment for 48 hours significantly increased the proliferation, 
whereas 24 hours recovered the proliferation inhibited with 5-FU by 16% (See Figure 
5.33.B).  
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Figure 5.33: 3H incorporation in placental choriocarcinoma cell lines treated with 5-
HT.     
 
Statistical analysis was carried out using two-way ANOVA (Tukey’s multiple comparisons 
test). The results are a representation of the mean values for data from an experiment 
performed in triplicates ± SEM; *, p<0.05. 
 
 
In conclusion 5-HT treatment improved the proliferation of BeWo cell line at 24 hours 
incubation. The recovery effect of 5-HT on cell proliferation was observed only in JEG3 cell 
line.   
 
• Effect of 5-HT on fibrosarcoma proliferation 
5-HT had no significant effect on the proliferation of fibrosarcoma cell line, HT1080 (See 
Figure 5.34).  
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Figure 5.34: 3H incorporation in fibrosarcoma cell line treated with 5-HT. 
 
Statistical analysis was carried out using two-way ANOVA (Tukey’s multiple comparisons 
test). The results are a representation of the mean values for data from an experiment 
performed in triplicates ± SEM. 
5.2.3.4 Effect of 5-HT on cell migration under hypoxic conditions 
In Section 5.2.2.4 it is clear that 5-HT induced the migration of transformed trophoblast cell 
lines at optimal doses of 20µM-40µM under normoxia (20% v/v O2). However, due to the 
disparity in cell migration (and/or invasion) under hypoxic conditions in literature it was 
imperative to investigate the effects of 5-HT under hypoxic conditions too. Therefore, the 
scratch/wound healing assay was performed under 2% v/v O2 treated with different doses of 
5-HT. The oxygen concentration was recorded to confirm/maintain 2% v/v O2 throughout 
the experiment period. Additionally the cells were not stained with fluorescent dye in order 
to minimise any stress to the cells under hypoxic conditions. Therefore, the images using 
confocal microscopy were taken with bright field and analysed again using Wimasis®. 
Images were only analysed for 12 hours as to avoid any changes in oxygen levels due to 
experimental set up. The variances were analysed as mentioned earlier in Section 5.2.2.4. 
 
 Effect of 5-HT on transformed trophoblast cell migration 
Unusually, 5-HT at lower doses (20, 40 and 60µM) seemed to have little or no effect on the 
migration of transformed trophoblast cells (See Figure 5.35). In TEV-1 cells at high 
concentrations of 80µM and 100µM showed a significant reduction in wound healing 
(p<0.05). However, in HTR8/SVneo cells, only 100µM showed significant reduction in 
wound covered area beginning from 6 hours. Although not significant, 60µM 5-HT treated 
HTR8/SVneo cells showed slight improvement in wound coverage when compared to 
control.  
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Figure 5.35:  Effect of 5-HT on transformed trophoblast cell migration under hypoxic conditions. 
 
Panel A: Represents the wound covered area (%) and scratch images at 0 and 12 hours for TEV-1 cells. No improvement in wound coverage was 
observed with 5-HT treatment. There was a significant reduction in wound covered area with higher doses of 80 and 100µM 5-HT (n=2 ±SEM; 
*p<0.05).  
Panel B: Represents the wound covered area (%) and scratch images at 0 and 12 hours for HTR8/SVneo cells. The 60µM treated cells showed higher 
wound coverage compared to control. However 100µM significantly reduced wound coverage (n=2 ±SEM; *p<0.05).      
The grey shaded area in the graphs represents the wound covered area by control cells. Magnification of images 200X. 
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 Effect of 5-HT on placental choriocarcinoma cell migration 
The effect of 5-HT on placental choriocarcinoma cells under hypoxic conditions were also 
comparable to transformed trophoblast cells (See Figure 5.36). Both BeWo and JEG3 treated 
with 5-HT showed lower wound coverage when compared to the controls. Only 5-HT 
concentrations of 60µM in BeWo and 40µM in JEG3 showed similar wound coverage to 
control cells.  However even the wound coverage by control cells within 12 hours was only 
approximately 5%.  This wound coverage area at 12 hours for BeWo under hypoxic 
conditions was lower by approximately 15% in control cells under normoxia at the same 
time point (See Section 5.2.2.4). Conversely the wound coverage area was almost similar 
under normoxia and hypoxia for JEG3 at the same time point.  
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Figure 5.36:  Effect of 5-HT on placental choriocarcinoma cell migration under hypoxic conditions. 
 
Panel A and B: Represents the wound covered area (%) and scratch images at 0 and 12 hours for BeWo and JEG3 respectively. No improvement in 
wound coverage was observed with 5-HT treatment compared to control. Furthermore the wound covered area by control was very low (n=2 ±SEM).  
The grey shaded area in the graphs represents the wound covered area by control cells. Magnification of images 200X. 
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 Effect of 5-HT on fibrosarcoma cell migration 
Comparable to the transformed trophoblast cell line HTR8/SVneo, there was a significant 
improvement in wound coverage of HT1080 treated with 60µM 5-HT when compared to 
control (seen in Figure 5.37).  However, 5-HT concentrations below 60µM showed no 
significant improvement, whilst higher dose (100µM) reduced the wound healing. Overall, 
hypoxia reduced the migration of all the cells treated with 5-HT and only 60µM showed 
improvement when compared to control.  
Figure 5.37: Effect 
of 5-HT on HT1080 migration under hypoxia.  
 
Significant increase in wound covered area was seen with 60µM 5-HT treated cells 
compared to control (n=2±SEM; *p<0.05). Unlike normoxia, there were scratch areas still 
visible after 12 hours.  
 
Overall, hypoxia reduced the cell migration of all the cells investigated except for JEG3 
which showed similar wound healing under both conditions. In transformed trophoblast and 
fibrosarcoma cells, 60µM 5-HT showed an increase in cell migration. However, there was 
no improvement of migration of placental choriocarcinoma cells with 5-HT under hypoxia. 
Furthermore, higher doses of 5-HT (80-100µM) were detrimental to the cells.  
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5.2.3.5 Effect of 5-HT on cell invasion under hypoxic conditions 
Interestingly, since hypoxia had reduced the migration of the cells, even in fibrosarcoma 
cells, the effects of 5-HT on cell invasion under hypoxia were investigated in order to 
determine the effects of 5-HT on cell invasion under hypoxic conditions. Variances were 
analysed using one-way ANOVA and compared against positive control using Dunnett’s 
test. 
 
 Effect of 5-HT on transformed trophoblast cell invasion 
In TEV-1, a significantly higher number of non-invaded cells in CTL scans were observed 
in cells treated with 20µM and 80µM 5-HT when compared to control (positive) (p<0.05) 
(See Figure 5.38.A). Although 60µM showed reduction in non-invaded cells, it was not 
statistically significant. There was correlation between CTL scans and the Image J results. 
The same doses of 5-HT (20 and 80µM) showed less invaded cells in the membrane. 
Similarly, in HTR8/SVneo cells, the 60µM treated cells showed a significant increase in cell 
invasion compared to control, as confirmed by both CTL scan (lowest number of non-
invaded cells) and Image J counts (highest number of invaded cells; p<0.05). The increase 
was almost 100%, more than the control, as seen from Figure 5.38.B. The 80µM 5-HT 
treatment once again significantly reduced the cell invasion in HTR8/SVneo cells. Therefore 
60µM 5-HT was considered as the optimal concentration for improvement of transformed 
trophoblast cell invasion under hypoxic conditions. Concentrations above and below 60µM 
5-HT reduced the cell invasion.  
 
 Effect of 5-HT on placental choriocarcinoma cell invasion 
When the effects of 5-HT on placental choriocarcinoma cell invasion were investigated, 
there was no significant changes reported within treated and control groups (See Figure 
5.39). The 60µM 5-HT showed very little or slight increase in invaded cell numbers when 
compared to control. Image J analysis demonstrated that 80µM 5-HT treated cells showed 
significantly lower number of JEG3 cells on bottom of the membrane.  
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Figure 5.38: Effect of 5-HT on transformed trophoblast cell invasion under hypoxic conditions. 
 
A correlation was observed between CTL (I) and Image J (II) analysis.  
 
Panel A: Represents the invasion in TEV-1 cells. I. There was significantly high percentage of non-invaded cells seen in negative, 20 and 80µM 5-HT 
when compared to control (positive) (n=2±SEM;**p<0.01; *p<0.05). The same doses showed reduced number of invaded cells (II).  
 
Panel B: Represents the invasion of HTR8/SVneo. I. The 80µM 5-HT showed the highest % non-invaded cells when compared to positive and other 5-
HT treated cells. II. Approximately 100% significant increase in invaded cells were observed with 60µM when compared to control (n=2±SEM; **p<0.01; 
*p<0.05). More invaded cells were seen on bottom of membrane in positive and 60µM. 
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Figure 5.39: Effect of 5-HT on placental choriocarcinoma cell invasion under hypoxic conditions. 
 
A correlation was observed between CTL (I) and Image J (II) analysis.  
 
Panel A: Represents the invasion in BeWo. I. There was no significant changes in cell invasion with 5-HT treatment when compared to control (positive) 
(n=2±SEM). II. Only negative control showed a significantly lower number of invaded cells (***p<0.001). 
 
Panel B: Represents the invasion of JEG3. I. 5-HT treated JEG3 cells showed very little or slight variation in cell invasion when compared to control 
(positive). II. The 80µM 5-HT however shows a significant reduction in invaded cells by Image J analysis (n=2±SEM; *p<0.05).  
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 Effect of 5-HT on fibrosarcoma cell invasion 
Although a significantly  lower number of non-invaded cells (p<0.05) were observed in 
60µM 5-HT treated HT1080 cells, it failed to show similar significance in increase of 
invaded cells when compared to control (See Figure 5.40). The cell invasion reduced with 
80µM 5-HT. Therefore there was no improvement of fibrosarcoma invasion with 5-HT 
under hypoxic conditions.  
 
Figure 5.40: Effect of 5-HT on fibrosarcoma cell invasion under hypoxic conditions. 
 
A significantly low number of non-invaded cells (%) were observed with 60µM 5-HT 
treatment from the CTL analysis (n=2±SEM; *p<0.05). Although CTL and Image J analysis 
showed same patterns of invasion for 5-HT treated cells, the 60µM increase was not higher 
than control. 
 
Overall, among all the 5-HT doses investigated, only 60µM 5-HT improved the invasion of 
all the five cell lines under hypoxic conditions, whereas higher or lower doses reduced the 
cell invasion.  When compared to the invasion in normal conditions, the invasion under 
hypoxic conditions with 5-HT were reduced.   
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5.3 Discussion      
Systematic investigation on the status of any proteins/biomarkers in placenta in situ has 
always been challenging due to ethical constraints. In addition, the morphology of placenta 
is distinctly different from one another, even in NT pregnancies. To circumvent these 
problems, placental explants and many different types of placental cells have been isolated 
and immortalised to be used as in vitro models (Orendi et al, 2011).  These cell lines have 
been convenient in vitro models for expression analysis with/without interventions. In this 
study, four placental cell lines; TEV-1, HTR8/SVneo (representing early first trimester 
trophoblast), BeWo and JEG3 (choriocarcinoma) were used along with a positive 
fibrosarcoma cell line HT1080.  
It is a proven fact that in PE pregnancies, the circulating 5-HT is increased (Cruz et al, 1998). 
Furthermore, it has been postulated that 5-HT and its receptors may have a fundamental role 
in placental development and pregnancy maintenance (Oufkir et al, 2010). However, due to 
ethical constraints, it is impossible to compare the effects of 5-HT on the expression of its 
receptors between early stages of human pregnancy and term placentae. A few previous 
studies have looked at the expression profiles of 5-HT receptors in vitro using term 
choriocarcinoma cell lines such as JEG3 and BeWo (Sonier et al, 2005). However, there was 
not enough information on the effects of 5-HT on early first trimester trophoblast (EVT) cell 
lines. This current study gives an outline of the events occurring in these cell lines due to 5-
HT treatment. The results from this chapter are summarised in Table 5.2.   
 Effect of 5-HT on cell viability: 
The morphological changes monitored by H&E staining in the cells treated with 5-HT 
showed that the cell density increased at 20-40µM of 5-HT concentrations. However, at 
higher concentrations there was an increase in the amount of apoptosis and/or necrosis. In 
addition, giant anaplastic cells with distorted features such as multiple nuclei were also 
observed at these concentrations (especially at 80µM 5-HT treatment). Therefore, to confirm 
the behaviour of these cells upon 5-HT treatment, two assays were performed for cell 
viability (MTT) and toxicity (LDH). The MTT results for the effect of 5-HT confirmed that 
the mitochondrial activity of the cells also increased at 20-40µM concentrations. The LDH 
assay on the other hand showed minimum LDH release in cells treated with 20-40µM 5-HT 
concentrations, but maximum LDH releases was observed with higher concentrations 
(80µM). This shows that, at lower concentrations, 5-HT enhances mitochondrial activity; 
whereas at higher concentrations, it reduces it. This variation in cell behaviour with dose 
confirms the biphasic effects of 5-HT that have been reported earlier in mammary cells (Pai 
and Horseman, 2008). This increased mitochondrial activity at 20-40µM could also be due 
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to the inhibition of apoptosis. Previous studies using similar doses have shown inhibition of 
apoptosis in monocytes (Soga et al, 2007). There were very limited variations in the cells 
plated along with 5-HT and the cells treated with 5-HT after attachment (24 hours of cell 
recovery). This shows 5-HT does not have any immediate effects on the cell viability or cell 
attachment. However, prolonged treatment with optimum doses may increase viability 
(mitochondrial activity) of the cells. This phenomenon has also been reported in hepatic 
tumour cells (Ahlund et al, 1989). 
Table 5.2: Summary of the effects of 5-HT on cell behaviour. 
 
The significant changes in the cell behaviour due to 5-HT treatment are shown compared to 
control (non-treated) cells. The 5-HT concentration that induces these changes are given 
below the changes. +++ = High increase; ++ = Moderate increase; + = Low increase; - - = 
Moderate decrease; - = Low decrease; nc= no change.  
 
 Effect of 5-HT on cell proliferation: 
It should be noted that MTT and LDH assays can only show the viability (or the 
mitochondrial activity) and toxicity of the 5-HT respectively. In other words, it is impossible 
to predict whether the increase in mitochondrial activity (and therefore cell viability) is a 
direct results of increased cell proliferation or due to the enhanced cellular metabolic activity. 
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In order to prove the increased mitochondrial activity by 5-HT was mainly due to cell 
proliferation, tritium labelled (3H) thymidine incorporation assay was employed. In the 
method, the methyl group of thymidine is labelled with tritium to give radioactive 3H-
thymidine. During cell proliferation the cells undergo DNA duplication and cell division at 
S phase of the cell cycle (Cavanagh et al, 2011). At this stage, treated cells will 
incorporate 3H-thymidine into the duplicating DNA instead of thymidine thus labelling all 
the daughter cells. Thus, the detection of radioactivity of 3H-thymidine at the end of the assay 
would indicate cell proliferation.  
Furthermore, the effect of 5-HT on cell proliferation recovery were also examined. The cells 
were treated with 5-Fluoro-Uracil (5-FU) for 24 hours before 5-HT treatment. 5-FU is a 
pyrimidine analogue with a fluoride atom attached to the base of pyrimidine ring. 5-FU has 
extensively been used as an anti-metabolite to treat solid tumours such as colorectal, breast 
and liver carcinomas (Ghoshal and Jacob, 1997). 5-FU has also been used as anti-mitotic 
agents in cell culture to differentiate mitotic cells from migrating cells (Gordon et al, 2005). 
Therefore, by pre-treating the cells with 5-FU, it was possible to study the effects of 5-HT 
on cell recovery. However, no studies could be found on this in the literature.     
The results for 3H thymidine incorporation indicated that 5-HT did not improve the cell 
proliferation of these cell lines significantly. This shows that 5-HT at lower concentrations 
may increase both the viability and proliferation of placental trophoblast, choriocarcinoma 
and fibrosarcoma (the positive control) cell lines. However, 5-HT was also able to recover 
placental choriocarcinoma cell lines (BeWo and JEG3) proliferation which were inhibited 
with 5-FU treatment previously. Thus, 5-HT had a recovery effect on inhibited proliferation 
of only cancerous and not transformed trophoblast cell lines. This effect could be mediated 
through the interaction of 5-HT with several 5-HT receptors studied in previous chapters 
which trigger several signalling pathways. However, there are no previous reports on this 
and need to be critically reviewed. 
   
 Effect of 5-HT on cell migration and invasion: 
The study of 5-HT inducing human aortic endothelial cell migration by Matsusaka and 
Wakabayashi in 2005 instigated similar interests in placental cells. The scratch/wound 
healing assay on placental cell lines indicated that 5-HT could improve the ‘wound healing’ 
response compared to untreated cells (control). When the wound closure of transformed 
trophoblast cells, TEV-1 and HTR8/SVneo were compared, it was observed that lower doses 
of 5-HT (20-40µM) improved the migration.  
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The wound closure of TEV-1 cells was higher at the end of the assay than HTR8/SVneo. 
Similar concentrations of 5-HT (30µM and 40µM) in placental choriocarcinoma cells 
(BeWo and JEG3), showed higher rates of wound healing compared to controls. However, 
when the wound healing of the two placental cell types were compared, transformed 
trophoblast cells showed higher wound coverage than placental choriocarcinoma. This 
unexpectedly reduced rate of wound healing in BeWo and JEG3 may be due to the fact that 
these cell lines, despite having originated from carcinoma, have a syncytial-like morphology. 
That is, they both grow in clusters of cells and migrate as sheets or clumps. Therefore, 
individual cell motility cannot be observed as in transformed trophoblast cells. As expected, 
the fibrosarcoma cell line (HT1080) which was used as positive control showed the fastest 
wound coverage within 12 hours of the assay. Also, all the doses of 5-HT seemed to increase 
the wound coverage when compared to untreated cells.  
It should be noted during the migration assay, cells were treated with 5-FU. This, together 
with the fact that all migration assays were carried out using serum free media (SFM) rules 
out any effects of 5-HT induced cell proliferation. Therefore it can be safely argued, under 
the present experimental conditions, 5-HT activated cell migration; may be via a different 
intra-cellular pathway. Previously, it was reported that lower doses of 5-HT increased the 
migration of neural crest cells during early development (Reviewed by Moiseiwitsch, 2000). 
However, treatment with higher doses of 5-HT resulted in the reduction of cell migration 
and promoted differentiation. 5-HT is also known to play an important role in epithelial 
homeostasis of the lung, breast, liver and prostate (Pai et al, 2009). The studies on tumour 
cell lines such as breast and hepatocellular cancer have confirmed the migratory effects of 
5-HT through its interactions with various 5-HT receptors, especially via 5-HT2B receptor 
subtype (Pai and Horseman, 2008; Soll et al, 2010). These studies have also suggested the 
role of 5-HT on the epithelial-to-mesenchymal cell transition (EMT) which is one of the 
important features for cell migration and invasion. Although the signalling pathways for the 
5-HT receptors have been investigated in placental choriocarcinoma cell lines (BeWo and 
JEG3) (Sonier et al, 2002), no previous studies could be found on the migratory effects on 
transformed trophoblast cell lines (TEV-1 and HTR8/SVneo). 
The data from the invasion assay did not correlate with data from above migration studies. 
There was no significant increase in cell invasion with 5-HT treated for transformed 
trophoblast cell lines. However, 20-30µM 5-HT increased the invasive capacity of placental 
cancer cell lines (BeWo, JEG3 and HT1080). This was expected, as cancerous cells show 
higher cell invasion than normal cells. Overall, this study has confirmed 5-HT increases the 
migration of all the four placental cell lines (TEV-1, HTR8/SVneo, BeWo and JEG3), but 
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on the other hand, increases cell invasion only in placental choriocarcinoma cells. A study 
by Oufkir et al (2010), have proposed the involvement of 5-HT2A receptor in the invasion 
of BeWo and JEG3 cell lines. However, the pathways involving transformed trophoblast cell 
invasion are yet to be revealed.  
 Effects of 5-HT under hypoxic conditions: 
In this study, the cells under hypoxic conditions were treated with higher concentrations of 
5-HT to recreate a PE placental environment for the cells. As discussed earlier, during PE 
placenta the oxygen levels are low (less than 2% v/v) and the serotonin levels are higher 
(0.5-0.7µg/mg) than in normal placenta (0.4µg/mg) (Ramadan et al, 1973).  
The H&E staining revealed long extended cell morphology in transformed trophoblast cells 
with 20-80µM 5-HT treatment. At much higher dose of 100µM, frequent appearance of 
apoptotic cells with blebbing were observed. However, due to the syncytial-like appearance 
of the placental choriocarcinoma cells, these features were not distinguishable in BeWo and 
JEG3. There was frequent appearance of anaplastic cells with some showing chromosomal 
distortions at higher concentrations. The fibrosarcoma cells also showed similar features. 
The MTT and LDH data suggest that 5-HT increased the viability of all the cell lines except 
for BeWo under hypoxic conditions. This proves the earlier finding within this chapter that 
the effects of 5-HT on cell viability may be cell line dependant. The optimum 5-HT dose 
which induced the highest cell viability in all cell lines was found to be 60µM. Cells treated 
with 100µM 5-HT showed the least viability with maximum release of LDH, indicating this 
dose was toxic to the cells under hypoxic conditions.  
The 3H assay revealed 5-HT did not have any significant effect on the proliferation of 
transformed trophoblast cells and also did not show recovery of inhibited proliferation. 
However, in placental choriocarcinoma cells, BeWo and JEG3, 5-HT induced significant 
increase in proliferation and also recovery. Although a slight increase in fibrosarcoma cell 
proliferation was observed, this was not significant.  These studies have confirmed that 
placental cells are tolerant to hypoxic conditions and the mitogenic effects of 5-HT under 
hypoxic conditions in cancerous cell lines. 
On the other hand, under hypoxic conditions, no improvement in cell migration was 
observed with 5-HT except for 60µM in HT1080. In contrast, in invasion studies, 
HTR8/SVneo and JEG3 showed an increase in cell invasion with 60µM 5-HT. There was 
no significant changes with 5-HT in the remaining cell lines. This was paradoxical, as 
increased invasion was expected during hypoxic conditions, especially in cancerous cell 
lines (such as BeWo and HT1080).  
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Although the cells were more tolerant to high doses of 5-HT under hypoxic conditions, the 
migratory and invasive properties induced by 5-HT were not significant. It is also a very 
well-known fact that hypoxia alters the expressions of genes involved in migration and 
invasion (Graham et al, 2000). The data from this chapter confirms that high levels of 5-HT 
may not enhance placental cell migration or invasion under hypoxic conditions. This agrees 
with the findings that high levels of circulating 5-HT in PE conditions may result in shallow 
placental invasion. This may be due to the alterations in the 5-HT receptors. To confirm 
these effects of 5-HT on the cell behaviour, receptor expression studies need to be carried 
out (See Chapter 6). 
 
Conclusion: 
The data from this chapter suggests that under normoxic conditions 5-HT at low 
concentrations induces migration and invasion of the placental cells. However under hypoxic 
conditions the cells are more “tolerant” to higher doses of 5-HT and therefore do not show 
any changes either in migration or invasion.  
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6.1 Introduction 
Although 5-HT is one of the most extensively studied molecules in human 
physiology/pharmacology, previous studies mainly concentrated on the brain and neuronal 
development (Burnet et al, 1995). The effect of 5-HT on cell migration and invasion via its 
interaction with 5-HT receptors have been reported in glioma and hepatocellular cancer cells 
(Merzak et al 1996; Soll et al, 2010). The few studies that have investigated the involvement 
of 5-HT on regulation of placental choriocarcinoma cell lines (JEG3 and BeWo) migration 
have only highlighted the importance of 5-HT2AR subtype (Klempan et al, 2011; Sonier et 
al, 2005). Interestingly, these studies have concluded that the differential expression patterns 
of several intracellular mitogenic proteins are dependent on the concentration of 5-HT. 
However, both BeWo and JEG3 are tumour originated cell lines. Therefore, it is essential to 
repeat this study using cell lines that are derived from first trimester trophoblast (TEV-1 and 
HTR8/SVneo) which are involved in early placental invasion. Moreover, 5-HT has been 
reported to be involved in early trophoblast invasions (Ugun-Klusek et al, 2011; Oufkir et 
al, 2010; Bolte et al, 2001). Therefore, it is essential to study the effects of 5-HT on its main 
receptors using cell lines derived from early first trimester trophoblast. 
On the other hand, neither the expression of C/T antigens in placental cell lines, nor the 
effects of 5-HT on C/T antigen expressions, have ever been studied before. In fact, C/T 
antigens are expressed mainly in tumour and germ cells (such as testis). Therefore, very little 
is known about the functions of these antigens. From the few studies that have been carried 
out, these antigens are known to be involved in invasion, tumorigenesis, and apoptosis 
(Olesen et al, 2011; Sang et al, 2011; Gjerstorff et al, 2006). Interestingly, from Chapter 3, 
it was clear that C/T antigens were expressed in human placenta, both NT and PE. The 
immunohistochemistry has revealed that these antigens are mostly expressed in the 
syncytiotrophoblast (STB) and cytotrophoblast (CTB) layers. Given the fact that the 
expression of many C/T antigens are generally altered in PE where the circulating 5-HT is 
increased (Sivasubramaniam, 2002), it would be interesting to see if there are changes in 
C/T antigen expression with 5-HT. In addition, the data from Chapter 5 have confirmed that 
the migration and invasion of transformed trophoblast and choriocarcinoma cell lines are 
affected by different doses of 5-HT. This, together with the fact that 5-HT receptors and C/T 
antigens have shown differential expression patterns in NT and PE placentae (See Chapter 
3), have warranted the need to study whether 5-HT (a) brings about its mitogenic actions via 
5-HT1BR and 5-HT2BR;   and (b) affects the expression of  C/T antigen. 
6.2 Results 
The expression of the 5-HT receptors and C/T antigens in NT and PE placentae were 
compared previously in Chapter 3. This chapter deals with the effects of 5-HT on the 
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functional expression of the above receptors/antigens, using transformed trophoblast (TEV-
1 and HTR8/SVneo) and placental choriocarcinoma (BeWo and JEG3) cell lines. Firstly, the 
basal expressions of 5-HT receptors and C/T antigens in placental cell lines were studied 
using qRT-PCR, to confirm that the cell lines used express these receptors and especially the 
C/T antigens. These cells were treated with different doses of 5-HT for 24 hours to analyse 
the mRNA (qRT-PCR) and protein (Western blotting) expression (see Chapter 2; Sections 
2.6.5 and 2.7.4). Commercially available total RNA and proteins (Clontech, UK) from 
human brain and testis were used as positive controls for 5-HTR and C/T antigens 
respectively (data not shown).  
A one-way ANOVA statistical analysis was performed on the 2-∆∆Ct values from qRT-PCR 
(two individual experiments each for two different passage numbers; n=4) and densitometry 
data from Western blots (one blot each for two different passages; n=2). Where appropriate, 
the cellular localisation of the receptors and antigens were also investigated by 
immunofluorescent labelling with FITC (green) and nuclear counter staining with DAPI 
(Section 2.9.4).  
 
6.2.1 5-HT receptors 
The two 5-HT receptor subtypes, 5-HT1BR and 5-HT2BR were investigated in transformed 
trophoblast and placental choriocarcinoma cell lines.  
6.2.1.1 Basal 5-HT1B receptor expression in cell lines 
The mRNA expression of 5-HT1BR were investigated in the cell lines relative to expression 
in human brain (positive; arbitrarily set to 1) (See Figure 6.1). The mRNA expression of 5-
HT1BR in brain was significantly higher than the expressions in the cell lines 
(****p<0.0001). When the expressions were compared amongst cell lines, the level of 5-
HT1BR in transformed trophoblast group was significantly higher than other groups. On the 
other hand, the placental choriocarcinoma group expressed the lowest level of 5-HT1BR 
which was significantly lower to HT1080 (*p< 0.05) 
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Figure 6.1: Basal mRNA expression of 5-HT1BR in cell lines. 
 
The data are means of 2 experiments (each performed in tripliactes; ±SEM; ****, 
****p<0.0001; +p<0.05). The mRNA expression is relative to expression in brain 
(arbitrarily set to 1).  
 
 
 The effects of 5-HT on 5-HT1BR expression  
Although the expression of 5-HT1BR was detected at mRNA level for 5-HT treated placental 
choriocarcinoma cells (BeWo and JEG3), these differences in expression were not 
confirmed by Western blotting and immunofluorescence. Thus, only 5-HT1BR expression 
patterns in transformed trophoblast cells are discussed below. 
As can be observed from Figure 6.2 (Panels A and B), a significant increase in expression 
of 5-HT1BR was observed in TEV-1 cells treated with 5-HT relative to the control (not 
treated). The mRNA and protein expressions showed similar trends with 10µM 5-HT treated 
cells showing the maximum up-regulation. The highest concentration of 80µM 5-HT showed 
a down-regulation in mRNA expression relative to control. On the other hand, Western blots 
have shown a significant increase in the 5-HT1BR with all the different concentrations of 5-
HT. The immunofluorescent staining for 5-HT1BR showed a cytoplasmic localisation and 
the fluorescence intensity correlated with the protein expression data (See Figure 6.2.C).  
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Figure 6.2: Effect of 5-HT on 5-HT1BR expression in TEV-1 cells.  
 
Panel A represents the relative mRNA expression of 5-HT1BR to control (n=4; ±SEM) 
which shows a significant up-regulation with 10µM 5-HT treatment (**p<0.01). Panel B 
represents the densitometry analysis of the western blots (n=2 ±SEM). Bands for 5-HT1BR 
were visible at 33kDa. Equal loading of protein concentration was confirmed by β-actin 
expression. There was a significant increase of 5-HT1BR proteins with 5-HT treatment 
(average *p<0.05). Panel C reveals the cytoplasmic localisation of 5-HT1BR (FITC-Green). 
Nucleus was counter stained with DAPI (blue). [Objective magnification: 40X (Scale bar= 
50µm) and 100X (Scale bar= 125µm)]  
    
The 5-HT treatment in the second transformed trophoblast cell line, HTR8/SVneo, produced 
an overall increase of 5-HT1BR (See Figure 6.3).  There was a gradual up-regulation in 
mRNA expressions with increasing concentrations of 5-HT (except the cells treated with 
10µM). Significant increase in 5-HT1BR was seen in 30µM and 40µM 5-HT treated cells 
(p<0.01). The densitometry analysis of the Western blots correlated to mRNA expression. 
However, the expression patterns were not significant at protein levels. The immunostaining 
also revealed cytoplasmic localisation. There were no differences in fluorescent intensities 
observed between the 5-HT treated and control cells. 
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Figure 6.3: Effect of 5-HT on 5-HT1BR expression in HTR8/SVneo cells.  
Panel A and B represent the relative mRNA (n=4) and protein (n=2) expression of 5-HT1BR 
in HTR/SVneo. The mRNA expression was upregulated with 30 and 40 µM (±SEM; 
**p<0.01).  The cytoplasmic localisation of 5-HT1BR (FITC) is confirmed by 
immunofluorescent staining in Panel C and nucleus counter stained (DAPI). [Objective 
magnification: 40X (Scale bar= 50µm) and 100X (Scale bar= 125µm)]     
 
 
6.2.1.2 Basal 5-HT2B receptor expression in cell lines 
The placental choriocarcinoma cell lines (BeWo and JEG3) showed a significantly higher 
level of 5-HT2BR mRNA expression when compared to all other cell lines (see Figure 6.4). 
When the expressions were compared within the groups, there was a significant difference 
observed between the two transformed trophoblast cell lines, TEV-1 and HTR8/SVneo 
(*p<0.05). It was also observed that the mRNA expression was significantly higher in human 
brain (positive control). 
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Figure 6.4: Basal mRNA expression of 5-HT2BR in cell lines.  
 
The data are means of 2 experiments (each performed in triplicates; ±SEM; ***p<0.001; 
**p<0.01; *,*, *p<0.05). The mRNA expression is relative to expression in brain (arbitrarily 
set to 1).   
 
 
 The effects of 5-HT on 5-HT2BR expression 
Both the transformed trophoblast cells, TEV-1 and HTR8/SVneo were investigated for 5-
HT2BR expressions. However, only JEG3 from placental choriocarcinoma group contributed 
to expression data for 5-HT2BR. 
 
• The effects of 5-HT on 5-HT2BR expression in transformed trophoblast cell lines 
The TEV-1 cells treated with 5-HT showed a significant reduction in 5-HT2BR expression 
when compared to control (See Figure 6.5.A and B). This difference in expression was 
observed at both mRNA and protein level. A single protein band of approximately 53kDa 
was detected on the Western blots (molecular weight as specified by the primary antibody 
supplier, biorbyt, UK). However, a greater staining of the cell membrane rather than a diffuse 
cytoplasmic stain was observed by immunofluorescent staining (FITC) (Figure 6.5.C). 
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Figure 6.5: Effect of 5-HT on 5-HT2BR expression in TEV-1 cells. 
Panel A represents the relative mRNA expression of 5-HT2BR [(n=4) ±SEM] which shows 
significant down-regulation in 5-HT treated cells (except 20µM). The significance is 
generally *p<0.05). Panel B represents the immunoblot analysis [(n=2) ±SEM]. Protein 
bands were visible at 50kDa. Significant reduction in protein concentrations were also 
observed with 5-HT treatment (*p<0.05). Panel C displays the cytoplasmic localization of 
5-HT2BR (FITC) with nuclear staining (DAPI). [Objective magnification: 40X (Scale bar= 
50µm) and 100X (Scale bar= 125µm)]  
    
In HTR8/SVneo cells, there was a significant up-regulation in expression of 5-HT2BR 
mRNA in 5-HT treated cells. This change was not demonstrated on the basis of protein 
expression. Instead, the protein expression was significantly only increased following 10µM 
5-HT treatment, with a gradual decrease with increasing 5-HT concentrations. Like TEV-1 
cells, a cytoplasmic localisation of 5-HT2BR is evident in immunofluorescent cytochemistry 
(Figure 6.6).  
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Figure 6.6: Effect of 5-HT on 5-HT2BR expression in HTR8/SVneo cells. 
Panels A and B represent the relative mRNA (n=4) and protein (n=2) expression of 5-
HT2BR. The mRNA expression was up-regulated with 10µM (**p<0.01), 30 µM (*p<0.05) 
and 40 µM (*p<0.05) 5-HT treatments. 10µM also shows a significant increase in protein 
expression. Panel C displays the cytoplasmic localisation of 5-HT2BR (FITC) with nuclear 
staining (DAPI). [Objective magnification: 40X (Scale bar= 50µm) and 100X (Scale bar= 
125µm)]  
 
 
• The effect of 5-HT on 5-HT2BR expression in placental choriocarcinoma cell lines 
Although the mRNA expression of 5-HT2BR in both BeWo and JEG3 were analysed by 
qRT-PCR, the expression at protein levels was confirmed only for JEG3 by western blotting. 
The immunofluorescent cytochemistry was unsuccessful for both cell lines. The expression 
patterns in JEG3 were similar to HTR8/SVneo (See Figure 6.7). A significant increase was 
seen with 10µM 5-HT treatment in both mRNA and protein expressions (p<0.01). However 
the higher concentrations of 5-HT reduced the expression of 5-HT2BR. 
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Figure 6.7: Effect of 5-HT on 5-HT2BR expression in JEG3 cells. 
Panel A and B, represent the relative mRNA (n=4) and protein (n=2) expressions of 5-
HT2BR in JEG3 respectively. The mRNA and protein expressions were significantly up-
regulated with 10µM 5-HT treatment (**p<0.001). On the other hand, higher concentrations 
up to 30 µM of 5-HT has significantly reduced the protein expressions (***p<0.001; 
*p<0.05).  
 
6.2.2 C/T antigens 
The six C/T antigens; CAGE1, FATE1, GAGE1, GAGEE1, MAGEA1 and MAGEA4 were 
investigated at mRNA and protein levels in in vitro. Since the status of these antigens in any 
of these cell lines have not been studied before, the basal (mainly mRNA) expressions of 
these antigens in different placental cell lines were checked in comparison with fibrosarcoma 
(cancer) cell line and testis (positive; arbitrarily set to 1). 
 
6.2.2.1 Basal expression CAGE1 in cell lines  
There were no differences in the basal mRNA expression observed between the three groups 
of cells namely transformed trophoblast, placental choriocarcinoma and fibrosarcoma (See 
Figure 6.8). However, there was significant differences reported within the members of the 
placental choriocarcinoma group, BeWo and JEG3 (***p<0.001).  The fibrosarcoma 
HT1080 cell line unexpectedly showed the lowest level of expression for CAGE1 when 
compared to placental originated cells. As expected, the mRNA expression of CAGE1 in 
testis sample was significantly higher when compared to all the cell lines (****p<0.0001).  
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Figure 6.8: Basal mRNA expression of CAGE1 in cell lines.  
 
The data are means of 2 experiments (each performed in triplicates; ±SEM; ****p<0.0001; 
***p<0.001). The mRNA expression is relative to expression in testis (positive set as 1).  
 
 
 The effect of 5-HT on CAGE1 expression  
Although the effect of 5-HT on CAGE1 mRNA expression were investigated in all the four 
cell lines, confirmation of expression at the protein level was only possible for TEV-1 and 
BeWo, discussed as follows. 
 
• The effect of 5-HT on CAGE1 expression in transformed trophoblast cell lines 
The mRNA expression of CAGE1 in TEV-1 did not correlate to the protein expression, as 
determined using the Western blot (See Figure 6.9.A and B). A significant down-regulation 
of the antigen at mRNA was seen in 5-HT treated TEV-1 cells when compared to control 
(p<0.001). However, only higher concentrations (40µM and 80µM) of 5-HT have resulted 
in significant reduction of CAGE1 at protein level (p<0.05). In contrast, there was increased 
expressions of the protein in 10µM (p<0.05) and 30µM (p<0.01) 5-HT treated cells. 
Granular cytoplasmic staining of CAGE1 can be seen in immunofluorescence cytochemistry 
(See Figure 6.9.C). However, there was no significant difference in staining intensities 
between 5-HT treated and control cells. 
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Figure 6.9: Effect of 5-HT on CAGE1 expression in TEV-1 cells. 
Panel A and B represent relative mRNA (n=4) and protein (n=2) expressions of CAGE1 
(±SEM; ***p<0.001; **p<0.01; *p<0.05). Single band for CAGE1 in Western blot was 
observed at approximately 100kDa. Granular cytoplasmic localisation of CAGE1 (FITC) 
was confirmed by immunofluorescent staining in Panel C. [Objective magnification: 40X 
(Scale bar= 50µm) and 100X (Scale bar= 125µm)]  
 
 
• The effect of 5-HT on CAGE1 expression in placental choriocarcinoma cell lines 
The expression of CAGE1 was significantly up-regulated in BeWo cells treated with 10-
80µM 5-HT when compared to control. The mRNA and protein expression patterns were 
comparable (See Figure 6.10). A significant peak of protein expression was observed at 
40µM 5-HT treatment (p<0.0001). However, at highest concentration (of 80µM) the 
expression levels declined.  
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Figure 6.10: Effect of 5-HT on CAGE1 expression in BeWo cell line. 
Panel A represents mRNA expression of CAGE1 in 5-HT treated cells relative to control 
(n=4±SEM). Panel B confirms the significant increase in protein expression in 5-HT treated 
cells (n=2 ±SEM; ****p<0.0001;**p<0.01;*p<0.05).  
 
6.2.2.2 Basal expression of FATE1 in cell lines 
The placental choriocarcinoma cell lines (BeWo and JEG3) showed a significantly higher 
FATE1 mRNA expression than the transformed trophoblast (*p<0.05) and fibrosarcoma 
(*p<0.05) cell lines (shown in Figure 6.11). Testis (positive control) showed a significantly 
higher level of expression to all the cell lines (****p<0.0001).  
 
Figure 6.11: Basal mRNA expression of FATE1 in cell lines.  
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The data are means of 2 experiments (each performed in triplicates; ±SEM; ****p<0.0001; 
*, +,*p<0.05). The mRNA expression is relative to expression in testis (positive set as 1) 
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 The effects of 5-HT on FATE1 expression  
The mRNA and protein expression of FATE1 in 5-HT treated cells were investigated. 
However, as stated earlier the localisation of the protein by immunofluorescence was not 
possible. 
• The effect of 5-HT on FATE1 expression in transformed trophoblast cell lines 
There was no correlation between the mRNA and protein expression of FATE1 in the two 
transformed trophoblast cell lines, TEV-1 and HTR8/SVneo. Nevertheless, both cells 
showed down-regulation of the FATE1 mRNA as well as protein expressions with high 
concentrations of 80µM 5-HT (See Figure 6.12). The protein bands on the Western blots 
were detected at approximately 20kDa molecular weight.  
 
 
Figure 6.12: Effect of 5-HT on FATE1 expression in transformed trophoblast cells. 
 
Panels A and B represent relative mRNA and protein expression of FATE1 in TEV-1 cells 
respectively (n=2; ±SEM; **p<0.01). Panels C and D represents relative mRNA and protein 
expression in HTR8/SVneo cells respectively (n=2; ±SEM; *p<0.05). No significant 
differences in protein expression were detected.  
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• The effect of 5-HT on FATE1 expression in placental choriocarcinoma cell lines 
There was significant down-regulation of FATE1 mRNA in 10µM and 80µM 5-HT treated 
BeWo and JEG3 cells (See Figure 6.13.A and C). However, the mRNA expression in both 
the cells treated with concentrations between 20-40µM 5-HT showed minimum variations 
to control. As for protein expression, high concentrations of 5-HT (40µM and 80µM) have 
shown a non-significant reduction of FATE1. Remarkably, there was a significant up-
regulation in protein expression in 20µM 5-HT treated BeWo cells. Unlike FATE1 protein 
expression in transformed trophoblast cells, the immunoblots of FATE1 in placental 
choriocarcinoma cells showed two distinct bands at 20kDa and 25kDa.   
 
Figure 6.13: Effect of 5-HT on FATE1 expression in BeWo and JEG3 cells. 
Panels A and B represent relative mRNA and protein expression of FATE1 in BeWo cells 
(n=2; ±SEM; *p<0.05). Panel C and D represents relative mRNA expression in JEG3 cells 
(n=2; ±SEM; *p<0.05, **p<0.01). Two distinct bands are seen in the western blot images. 
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6.2.2.3  GAGE family 
The expression of two members of the GAGE family, GAGE1 and GAGEE1, were 
investigated in the cell lines.  
6.2.2.3.1  Basal expression of GAGE1 in cell lines 
As can be seen in Figure 6.14, there was no variation in GAGE1 mRNA expression between 
the transformed trophoblast and placental choriocarcinoma cell lines. The expression in 
human testis and HT1080 cells was significantly higher when compared to the cells 
originated from placenta.  
 
 
Figure 6.14: Basal mRNA expression of GAGE1 in cell lines.  
 
The data are means of 2 experiments (each performed in triplicates; ±SEM; ****, 
****p<0.0001). The mRNA expression is relative to expression in testis (positive set as 1). 
 
 The effects of 5-HT on GAGE1 expression  
The mRNA and protein expression of GAGE1 was investigated in all the four cell lines. 
• The effect of 5-HT on GAGE1 expression in transformed trophoblast cell lines 
The 5-HT treatment altered the expression of GAGE1 in TEV-1 and HTR8/SVneo cells. In 
TEV-1, with 10µM 5-HT treatment, the mRNA and protein expression was reduced when 
compared to control (See Figure 6.15.A and B). However, with increasing concentrations of 
5-HT the expression of GAGE1 was slightly increased. A significant increase was observed 
with 40µM 5-HT, then expression level decreased at 80µM 5-HT. Two protein bands were 
detected on the western blots with molecular weights between 30-40kDa, which was within 
the predicted range specified by the antibody supplier (Novus). Granular cytoplasmic 
localisation of GAGE1 was also detected with immunofluorescent staining with FITC as 
seen in Figure 6.15, Panel C.   
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Figure 6.15: Effect of 5-HT on GAGE1 expression in TEV-1 cells. 
Panels A and B represent relative mRNA (n=4) and protein (n=2) expression of GAGE1 in 
TEV-1 cells (±SEM; *p<0.05). Two bands within 30-40kDa were observed in Western blots. 
Granular cytoplasmic localisation of GAGE1 (FITC) was confirmed by immunofluorescent 
staining in Panel C. [Objective magnification: 40X (Scale bar= 50µm) and 100X (Scale 
bar= 125µm)]  
 
 
The expression of GAGE1 in 5-HT treated HTR8/SVneo cells followed comparable 
expression patterns to TEV-1 (See Figure 6.16). However these differences in mRNA and 
protein expressions were not statistically significant except for 80µM treated. Furthermore 
the immunofluorescent labelling of GAGE1 revealed very faint marginal staining of the 
cytoplasm in HTR8/SVneo.  
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Figure 6.16: Effect of 5-HT on GAGE1 expression in HTR8/SVneo cells.  
Panels A and B represents relative mRNA (n=4) and protein (n=2) expression of GAGE1 
in HTR8/SVneo cells (±SEM; *p<0.05). The immunofluorescent labelling of GAGE1 
(FITC) reported a marginal staining of the cytoplasm (Panel C). [Objective magnification: 
40X (Scale bar= 50µm) and 100X (Scale bar= 125µm)]  
 
 
• The effect of 5-HT on GAGE1 expression in placental choriocarcinoma cell lines 
In BeWo cells, the mRNA and protein expressions of GAGE1 was observed to have 
increased with increasing concentration of 5-HT (See Figure 6.17.A and B). Compared to 
control, the level of mRNA expression was significantly up-regulated in 80µM 5-HT 
treatment. For protein expression, both 20µM as well as 80 µM treated BeWo cells showed 
significant increase relative to control. On the contrary, the expression of GAGE1 was 
significantly down-regulated in JEG3 cells treated with higher concentrations of 5-HT; 
especially with 80µM (See Figure 6.17.C and D).  Although the commercial antibody was 
able to detect the proteins in Western blot, it was unable to detect the localisation of GAGE1 
by immunofluorescence.  
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Figure 6.17: Effect of 5-HT on GAGE1 expression in BeWo and JEG3 cells.  
Panels A and B represent the relative mRNA and protein expression of GAGE1 in BeWo 
cell line respectively (*p<0.05). Panels C and D represent the relative mRNA and protein 
expression in JEG3 cells (**p<0.01). 
 
6.2.2.3.2  Basal expression of GAGEE1 in cell lines 
The mRNA expression of the second member of GAGE family, GAGEE1 (also known as 
PAGE5), was lower in transformed trophoblast cells (TEV-1 and HTR8/SVneo) when 
compared to placental choriocarcinoma cell lines (BeWo and JEG3). Furthermore, the 
expression was significantly lower when compared to fibrosarcoma (HT1080; **p<0.01) 
and testis (****p<0.0001) (See Figure 6.18). Furthermore, the mRNA expression of 
GAGEE1 in placental choriocarcinoma group (***p<0.001) and HT1080 (*p<0.05) was 
significantly lower when compared to testis.  
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Figure 6.18: Basal mRNA expression of GAGEE1/PAGE5 in cell lines.   
 
The data are means of 2 experiments (each performed in triplicates; ±SEM; ****p<0.0001; 
***p<0.001; **p<0.01; *p<0.05]. The mRNA expression is relative to expression in testis 
(positive set as 1) 
 
 
 The effects of 5-HT on GAGEE1 expression  
The mRNA and protein expression of GAGEE1/PAGE5 was verified in all the four cell 
lines. Although JEG3 showed higher mRNA expression to other cell lines in basal 
expression as discussed above, it was not detected by immunofluorescent labelling.  
• The effects of 5-HT on GAGEE1 expression in transformed trophoblast cell lines 
A bell shaped (or Gaussian distribution) GAGEE1 expression pattern was observed in both 
TEV-1 and HTR8/SVneo cells; with 10µM and 80µM 5-HT treated cells showing the lowest 
levels of expression. Although both the mRNA and protein expressions showed bell shaped 
pattern with increasing concentrations of 5-HT in TEV-1, the mRNA expression was 
significantly down-regulated in 5-HT treated cells when compared to control. However, the 
protein expressions in the same cells were increased when compared to control (See Figure 
6.19.A and B). Nevertheless, the significance was only observed in 30µM 5-HT treated cells 
for both mRNA and protein expressions (p<0.05). A single protein band of approximately 
20kDa in molecular weight was detected by Western blotting. Immunofluorescent labelling 
of GAGEE1 with FITC revealed cytoplasmic localisation of the protein in TEV-1 (See 
Figure 6.19.C). There was no significant reduction in staining intensities detected in 5-HT 
treated cells and control.  
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Figure 6.19: Effect of 5-HT on GAGEE1 expression in TEV-1 cells. 
Panels A and B represent relative mRNA (n=4) and protein (n=2) expression of GAGEE1 
in TEV-1 cells (±SEM; ***p<0.001; *p<0.05). A single protein band of ~20kDa was 
observed in Western blots. Granular cytoplasmic localisation of GAGEE1 (FITC) can be 
seen in the immunofluorescent staining in Panel C counter stained with DAPI for nucleus. 
[Objective magnification: 40X (Scale bar= 50µm) and 100X (Scale bar= 125µm)]  
 
 
 
In HTR8/SVneo cells, the expression levels of both GAGEE1 mRNA and protein were up-
regulated by 5-HT treatment when compared to control (See Figure 6.20). A significance 
was observable with 30µM 5-HT treatment (p<0.05). The staining was observed on overall 
cytoplasmic regions of the cells.  
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Figure 6.20: Effect of 5-HT on GAGEE1 expression in HTR cells. 
Panels A and B represent relative mRNA (n=4) and protein (n=2) expression of GAGEE1 
in HTR/SVneo cells, with significant up-regulation at 30µM 5-HT treatment (±SEM; 
*p<0.05). Intense staining for GAGEE1 (FITC) was observed in the cytoplasmic region of 
the cells (Panel C). [Objective magnification: 40X (Scale bar= 50µm) and 100X (Scale bar= 
125µm)]  
 
• The effect of 5-HT on GAGEE1 expression in placental choriocarcinoma cell lines 
There was a variation in expression of GAGEE1 observed in the two placental 
choriocarcinoma cell lines (BeWo and JEG3). The 5-HT treated BeWo cells expressed a 
similar bell shaped (Gaussian distribution) pattern with increasing concentrations of 5-HT 
as in transformed trophoblast cells (See Figure 6.21.A and B). At lower (10µM) and higher 
concentrations (40µM and 80µM) of 5-HT, the expression of GAGEE1 was down-regulated 
when compared to control. However, the mRNA as well as protein expression of GAGEE1 
were significantly increased with 30µM 5-HT treatment relative to control. Remarkably, of 
all the proteins investigated, only GAGEE1 protein was detected by immunofluorescent 
staining in BeWo cell lines and, interestingly, the staining were observed to be localised at 
certain regions of the cytoplasm, as illustrated from Figure 6.21.C. 
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Figure 6.21: Effect of 5-HT on GAGEE1 expression in BeWo cells. 
Panels A and B represent relative mRNA (n=4) and protein (n=2) expression of GAGEE1 
in BeWo, with significant up-regulation at 30µM 5-HT treatment (±SEM; *p<0.05). 
Localised staining of GAGEE1 (FITC) of the cytoplasm can be seen in Panel C. [Objective 
magnification: 40X (Scale bar= 50µm) and 100X (Scale bar= 125µm)]  
 
 
 
Although the GAGEE1 mRNA expression in JEG3 showed similar bell shaped (Gaussian 
distribution) expression pattern as BeWo, the protein expression did not reveal any 
comparable results. The two expression patterns were almost contrasting, as is illustrated in 
Figure 6.22.  The 10µM and 80µM 5-HT treatments resulted in down-regulation of mRNA 
expression, but significantly increased the protein expressions when compared to control 
(p<0.001; p<0.01).  
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Figure 6.22: Effect of 5-HT on GAGEE1 expression in JEG3 cells. 
Panel A shows a significant up-regulation of GAGEE1 mRNA expression in 30µM and 
40µM 5-HT treated JEG3 cells when compared to control [(n=4) ±SEM; *p<0.05]. As for 
protein expression, 10µM and 80µM 5-HT treated cells showed a significant up-regulation 
Panel B [(n=2) ±SEM; ***p<0.001; **p<0.01]. 
 
 
6.2.2.4  MAGE family 
The expression of two members of MAGE family, MAGEA1 and MAGEA4, were 
investigated in the cell lines. The protein expression of these antigens were not detected in 
placental choriocarcinoma cell lines, hence only expression analysis in transformed cells 
(TEV-1 and HTR8/SVneo) is discussed as follows.  
 
6.2.2.4.1  Basal expression of MAGEA1 in cell lines 
When the overall mRNA expression of MAGEA1 in the cell lines were compared, a 
significant difference in expression was observed between the transformed trophoblast and 
placental choriocarcinoma groups (**p<0.01; See Figure 6.23). It was also worth noting that 
the mRNA expression in the fibrosarcoma cell line, HT1080, was remarkably higher when 
compared to the other cell lines (****p<0.0001), as well as to the positive control (testis; 
*p<0.05).  
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Figure 6.23: Basal mRNA expressions of MAGEA1 in cell lines.   
 
The data are means of 2 experiments (each performed in triplicates; ±SEM; ****p<0.0001; 
**p<0.01; *p<0.05]. The mRNA expression is relative to expression in testis (positive set as 
1) 
 
 
 The effects of 5-HT on MAGEA1 expression analysis 
The mRNA and protein expression of MAGEA1 was observed to be down-regulated in 5-
HT treated TEV-1 cells when compared to control. There was a significant decline in the 
expression with increasing concentrations of 5-HT (See Figure 6.24). Two protein bands 
were observed on the Western blots, with molecular weights approximately 34kDa and 
36kDa. The predicted molecular weight supplied by the antibody provider was 34kDa. 
Granular cytoplasmic presence of the protein was indicated by fluorescent labelling of the 
protein by FITC.  
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Figure 6.24: Effect of 5-HT on MAGEA1 expression in TEV-1 cells. 
Panels A and B show a significant decline in mRNA and protein expression of MAGEA1 
in 5-HT treated TEV-1 cells respectively (****p<0.0001; ***p<0.001; **p<0.01; *p<0.05). 
Panel C shows the cytoplasmic localisation of the protein in the cells. [Objective 
magnification: 40X (Scale bar= 50µm) and 100X (Scale bar= 125µm)]  
 
 
 
The mRNA and protein expressions of MAGEA1 in 10µM 5-HT treated HTR8/SVneo were 
significantly increased when compared to control (p<0.05; See Figure 6.25.A and B).  
However, the expression declined at higher 5-HT concentrations. A statistically significant 
down-regulation was observed only for 80µM 5-HT treated HTR8/SVneo cells (p<0.05). 
The two protein bands at 34kDa and 36kDa were also detected in HTR8/SVneo cells. 
Granular staining in the cytoplasm was observed for MAGEA1 protein.  
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Figure 6.25: Effect of 5-HT on MAGEA1 expression in HTR8/SVneo cells.  
Panels A and B show significant changes in mRNA and protein expression of MAGEA1 in 
10µM and 80µM 5-HT treated HTR8/SVneo cells relative to control (*p<0.05). Panel C 
shows the cytoplasmic localisation of the protein labelled with FITC in the cells. [Objective 
magnification: 40X (Scale bar= 50µm) and 100X (Scale bar= 125µm)]  
 
 
 
6.2.2.4.2  Basal expression of MAGEA4 in cell lines 
There were no variations in the mRNA expressions of MAGEA4 between the three cell 
groups (See Figure 6.26). However, there were variations in expressions within the group 
members, with significant differences in expression between BeWo and JEG3 
(****p<0.0001). The expression was also significantly higher in testis when compared to all 
the cell lines.  
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Figure 6.26: Basal mRNA expression of MAGEA4 expression in cell lines. 
 
The data are means of 2 experiments (each performed in triplicates; ±SEM;****p<0.0001; 
***p<0.001; **p<0.01; *p<0.05]. The mRNA expression is relative to expression in testis 
(positive set as 1) 
 
 
 The effects of 5-HT on MAGEA4 expression analysis 
Although MAGEA1 and MAGEA4 belong to the same family of antigens, the expressions 
patterns for the two were different in the transformed trophoblast cell lines. Like MAGEA1, 
the expression of MAGEA4 was down-regulated in 5-HT treated TEV-1 cells compared to 
control (See Figure 6.27.A). When the expressions between the different doses of 5-HT were 
compared, the 10µM 5-HT showed the lowest expression of MAGEA4 and the levels 
increased with increasing concentrations of 5-HT. A single protein band was observed at 
approximately 35kDa by western blot investigation and at 80µM 5-HT treatment a 
significant up-regulation of MAGEA4 protein was detected (p<0.05). Overall, weak 
granular staining of the protein was shown by immunofluorescent labelling with few intense 
focalised regions.  
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Figure 6.27: Effect of 5-HT on MAGEA4 expression in TEV-1 cell line.  
Panel A represents the gradual increase in mRNA expressions with increasing concentration 
of 5-HT treatment in TEV-1 cells (n=4±SEM). Panel B represents the significant increase 
in the protein expression with higher concentrations of 5-HT (n=2±SEM; *p<0.05). Bands 
were observed at  ̴ 35kDa. Granular cytoplasmic staining of the MAGEA4 protein can be 
seen in Panel C. [Objective magnification: 40X (Scale bar= 50µm) and 100X (Scale bar= 
125µm)]  
 
 
In HTR8/SVneo cells, except for 30µM, the remaining 5-HT concentrations showed no 
significant variations in the mRNA and protein expression of MAGEA4 when compared to 
control (See Figure 6.28.A and B).  The 30µM 5-HT treated cells showed a down-regulation 
in the mRNA (p<0.05) and protein expressions (not significant). The MAGEA4 protein was 
located in the cytoplasm of the cells.  
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Figure 6.28: Effect of 5-HT on MAGEA4 expression in HTR8/SVneo cell line.  
Panel A shows a significant down-regulation of mRNA expression in 30µM 5-HT treated 
HTR8/SVneo cells when compared to control (n=4±SEM; *p<0.05). Down-regulation in the 
protein expression (but not significant) was also observed at the same 30µM 5-HT treated 
cells, as shown in Panel B (n=2). Panel C shows the granular cytoplasmic staining of the 
protein MAGEA4 (FITC). [Objective magnification: 40X (Scale bar= 50µm) and 100X 
(Scale bar= 125µm)]  
 
 
6.2.2.5  Basal mRNA expression of PASD1 in cell lines 
Overall, there was no significant variation in mRNA expression among the three cell groups, 
transformed trophoblast, placental choriocarcinoma and fibrosarcoma (See Figure 6.29). 
However, there were variations among the group members like placental choriocarcinoma, 
where the mRNA expressions were significantly higher in BeWo cells when compared to 
JEG3 cells (p<0.0001). Interestingly, the expressions in BeWo was the highest in the 
investigation. PASD1 was investigated only at the mRNA level, as the proteins were not 
detectable by Western blotting with the commercial antibody which was available for study. 
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Figure 6.29: Basal mRNA expression of PASD1 in cell lines. 
 
The data are means of 2 experiments (each performed in triplicates; ±SEM; ****p<0.0001; 
****p<0.0001). The mRNA expression is relative to expression in testis (positive set as 1).  
 
 
6.2.3  Relative mRNA expressions under hypoxic condition 
As seen in Section   5.2.3,   hypoxic conditions (2% v/v O2) altered the metabolic, 
proliferative, migrative and invasive effects induced by 5-HT on the cell lines.  After 
confirmation of the effect of 5-HT on gene expression above, the basal mRNA expressions 
of these genes under hypoxic conditions were also investigated (See Figure 6.30). The 
mRNA expression in the cell lines were evaluated relative to expression in positive controls 
(brain for 5-HT receptors and testis for C/T antigens). The mRNA expression under 
normoxia and hypoxia were then compared. Variance in mRNA expression was analysed 
using two-way ANOVA followed by Sidak’s test for comparison under normoxia and 
hypoxia. Significant up-regulation was observed in mRNA expression of most of the 
receptors and antigens under hypoxic conditions, except for PASD1 which was down-
regulated in BeWo cells under hypoxia. Thus, hypoxia altered the mRNA expression of these 
important receptors and antigens in the placental cell lines. These preliminary results need 
to be confirmed at the protein level (See Section 7.4). 
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Figure 6.30: Relative mRNA expression under hypoxic condition.  
The data are means of 2 experiments (each performed in triplicates; ±SEM; ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05]. The mRNA expression is 
relative to expressions in positive controls (brain and testis; arbitrarily set as 1). 
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6.3 Discussion 
The aim of this chapter was to investigate the effect of 5-HT on expressions of 5-HT 
receptors and C/T antigens in transformed trophoblast (TEV-1 and HTR8/SVneo) and 
placental choriocarcinoma (BeWo and JEG3) cell lines. Two different cells in each group 
were investigated, as there were variations in gene expression, even within the same group. 
The fibrosarcoma (HT1080) cell line was used as representative tumour cell line (as 
explained in Chapter 5). From the results, it can be seen that the effect of 5-HT on protein 
expression was dependant of the protein type, cell line and concentration of 5-HT. It was 
initially intended to compare the mRNA (by real-time PCR) and protein (quantitatively by 
immunoblotting and qualitatively by immunofluorescence). However, the commercially 
available antibodies were unable to detect the protein expression on some of the cell lines 
within the study period, despite repeated attempts. To the author’s knowledge, this is the 
first study to attempt to comparatively analyse protein and mRNA expressions of C/T 
antigens in placental derived cells.  
 
• Comparison of Basal mRNA expressions 
Since the status of C/T antigens in trophoblast and choriocarcinoma cell lines are not known, 
their basal mRNA expression, together with the expression of 5-HT1BR and 5-HT2BR were 
compared with that which is present in fibrosarcoma (HT1080) cells. Also, it was important 
to compare the expression levels in all of the cell lines in order to select the best model for 
placental trophoblast study.  The obtained data suggest there is difference in basal mRNA 
expression patterns in different cell lines. The mRNA expression of the majority of C/T 
antigens in HT1080 (the control cancer cell line), were high and comparable with the positive 
control (human testis). The exceptions were FATE1 and CAGE1 mRNAs which were found 
to be the lowest in HT1080 amongst the cell lines used in this study. As for the main 5-HT 
receptors, the choriocarcinoma cells showed a very low expression pattern of 5-HT1BR. On 
the other hand, the transformed trophoblast cell lines have shown a relatively high basal 
expressions of 5-HT1BR. Nevertheless, compared to choriocarcinoma cells, the expression 
of 5-HT2BR was found to be lower in transformed trophoblast cells.  
The results also show the basal mRNA expressions of C/T antigens were generally lower in 
transformed trophoblast cell lines. This is consistent with the data from term and first 
trimester placenta (Chapters 3 and 4 respectively). In contrast, both choriocarcinoma cells 
exhibit higher mRNA expressions of many C/T antigens compared to HT1080 cells. This 
was expected as the C/T antigens are tumour-specific, and the choriocarcinoma cell lines are 
derived from placental tumours.  
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Between the choriocarcinoma cell lines, BeWo has shown higher mRNA expression of 
CAGE1, and PASD1 than JEG3 cells. In contrast, the mRNA expression for MAGEA1, 
MAGEA4 and GAGEE1 were found to be higher in JEG3 cells. The above results show the 
data from the in vitro studies are cell line specific, as has been highlighted by other authors 
in cancer research (Holliday and Speirs, 2011; Domcke et al, 2013).  
 
• Effect of 5-HT on expression of 5-HT receptors 
There was an increase in 5-HT1BR expression observed in both TEV-1 and HTR8/SVneo 
cells treated with 5-HT when compared to control. However, the expression of 5-HT2BR in 
TEV-1 and HTR8/SVneo cells did not correlate. Furthermore, the expression of only 5-
HT2BR was detected in JEG3 placental choriocarcinoma cell line, whereas the expression of 
this two receptors were not detected at protein levels in BeWo. The HTR8/SVneo and JEG3 
cells treated with 10µM 5-HT showed a significant increase in 5-HT2BR expression relative 
to controls. Thus it was noticed, at low 5-HT concentrations, that the expression of these two 
receptors were increased, but at higher concentration (80µM) the expression levels 
decreased. This suggests that 5-HT being a mitogen would enhance the expression of 5-
HT1BR and 5-HT2BR at low concentrations, yet down-regulate expression at higher 
concentration.  
The cellular localisation of the proteins in the cytoplasm was confirmed by 
immunofluorescent staining. However, these were not detected in placental choriocarcinoma 
cells. One reason for this could be that the syncytial nature of choriocarcinoma cells with 
minimal cytoplasmic mass hinders the epitope binding of the antibodies. Both 5-HT1B and 
5-HT2B receptors have been reported to show increased expression during hepatocellular 
cancers and the mitogenic effects of 5-HT in liver cells have been confirmed (Soll et al 2010; 
2012).  In a previous placental study, the presence of 5-HT as well as its receptors on 
trophoblast cells suggested that the physiological effects of 5-HT are mediated via its 
autocrine and paracrine interactions to receptors (Huang et al, 1998).  
As can be seen in Chapter 5, there is a direct correlation between effects of 5-HT on cell 
proliferation, migration and invasion of TEV-1, HTR8/SVneo and JEG3, and the observed 
effects of 5-HT on 5-HT1B and 5-HT2BR receptor expression.  This suggests that the 
physiological actions of 5-HT on these cell lines may be via 5-HT1B and 5-HT2BR receptors.  
Since 5-HT has been implicated in the implantation (Cikos, 2011), the finding that the 
expression of 5-HT1BR and 5-HT2BR in both HTR8/SVneo and JEG3 cells are enhanced 
would confirm the role of 5-HT in trophoblast invasion. Also, the finding that 5-HT at high 
concentrations reduces both receptors in these cell lines, confirms the hypothesis (explained 
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in Chapter 1) that the drastic increase in the circulating 5-HT may be the cause for the 
reduced trophoblast invasion in PE (Bolte et al, 2001; 2001a, Sivasubramaniam et al, 2002). 
 
• Effect of 5-HT on expression of C/T antigens 
The C/T antigens have not been investigated earlier in transformed trophoblast (TEV-1 and 
HTR8/SVneo) and placental choriocarcinoma (BeWo and JEG3) cell lines. In fact, there is 
no literature on the effects of 5-HT on C/T antigen expressions overall. Therefore, this 
element of the research was focussed on establishing whether 5-HT may have an effect on 
C/T antigens. The 5-HT treatment either increased or decreased the expression of the C/T 
antigens compared to control. The effects were dependant on specific antigens, the 
concentration of 5-HT and the origin of cell line. Most of the C/T antigens like CAGE1, 
FATE1 and GAGE family (GAGE1 and GAGEE1) showed a bell shaped (or Gaussian 
distribution) expression patterns with range of 5-HT concentrations in nearly all the cell 
lines. At the lowest (10 µM) and highest (80 µM) concentrations, the levels of C/T antigen 
expression were relatively low. However, between 20-40µM, the expression levels 
increased, with the highest being shown at 30-40µM 5-HT. This suggests that 5-HT at 
concentrations between 20 to 40µM may be the most probable optimal range to produce 
effective changes in the expressions of these C/T antigens.  In contrast, MAGEA1 expression 
levels decreased with increasing concentration of 5-HT, whilst MAGEA4 expression was 
directly proportional to 5-HT concentrations. In general most of the C/T antigens expressions 
were reduced at 80µM 5-HT.  
On the protein expression analysis, the Western blots of some of the C/T antigens such as 
FATE1, GAGE1 and MAGEA1 showed two distinct bands. Similar band patterns were also 
observed in placental tissue samples (See Section 3.2.3.5). The appearance of two distinct 
protein bands could be either due to transcript variants of the antigens or post-translational 
modifications. FATE1 expression showed two bands in the immunoblots of placental 
choriocarcinoma cell lines (BeWo and JEG3) similar to placental tissues. However, both 
TEV-1 and HTR8/SVneo cells showed only a single band in the Western blots. It is not clear 
whether the appearance of the two bands in choriocarcinoma cells is a result of splice 
variants specific to these cells.  Although functions of most of the C/T antigens have not 
been confirmed, some of them are implicated in  cell differentiation (MAGEA1), tumour 
suppression (MAGEA4), apoptosis (GAGE1; GAGEE1) and tumorigenesis (FATE1) 
(Monte et al, 2006; Sang et al, 2011; Gjerstorff et al, 2006; Olesen et al, 2011).      
Interestingly, it was noticed in TEV-1 cells the increasing concentration of 5-HT has 
decreased the MAGEA1 antigen expression, whilst in the same cell line the MAGEA4 
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expression increased with increasing concentrations of 5-HT. Thus, there appears to be an 
inverse correlation between cell differentiation (suggested function of MAGEA1) and 
tumour suppression (function of MAGEA4) in this cell line. Furthermore, the expression of 
other antigens involved with apoptosis (such as GAGE1 and GAGEE1) was decreased with 
high 5-HT concentrations, thereby inhibiting the apoptotic effects of 5-HT at these 
concentrations. These findings suggest that high concentrations of 5-HT decrease the cell 
proliferation through different mechanism. Previous hepatocellular cancer studies have 
suggested that high concentrations of 5-HT may activate an autophagy mechanism (Soll et 
al, 2010). Similar mechanism may have been involved in these cell lines. The 
immunofluorescent cytochemistry confirmed the cytoplasmic localisations of many of these 
antigens in transformed trophoblast cells especially in TEV-1. However, it was not possible 
to show the cellular localisation of all the antigens in some cell lines. Although a complete 
comparison of mRNA, protein and localisation of all C/T antigen was not achieved due to 
time constraints, to the best of author’s knowledge this is the first study which reports basal 
expressions of these C/T antigens in placental cell lines and its regulation by different doses 
of 5-HT. 
 
• Conclusion: 
Since this was a preliminary investigation and no previous studies were available for 
comparison, concrete conclusions could not be drawn from the data available. However, the 
study has shown that all the placental cell lines express most of the C/T antigens similar to 
the expression patterns of placenta. Therefore, these cell lines, especially TEV-1 and 
HTR8SV/neo cells can be used as in vitro models in the functional studies involving C/T 
antigens. 
Also, it could be suggested that 5-HT affects the expressions of the C/T antigens and their 
functions.  An in depth analysis of the intracellular pathways of C/T antigens and the 
influence of 5-HT on these pathways is needed to establish link between them (see Chapter 
7).  
 
 
 249 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7                           
General Discussion 
 
 
 
 
 
Chapter 7: General Discussion 
 
250 
 
7.0  Discussion 
The aims of this thesis were firstly to establish the status and the regional expression of (a) 
all 5-HT receptor subtypes and (b) C/T antigens in pre-eclamptic (PE) placentae in 
comparison with normotensive (NT).  Following this, an analysis of the expression of 5-HT 
receptors and C/T antigens in the placentae from first trimester (FT) pregnancies was carried 
out. This was followed by an investigation on the effects of 5-HT on the invasive potential 
of transformed early first trimester placental cells in relation to choriocarcinoma (placental 
cancer) cell lines under normoxic/hypoxic environment and an elucidation on  the effects of 
5-HT on the expressions of C/T antigens in placental cell lines under normal and hypoxic 
conditions. 
 
To satisfy the initial aim, the expression profiles of 5-HT receptors and C/T antigens were 
investigated in three different human placental samples (NT, PE and FT) with different 
trophoblast invasive potentials. A three way status analysis of these receptors and antigens 
was conducted, firstly between NT and PE placentae, followed by FT and term. After the 
confirmation of differences in expression between these placental groups, the study focussed 
on the effects of 5-HT on trophoblast invasion and the expression of the above 
receptors/antigens using placental cell line models. The expression of C/T antigens was 
investigated with 5-HT insult- firstly to identify the antigens that are differently expressed 
with 5-HT and, secondly, to elucidate any probable functions of these antigens in placental 
invasion and development.  
 
7.1 Expression analysis on placental samples 
7.1.1  Normotensive versus pre-eclamptic placentae 
In the past, the effects of 5-HT and the status of 5-HT1 and 5-HT2 receptors on placental 
vessels have extensively been studied (Cruz et al, 1998; Ugun-Klusek et al, 2011; Cordeaux 
et al, 2008). Apart from its vascular effects, 5-HT is involved in proliferation and migration 
of cells. These effects were found to be brought about by 5-HT1B (Sibella-Argüelles, 2001; 
Banasr et al, 2004; Gurbuz et al, 2014; Matsusaka and Wakabayashi, 2005) and 5-HT2B 
receptors (Pai and Horseman, 2008; Soll et al, 2012).   To begin with, the mRNA expression 
of the seven 5-HT receptor families and their sub-types was compared in NT and PE 
placentae. The expression was compared with that in brain (positive) control after 
normalisation with house-keeping genes. Significant down-regulation of mRNA expressions 
of 5-HT1B, 5-HT1D, 5-HT1E and 5-HT2B receptors in PE was observed.  
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Due to the close homology of the members of 5-HT1 receptor subtype, the protein expression 
of only 5-HT1B and 5-HT2B receptor was examined. Although the difference in protein 
expression of 5-HT1BR in NT and PE was not significant, it agreed with the mRNA 
expression patterns. Both 5-HT1B and 5-HT2B receptors showed cytoplasmic staining in the 
STB and CTB layers of villi by IHC. The staining in the decidua of PE samples was more 
intense than in the villous section.  
The findings from this study suggest that the proliferative and migratory effects of 5-HT 
cannot be exploited due to the low expression levels of 5-HT1B and 5-HT2B receptors in PE, 
although high levels of 5-HT have been reported during PE (Cruz et al, 1998). Hence, lack 
of proliferation and migration of the placental cells leads to poor placental development.  
The present study represents the first time that the expression profiles for C/T antigens 
between NT and PE have been compared. Earlier studies have only reported localisation of 
some antigens by IHC (Jungbluth et al, 2007) and expression of one C/T antigen (CAGE1) 
by Western blotting in FT (Khan et al, 2014). In the present study, it was observed that seven 
C/T antigens displayed significant differences in mRNA expression between NT and PE, 
thus the hypothesis was proved to be true atleast at the mRNA level. This was followed by 
protein validation, which correlated to mRNA expression with the exception of FATE1. The 
protein levels of FATE1 showed an increase in PE when compared to NT, whereas the 
mRNA expressions were the opposite.  It may be due to the half-life of mRNA, as protein 
cannot be translated from mRNA with very short or long half-life (Wang et al, 2002; Yang 
et al, 2003).  
As explained by one of the manufacturers (Sigma-Aldrich – www13), Western blots can give 
four different types of result: 
•  a supportive result which shows the band of predicted size (e.g. MAGEA4 and 
PAGE5); 
•  a supportive result of predictive size band with additional bands present (as in FATE, 
CAGE1 and GAGE1); 
•  an uncertain result, with no/very faint bands (e.g. MAGEA1); or with a single band 
differing more than +/- 20% from the predicted size; 
• None-supportive results with weak bands of predicted sizes but with additional bands 
of higher intensity also present. 
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Interestingly, none of the Western blot data presented herein showed bands differing more 
than +/- 20% from the predicted size; nor were there bands beyond predicted sizes. 
Additionally, two bands of different molecular weights (20kDa and 25kDa) were observed 
for FATE1 in placental samples as well as the positive control (human testis). In testis, the 
intensity of the 20kDa band was higher than that of the 25kDa, whereas for placental samples 
the opposite was observed. Although no splice variants have been reported for FATE1, 
Olesen et al, (2003) reported two mutations within FATE1 gene which were linked to 
infertility in males. Therefore, it would be interesting to explore the nature of these two bands 
further to identify any possible variants. In addition, this C/T antigen is predicted to be 
involved in tumourigenesis, due to the presence of binding sites for steroidogenic factor-1 
(SF-1) and Wilms’ tumor gene 1 (WT1) (Yang et al, 2005). Both SF-1 and WT1 have been 
reported to be expressed in placental trophoblast linking to placental growth and invasion 
(Bamberger et al, 1993; Feingold et al, 1998).  Hence, a possible function for FATE1 in 
placenta could also be trophoblast differentiation and invasion.  
Similar observations were made for CAGE1 and GAGE1 proteins with additional molecular 
weight bands. Since these bands were also consistently shown in positive controls, the total 
sum of the intensities of these bands was comparatively analysed. Although this may be a 
limitation of this study, it was not feasible, within the study period, to extensively analyse 
whether these extra bands actually represent the original protein or if they are the splice 
variants. The current study is one of the very few that has used C/T antigen specific 
antibodies in Western blots. Since all the antibodies used were polyclonal in nature, these 
additional, but faint, bands may also be due to non-specific binding. A comparable band 
pattern for FATE1 and GAGE1 was also observed in in vitro expression analysis (see Section 
7.2).  
The CAGE1 antigen was down-regulated in PE placentae. Although the function of CAGE1 
in placenta is unknown, differential expression patterns with gestational age (weeks) have 
been described sooner in FT placentae (Khan et al, 2014). Unusually, antigens involved in 
tumour suppression and apoptosis (MAGEA4, GAGE1 and GAGEE1/PAGE5) were 
significantly down-regulated in PE placentae. As higher apoptotic rates were shown in STB 
during PE complications (Ishihara et al, 2002), an up-regulation of these antigens was 
expected. This paradox may suggest alternative functions for these antigens in placenta. The 
fact that the CTB cells in PE are not as physiologically active as in NT to undergo constant 
differentiation, proliferation and apoptosis cycle may also be a likelihood.  
Although the MAGEA1 mRNA expression was up-regulated in PE, protein bands on 
Western blots were found to be too faint for analysis. Similarly, the PASD1 down-regulation 
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in PE was investigated only at mRNA level. Due to this, the cellular localisation of these 
antigens in NT and PE placentae was also investigated using immunohistochemistry (IHC). 
The immunoreactivity (IRS) for MAGEA1 staining intensity confirmed the unfaithful 
translation of MAGEA1 mRNA to protein in PE. As MAGEA1 is linked with cell 
differentiation in spermatogenesis and cell signalling (Monte et al, 2006), the  low levels of 
this antigen in PE can thus be linked to poor differentiation of the CTB stem cells into STB 
during early placentation . However, it can also be argued that, as the presence of CTB stem 
cells is low even in NT term placentae, their prevalence is lower in PE, possibly accounting 
for the low expression of the antigen. 
 
Finally, PASD1 mRNA expression was significantly down-regulated in PE, but not 
confirmed by IRS. Very little is known about this antigen, but its function is predicted to be 
stimuli-dependent (Campbell et al, 2011). 
 
The C/T antigens, like 5-HT receptors, were mostly localised on the STB and CTB layers of 
the villi in NT. In PE the staining was concentrated around the decidua, embedded with giant 
cells and iCTB. The staining of these antigens appeared in the cytoplasm of these cells; even 
though FATE1 and PASD1 were reported to be present in the nucleus in the Uniprot database 
(Q969F0; Q8IV76). Previous studies have also reported both cytoplasmic and nuclear 
localisation of FATE1 and PASD1 (Yang et al, 2005; Ait-Tahar et al, 2009). In general, 
these C/T antigens which are involved in tumour development are more prevalent in the 
trophoblast cells which share invasive characteristics with cancer cells.  
 
7.1.2 First trimester versus term placentae 
The reliability and practicality of microarray studies have led to several expression analyses 
on first trimester (FT) placentae (Sitras et al, 2012; Chen et al, 2002; Khan et al, 2010, 2004). 
In the present study the first obvious difference in expression pattern was observed between 
FT and term placentae due to the placental structure and thus the second hypothesis was 
proved to be true (Chapter 1: Introduction). The C/T antigen mRNA expression in FT were 
significantly up-regulated in FT when compared to term placentae, except for 
GAGEE1/PAGE5.  The up-regulation of these antigens that are predicted to be involved in 
placental development agrees with the high metabolic activity of trophoblast cells during FT 
than at term (Huppertz, 2008; Jones and Fox, 1991). However, the down-regulation of 
GAGEE1 and 5-HT2B receptor in FT could not be explained (as up-regulation was expected). 
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On a closer examination, a heterogeneity in the mRNA expression was observed for FT 
placentae for these receptors and antigens, which was comparable to previous findings with 
gestational ages (weeks 6-8) (Khan et al, 2010, 2004). No changes in mRNA expression 
were observed for 5-HT1B and 5-HT2B receptors between weeks 7 to 9 of FT placentae. 
Although the number of samples was limited, the data from the current study agreed with 
previous expression analyses carried out by Huang et al (1998). Using IHC, these reported 
that the 5-HT staining intensity in STB reduced with gestational age, but that 5-HT receptors 
staining showed no variations with age. 
Some of the C/T antigens (GAGE family and FATE1) have also been reported to show 
differences in expression with maturity of the germ cells (spermatocytes) (Gjerstorff et al, 
2008; Yang et al, 2005). Therefore, it was of primary importance to check if the expression 
of C/T antigens also differed with pregnancy progression. 
The current study shows CAGE1 mRNA expression was up-regulated in weeks 7 and 9, but 
was down-regulated in week 8. This agreed with previous findings by Khan et al (2014) of 
CAGE1 expression in FT samples of weeks 6 to 8. Significant differences were also 
observed for FATE1, GAGE1 and MAGEA1 with down-regulation at week 8, but up-
regulation at week 9. This might be a result of the dramatic changes in trophoblast invasion 
and placental development during these weeks. It would be interesting to explore this further 
using a larger number of samples (See Section 7.4). 
Protein localisation of 5-HT receptors and C/T antigens was investigated by IHC in villous 
and decidua of FT. The two receptors, 5-HT1B and 5-HT2B were localised on the cytoplasm 
of the STB and CTB layers of the villi. The mesenchymal cells were also positive for only 
5-HT1B receptors. Staining of the receptors was focused on the stromal cells, epithelial cells 
(uterine and luminal) and spiral arteries of the endometrium. The expression of 5-HT 
receptors on the decidua may indicate the effects of 5-HT on decidua. This finding could be 
linked to observation of the effects of 5-HT on the endometrium development before 
implantation (reviewed by Cikos et al, 2011), and suggests that the decidualisation of the 
endometrium controls the invasion of the trophoblast cells (Norwitz et al, 2001; Arnold et 
al, 2001). The presence of C/T antigens on the endometrial cells also indicates these antigens 
play parallel roles during early implantation.  
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7.2 In vitro expression analysis 
Studies involving human tissue samples are always challenging due to various constraints 
such as ethics, sample availability and delay in collection. During the course of this study, 
13 normal (NT) and 12 PE samples were studied. NT and PE samples were comparable in 
their gestational ages. In addition, it was possible to collect only 11 fresh FT samples from 
the EU collaborator and it was not feasible to collect considerable amounts of RNA and 
protein due to the minute structure of FT placentae from aborted pregnancies. However, 
previous small scale placental studies have reported identification of new proteins involved 
in placental development (Apps et al, 2011; Khan et al, 2010, 2004). Hence, to overcome 
the shortage of samples, placental cell lines were used for the rest of the study.  
As mentioned earlier, the 5-HT levels in PE are higher than in normal placentae and placental 
trophoblast invasion is also shallow in PE. Hence, the next phase was to investigate the 
effects of 5-HT on trophoblast cell lines. Four cell lines originating from placenta, TEV-1 
and HTR8/SVneo (transformed first trimester trophoblast cell lines) and BeWo and JEG3 
(choriocarcinoma) were used for this study.  
Increased apoptotic and anaplastic features were observed in cells treated with high doses of 
5-HT (80-100µM) visualised with H&E staining under normoxia (20% v/v O2) and hypoxia 
(2% v/v O2). There were differences in cell density at various 5-HT concentrations. Thus, 
an in depth analysis using three different assays was implemented to study the effects of 5-
HT on the behaviour of cells of placental origin. 
It was deduced that the effect of 5-HT was bi-phasic i.e. at very low (10µM) and high 
concentrations (80-100µM) the mitogenic effects of 5-HT on all the cell lines were minimal. 
However, at certain concentrations (20-40µM for normoxia and 60µM for hypoxia) cells 
showed the highest mitochondrial activity with minimum LDH release. The proliferation 
rates were also maximal at these concentrations. Former studies have also reported such bi-
phasic and mitogenic effects of 5-HT on other cell lines (Pai and Horseman, 2008). 
Remarkably, 5-HT also showed recovery of cancerous cell proliferation (BeWo, JEG3 and 
HT1080) inhibited with 5-FU treatment under both normoxia and hypoxia. Under hypoxia 
the cells were more tolerant to higher doses of 5-HT (60µM). The fibrosarcoma HT1080 
showed the highest proliferation rates and activity, thus proving to be the ideal positive 
control for the migration and invasion assays conducted. The cell lines in each group were 
identical in their behaviour under 5-HT insult.   
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5-HT is a multifunctional monoamine which triggers various activities in the cells. Migration 
of other cells from normal as well as a malignant origin prompted by 5-HT have been 
described in the past (Matsusaka and Wakabayashi, 2005; Pai et al, 2009). No reference to 
the migratory effects of 5-HT on trophoblast could be found in the literature. Therefore, the 
effects of different doses of 5-HT on migration of four different placental cell lines were 
investigated by performing a simple wound-healing (scratch) assay. The bi-phasic effect of 
5-HT was also observed on the migratory pattern of the cells. 5-HT in moderate doses of 20-
40µM (TEV-1 and HTR8/SVneo) and 30-40µM (BeWo and JEG3) showed increased wound 
coverage when compared to controls (without 5-HT treatment). 
The findings described in this study confirm the bi-phasic effects of 5-HT on cell migration 
as reviewed by Moiseiwitsch (2000) who reported that high doses of 5-HT reduced the 
migration of neural crests and induced differentiation of the cells instead.  Unexpectedly the 
wound covered area was greater for transformed trophoblast cell lines than for 
choriocarcinoma cell lines. This may be due to the syncytial nature of these choriocarcinoma 
cell lines which would hinder cell migration.  HT1080 being the positive and cancerous cell 
lines showed the fastest wound coverage within 12 hours. Since the assay was performed 
after 24 hours treatment with 5-FU and with serum free media (SFM) the possibility of 
movement by proliferating cells was ruled out.  
These assays were repeated under hypoxia with constant monitoring of percentage O2 with 
an oxygen sensor for 12 hours. The effects of 5-HT on the migration of these cells under 
hypoxia and normoxia were compared for 12 hours. Hypoxia, overall, increased the wound 
covered area of all the cells, except JEG3. Only 60µM 5-HT treated transformed trophoblast 
and fibrosarcoma cells showed improved wound coverage (in comparison) to the control.  
Hence, it was confirmed that optimal doses of 5-HT induced the migration of all cell lines 
under normoxia, but induced only migration of transformed trophoblast and fibrosarcoma 
cells under hypoxia. Higher wound coverage was expected for choriocarcinoma due to their 
cancerous nature in comparison to transformed trophoblast cells. It can thus be proposed that 
the trophoblast cells are more tolerant under hypoxic conditions (hypoxia during placental 
development) than choriocarcinoma (hypoxia during tumour formation).   
Since this was the first study to report 5-HT induced migration of transformed first trimester 
trophoblast, it was reasonable to investigate if the 5-HT also affected cell invasion. BD 
Falcon™ BioCoat tumour invasion systems coated with BD matrigel Matrix were used to 
investigate the invaded cells and compared to migrated cells through uncoated plates.  
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Two methods of analysis were utilised to eliminate any drawbacks from either of the two 
methods and a reciprocal agreement was derived. It was confirmed that 5-HT only improved 
the invasion of cancerous cell lines (BeWo, JEG3 and HT1080), but not transformed cell 
lines. This could be due to the highly invasive nature of the cancerous cells when compared 
to the trophoblast cells. Under hypoxic conditions, only HTR8/SVneo and JEG3 cells 
showed increased invasion with 60µM 5-HT when compared to controls. Thus, a cell line 
dependency was observed for the effect of 5-HT on cell migration and invasion. This proves 
that it is critical to choose the right cell models for placental study, and HTR8/SVneo and 
JEG3 cells can be considered to be the best models to investigate invasion during the 
developmental stages of placenta.  
The basal mRNA expressions of the two 5-HT receptors were analysed in all the cell lines. 
The mRNA expression of 5-HT1B receptor was higher in transformed trophoblast cell lines 
(TEV-1 and HTR8/SVneo), whereas 5-HT2B receptor expression was higher in placental 
choriocarcinoma cell lines (BeWo and JEG3). Thus, the expression of these receptors is cell 
line dependent. The 5-HT treatment increased the expression of the 5-HT1B receptor in 
transformed trophoblast cell lines and showed a similar Gaussian distribution, as seen for 
MTT, with lower doses (10-30µM) showing maximum expression. A significant increase in 
expression was observed for 5-HT2B receptor with 10µM 5-HT in TEV-1, HTR8/SVneo and 
JEG3 cell lines. It can be suggested that the effects of 5-HT are mediated through these two 
receptors, but further studies are needed for confirmation (See Section 7.4). The immuno-
fluorescent staining for these receptors verified the expression of these receptors in the 
cytoplasm of the cells, confirming the previous result obtained using IHC staining.  
Owing to the lack of literature on the expression of C/T antigens on placental cell lines, the 
four placental cell lines along with HT1080 were next analysed for C/T antigen mRNA 
expressions. 
As expected, the cancerous cell lines (BeWo, JEG3 and HT1080) showed higher levels of 
C/T antigens (as the name suggests). Though expression was higher in BeWo and JEG3, 
variations were observed between the two cell lines. Thus, the expression of C/T antigens 
was also cell line dependent. The expression patterns for some of the C/T antigens with 5-
HT doses followed a Gaussian distribution, similar to that of 5-HT receptors. These C/T 
antigens were CAGE1 (structural protein), FATE1 (tumourigenesis) and GAGE family 
(GAGE1 and GAGEE1; apoptosis). This hints that at optimal 5-HT concentrations (normal 
pregnancy), the receptors and antigens involved in proliferation, migration and 
tumourigenesis are maintained. The increase in the expressions of antigens related to 
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apoptosis at these concentrations maybe due to high proliferation, differentiation and 
apoptosis cycle of the trophoblast cells similar to cytotrophoblast during FT. 
Fascinatingly, MAGEA4 which has tumour suppressing properties increased with increasing 
5-HT concentrations. Thus, high 5-HT concentrations during PE can cause up-regulation of 
MAGEA4 antigen, which suppresses the proliferation of trophoblast cells. Conversely, 
MAGEA1 was the only gene which did not support the above hypothesis of 5-HT inducing 
expression of proteins involved in placental development. MAGEA1 is predicted to be 
involved in cell differentiation as confirmed earlier and its expression decreased with 
increasing 5-HT concentration. This substantiates the previous findings that 5-HT induces 
cell differentiation at higher concentrations (Reviewed by Moiseiwitsch, 2000). 
The effect of 5-HT also showed alteration under hypoxic conditions, therefore basal mRNA 
expressions of the receptors and antigens were investigated to examine any changes. 
Significant differences in basal mRNA expressions were observed under normal and hypoxic 
conditions in all the cell lines, a finding that needs to be confirmed by protein study.  
 
7.3 Conclusion  
The data from this study suggest that 
• The expression patterns of 5-HT receptors and C/T antigens are altered in PE placentae, 
demonstrating their importance in trophoblast functions. The expression of C/T 
antigens were also different between FT and term placentae, indicating their functional 
importance in the early trophoblast invasion.  
• 5-HT acts as a mitogen for placental cell lines and induces migration as well as 
invasion, signifying the importance of optimum 5-HT levels especially during FT. The 
levels of 5-HT in FT, may alter the expression of 5-HT receptors and C/T antigens and 
therefore regulate their functions during trophoblast invasion and placental 
development. The effects of 5-HT on these cell lines is altered during hypoxia which 
may be linked to expression of these receptors and C/T antigens. 
• In cell culture models it is important to use more than two different cell lines for 
effective analysis of the proteins/factors and their functions. Compared to other cell 
lines, HTR8/SVneo and JEG3 cells can be considered to be the best models to 
investigate invasion during the developmental stages of placenta. 
Refer to Table 7.1 and Table 7.2 for overall summary of results obtained for human placental 
and in vitro study.   
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Table 7.1: Summary of human placental study. 
 
  C&F- Collagen & fibrin; CTB- Cytotrophoblast; D-Decidua; DS-Decidual stroma; EVT-Extravillous trophoblast; MC- Mesenchymal cells; SA-Spiral arteries; STB- Syncytiotrophoblast; UE-Uterine epithelium; VS- Villous stroma;  
(-) down regulated; (+) upregulated; ND- Not detected  
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Table 7.2: Summary of in vitro study. 
The significant changes in the cell behaviour due to 5-HT treatment are shown compared to control (non-treated) cells. The 5-HT concentration that induces these changes are given below 
the changes. (+++) = High increase; (++) = Moderate increase; (+) = Low increase; (- -) = Moderate decrease; (-) = Low decrease; nc= no change; ND= Not detected; ns= Not significant.  
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7.4 Future directions 
The study needs to be extended with a larger number of samples used to confirm and validate 
its findings. This would include protein expression studies, especially for FT, possibly using 
specific monoclonal antibodies. Furthermore, the expression analysis can also be improved 
by cellular fractionation (cytoplasm, mitochondria and nucleus) of placental tissues. Micro-
dissection techniques should also be used to study and quantify the mRNA/protein 
expressions of these antigens, in particular cell groups such as CTB, STB and decidua.  
On the Western blotting side, if additional molecular weight bands persist (as in CAGE1, 
FATE1 and GAGE1), then it would be interesting to investigate the individual bands for 
detecting possible variants and/or post-translational modifications such as phosphorylation. 
The bands can be isolated from the gels and analysed using Mass-spectrometry to identify 
the peptide sequences, which can be further investigated for their properties and localisation 
in the cells.  
The 5-HT receptor inhibition studies are to be conducted to confirm the pathway followed 
by 5-HT to induce its effects on placental cell lines. The functions of the C/T antigens can 
be studied by performing knock-down using small interfering RNA (siRNA) or small hairpin 
RNA (shRNA). A further literature review is to be carried out on this to confirm the 
advantages of these techniques.  
The trophoblast cells from the PE and NT samples can be isolated and the effects of 5-HT 
studied on these primary cell cultures to categorise any changes. Preliminary studies on the 
effect of 5-HT on trophoblast cells isolated from FT villous have been performed under the 
supervision of Dr. Martin Gauster. The protocol for isolation and purification of the 
trophoblast has been optimised during this period. Using these established protocols, the 
primary cell culture can be carried out at least for a limited period of 2 weeks (8 passages). 
This will confirm the differences in the expressions of C/T antigens between NT and PE 
detected in this study.  
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A.2 Wimasis results 
 
Table A.1: Summary of the scratch 
 Speed 
[% / Time units] 
Start Point: 
Time [Time 
units] 
Start Point: 
Cell-covered 
Area [%] 
End Point: 
Time [Time 
units] 
End Point: 
Cell-covered 
Area [%] 
Overall Average 0.9229 0 51.6 48 95.9 
      
Image Name Time  
[Time units] 
Scratch Area 
[%] 
Cell-covered 
Area [%] 
Speed [% / 
Time units] 
Acceleration 
[% / (Time 
units)^2] 
Pos2TEV1_control-00.0 0 48.4 51.6 0.5333 0.9556 
Pos2TEV1_control-03.0 3 46.8 53.2 3.4 -0.4667 
Pos2TEV1_control-06.0 6 36.6 63.4 2 -0.1361 
Pos2TEV1_control-12.0 12 24.6 75.4 1.1833 -0.0767 
Pos2TEV1_control-24.0 24 10.4 89.6 0.2625  
Pos2TEV1_control-48.0 48 4.1 95.9   
 
 
Figure A.7.1: Representation of Cell-covered area [%] for TEV-1 control at different 
time points. 
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A.3 Clinical data of patients 
 
Serial No. Normotensive: Maternal age Gestational age Systolic BP Diastolic BP Placental Weight Mode of Delivery Gestational weight Gestational Sex BMI Protein in urine (g/L)
(Years) (Weeks) (mmHg) (mmHg) (Grams) (Kg)
N1 V6 34 38.4 122 60 855 Vaginal 4.24 male 21.6 N/D
N2 V7 32 38.9 120 90 700 Vaginal 3.3 female 24.5 N/D
N3 V8 29 40.1 140 68 520 Vaginal 3.8 male 23 N/D
N4 V9 36 39.2 128 68 579 Vaginal 3.12 male 24.2 N/D
N5 V10 39 39.2 130 70 636 Vaginal 3.03 male 23.5 N/D
N6 V11 35 38.1 120 70 654 Vaginal 3 male 23 N/D
N7 V12 34 38.3 120 72 725 Vaginal 3.33 female 23 N/D
N8 V13 40 38.4 123 70 852 Vaginal 4.24 male 24.2 N/D
N9 V15 29 39.2 122 66 625 Vaginal 3.21 male 23.5 N/D
N10 V23 36 39.1 110 70 579 Vaginal 3.01 male 24 N/D
N11 V24 35 39.2 125 71 560 Vaginal 3.01 female 24.7 N/D
N12 SITE-1 35 38.5 109 78 698 Vaginal 3.5 female 23.5 N/D
N13 ALISON 34 39.3 122 67 524 Vaginal 3.51 male 24.5 N/D
Average 34.46 38.92 122.38 70.77 654.38 3.41 23.63
STD 3.20 0.55 7.94 7.04 109.85 0.44 0.86
Serial no. Pre-eclamptic: Maternal age Gestational age Systolic BP Diastolic BP Placental Weight Mode of Delivery Gestational weight Gestational Sex BMI Protein in urine (g/L)
(Years) (Weeks) (mmHg) (mmHg) (Grams) (Kg)
P1 Kirsty 28 33 150 92 360 Vaginal 1.66 male 23.5 2.5
P2 PE3 27 36 168 95 470 Cesearean 2.3 male 22.8 1.5
P3 PE5 29 37 152 110 505 Cesearean 1.87 male 22.5 1.14
P4 V14 29 38 150 111 420 Vaginal 1.82 female 24.4 1.01
P5 V16 27 36 160 92 545 Cesearean 2.6 male 24.6 1
P6 V17 28 39 160 90 480 Cesearean 1.76 male 22.8 0.9
P7 V18 32 37 150 90 510 Cesearean 2.98 male 22.5 0.98
P8 V19 28 38 150 90 529 Cesearean 3.1 female 21 1
P9 V22 28 39.5 155 95 510 Cesearean 2.8 male 23.5 0.91
P10 V25 28 38 155 112 517 Cesearean 2.9 male 22.8 0.875
P11 V26 29 39 140 108 620 Vaginal 3.59 female 23 0.88
P12 Angela 29 39.4 156 98 610 Cesearean 3.12 male 22 1.1
Average 28.5 37.5 153.3 98.5 506.3 2.54 22.95 1.14
STD 1.31 1.86 6.99 8.98 71.79 0.64 0.98 0.46
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A.4 Accession numbers for target genes used for primer designing 
 
C/T antigen NCBI accession number 
BUC11 Primer provided by the John van Geest Cancer Research Centre 
CAGE1 NM_001170692 ; NM_01170693 ; NM_205864 
FATE1 NM_033085 
GAGE1 NM_001040663.2 
GAGE C1/PAGE 4 AK312039 
GAGE E1/PAGE 5 NM_001013435 
HAGE Primer provided by the John van Geest Cancer Research Centre 
MAGE A1 NM_004988 
MAGE A3 NM_005362 
MAGE A4 NM_001011548 ; NM_002362 ; NM_001011549 ; NM_001011550 
NY-ESO-1 Primer provided by the John van Geest Cancer Research Centre 
PASD1 NM_173493 
T128 Primer provided by the John van Geest Cancer Research Centre 
T21 Primer provided by the John van Geest Cancer Research Centre 
 
 
 
 
A.5 DNA confirmation by gels and sequencing 
A.5.1 Housekeeping genes 
 
5HT receptors NCBI accession number
5HT 1A NM_000524
5HT 1B NM_000863
5HT 1D NM_000864
5HT 1E NM_000865
5HT 2A NM_000621; NM_001165947
5HT 2B NM_000867
5HT 2C NM_000868
5HT 3 NM_213621; NM_000869; NM_001161772
5HT 4 NM_001040173; NM_001040172 NM_001040171; NM_001040169; 
NM_199453; NM_000870
5HT 5A NM_024012
5HT 6 NM_000871
5HT 7 NM_019860; NM_019859; NM_000872
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A.5.2 Temperature optimisation for 5-HT receptors 
 
A.5.3 Temperature optimisation for C/T antigens 
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A.5.4 Example of sequencing 
 
Figure A.7.2: The DNA sequencing data for PASD1 PCR product. 
The bases represented by N were replaced by the specific bases identified by their coloured peaks (A- 
Green, T- Red, G- Black and C- Blue). 
 
 
Figure A.7.3: Example of BLAST matching data for PASD1 sequence obtained from 
sequencing. 
 
The red bands shows >=200 alignment score for the DNA sequence received from the company and the 
gene of interest PASD1 (with 99% maximum identity).  
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A.6 Western blot whole blots 
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